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Gonorrhea is the second most common sexually transmitted bacterial infection in 
the United States, with nearly 600,000 cases reported in 2018 by the Centers for Disease 
Control. Alarmingly, the causative agent Neisseria gonorrhoeae has developed resistance 
to a number of antimicrobials over the last century. With limited options remaining, the CDC 
now recommends dual therapy with ceftriaxone and azithromycin to decrease the likelihood 
of resistance development. However, strains with combined cephalosporin and macrolide 
resistance have now emerged, raising concerns of a post-antibiotic future in which 
untreatable gonorrhea would impose enormous human and economic cost. The discovery 
and development of novel antigonococcal agents is, therefore, necessary to avoid a public 
health crisis.  
The pharmacologic receptors for β-lactams are a group of transpeptidases known 
as penicillin-binding proteins (PBP), which catalyze the cross-linkage of peptidoglycan, an 
essential component of the bacterial cell wall that plays major roles in cell growth and 
division. N. gonorrhoeae develops chromosomally mediated β-lactam resistance via 
alterations of PBPs affecting drug affinity, specifically through the acquisition of mutations in 
the penA gene encoding PBP2. Resistant strains harbor mosaic penA alleles encoding PBP2 
variants containing around 60 amino acid changes compared to wild-type. In this work, we 
examine inhibition of a mosaic form of N. gonorrhoeae PBP2 from the cephalosporin-
resistant strain H041, seeking to understand better which features of ligand structure 
enhance or diminish PBP2 binding in order to develop more effective PBP2 inhibitors.  
First, we report structure-activity relationships (SAR) for the cephalosporin class of 
β-lactams against PBP2 from N. gonorrhoeae H041 with the goal of identifying or designing 
cephalosporins effective against resistant strains. We find that structural features of the C7 
acylamino side chain (R1) correlate highly with the second-order rate of PBP2H041 
 xvii 
acylation, including increased size, modest lipophilicity, and two ring systems separated 
by a single branch point. The C3 side chain (R2) makes lesser, but still important, 
contributions to inhibition, with electronegative elements and planarity enhancing activity. 
We also found that many of the features enhancing target inhibition (e.g., lipophilicity, 
aromaticity) diminish antimicrobial activity against the H041 strain, perhaps due to 
decreased accumulation in the periplasm. Finally, we identify cefoperazone as highly 
active against PBP2H041 and similarly active against N. gonorrhoeae H041 both in vitro 
and in vivo compared to ceftriaxone. Second, we report the in silico discovery of novel 
noncovalent PBP2 inhibitors possessing a 1,1’-biphenyl system. Arylamide JEK-42 and 
its isosteric sulfonamide derivative JMT-1 are capable of inhibiting PBP2 from both β-
lactam-susceptible and -resistant gonococcal strains. Their cross-inhibition of P. 
aeruginosa PBP3, predicted binding modes showing interaction with highly conserved 
residues, and structural similarities to bicyclic β-lactam scaffolds indicate their potential for 
broader activity against class B PBPs. Using the structural similarities between JEK-42, 
JMT-1, and bicyclic β-lactam scaffolds (i.e., penam, carbapenem, and cephem), a three-
point pharmacophore was generated that can be used to identify additional PBP-inhibitory 
scaffolds. Third, we report the synthesis of 127 derivatives of JMT-1, showing specific 
substitutions that enhance the inhibition of PBP2 derived from both β-lactam-susceptible 
and -resistant strains. In keeping with the cephalosporin SAR, hydrophobic substitutions 
enhance PBP2 inhibition, likely through increased van der Waals contact with the active 
site, but they can also result in diminished antimicrobial activity. Together, our efforts yielded 
10 compounds that show near full inhibition of PBP2 from susceptible and resistant strains, 
as well as large zones of gonococcal growth inhibition in disc diffusion assays. These 
studies lay the groundwork for the development of several structurally diverse 














CHAPTER 1: Introduction  
 2 
1.1 Neisseria gonorrhoeae  
1.1.a. Epidemiology and clinical features of gonococcal disease 
Neisseria gonorrhoeae is a Gram negative diplococcus responsible for the sexually 
transmitted infection (STI) gonorrhea. Gonorrhea is a global problem and, despite a sound 
public health infrastructure, a growing issue in the United States. There are nearly 600,000 
cases reported annually by the Centers for Disease Control (CDC)1 and 87 million cases 
reported annually by the World Health Organization (WHO),2 and as with many infectious 
diseases, the true number of cases is expected to be much higher due to asymptomatic 
infection and underreporting. In the United States, overall rates of infection showed a 
substantial decline until 2009, reaching a low of 98.1 cases per 100,000 person years; in 
the last decade, however, an upward trend in infection rates has begun and persisted, 
with 179.1 cases per 100,000 person years reported in 20181 (Figure 1.1). The highest 
reported rates are seen among the following groups: adolescents and young adults, racial 
minorities, men who have sex with men (MSM) and persons living in the southeastern 
states1 (Figure 1.1). Symptomatic disease is generally associated with urethritis in men 
and cervicitis in women, although rectal and pharyngeal gonorrhea are not uncommon. 
Untreated, the infection can spread in an ascending pattern, resulting in epididymitis in 
males and pelvic inflammatory disease (PID) in females. These complications can result 
in serious sequelae, including infertility and ectopic pregnancy. Disseminated gonococcal 
infections result most commonly in suppurative arthritis or tenosynovitis but can cause 
more serious disease, such as endocarditis or meningitis.3-8 Importantly, gonococcal 
infection results in mucosal disruption and can therefore increase the risk of both 




Figure 1.1: Epidemiology of gonococcal disease in the United States. A. Reported incidence of 
gonorrhea in the United States over the last 70 years. The absolute incidence is shown in black, 
and the rate of change is shown in red. B. Incidence of gonorrhea stratified by age and sex. Data 
are from 2018. C. Incidence of gonorrhea stratified by age and ethnicity. Data are from 2018. D. 
Estimated incidence in gonorrhea stratified by sexual behavior. Values are modeled based on 
interviews of a random sample of reported cases (n = 6,482 patients). Key: men who have sex with 
men (MSM), men who have sex with women (MSW), women (W).  E. Heat map of gonococcal 
incidence by state. All data are from CDC infectious disease surveillance. 
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1.1.b. Emerging antimicrobial resistance  
Historically, gonorrhea was treated with sulfanilamide or penicillin, but due to 
increased prevalence of resistant strains, the Centers for Disease Control & Prevention 
(CDC) called for their withdrawal as recommended antibiotics for gonococcal infections 
due to emerging resistance.11-20 With the subsequent withdrawal of spectinomycin,21-25 
tetracyclines,26-30 and fluoroquinolones31-38 for the same reason, only third-generation 
cephalosporins (e.g., ceftriaxone and cefixime) remained as CDC-recommended drugs of 
choice in the United States39,40 (Figure 1.2). In the last two decades, strains of N. 
gonorrhoeae with decreased susceptibility to extended-spectrum cephalosporins (ESCs) 
have emerged, prompting concerns that gonococcal infections may soon become 
untreatable using monotherapy.41-59 For this reason, treatment guidelines now recommend 
dual therapy with ceftriaxone and azithromycin in the United States and Europe.60,61 
Alarmingly, strains exhibiting high-level resistance to ESCs have now been isolated on 
most continents (Asia, Australia, Europe, North America, and South America),62-87 and 
macrolide resistance has become increasingly common.48,88-93 While combined ESC and 
macrolide resistance is exceedingly rare, a few such cases have been reported.78-80 This 
rapidly changing landscape of antimicrobial resistance indicates that the currently used 


















































































































































































































































In addition to the human costs, STIs have a substantial impact on the national and 
global economies. Diagnosis and treatment alone cost the United States healthcare 
system $16B annually, with gonococcal infections contributing an estimated $162M in 
direct costs.99 With the present surge of multidrug-resistant gonorrhea, disease 
prevalence and severity are expected to rise due to treatment failure, augmenting the 
economic burden of gonorrhea and its sequelae. To date, there have been no strains 
exhibiting high resistance to ESCs isolated in the United States; however, with the recent 
international transmission of a ESC-resistant clone from Asia to Canada,67 the arrival of 
such a strain to the United States seems imminent. It is predicted that if antimicrobial-
resistant N. gonorrhoeae were to become established in North America, there will be 5.9 
million new cases, an added cost of approximately $780M, over a seven-year period.100  
1.2 β-Lactams and their biological targets 
1.2.a. Penicillin-binding proteins as the molecular targets for β-lactam antibiotics 
The pharmacologic receptors for β-lactams are a group of DD-transpeptidases 
known as penicillin-binding proteins (PBPs), which catalyze the cross-linkage of 
peptidoglycan via the formation of isopeptide bonds.101-103 Peptidoglycan is a mesh-like 
polymeric macromolecule consisting of glycan strands of β-1,4-linked N-acetylmuramic 
acid and N-acetylglucosamine covalently linked to L-alanyl-ɣ-D-glutamyl-L-diaminoacyl-D-
alanine peptide chains via amidation of the muramic acid carboxyl group by the L-alanine 
amino group104 (Figure 1.3). Cross-linkage of peptidoglycan units occurs when a unit of 
endogenous pentapeptide substrate, L-alanyl-ɣ-D-glutamyl-L-diaminoacyl-D-alanyl-D-
alanine, forms an isopeptide bond between the penultimate D-alanine and the side chain 
amine of the diaminoacyl residue at the expense of the D-alanyl-D-alanine peptide bond, 
a process catalyzed by the PBPs (Figure 1.4). Peptidoglycan is an essential component 
of the bacterial cell wall and plays major roles in cell growth and division, as well as 
protection from osmotic or tensile stress, and it has a natural turnover rate dictated by the 
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processes of synthesis and autolysis.104,105 There are three classes of PBP: class A are 
bifunctional enzymes, with transpeptidase and transglycosylase functionalities; class B 
are monofunctional transpeptidases; and class C catalyze either carboxypeptidase or 
endopeptidase reactions.102,103 Whereas PBPs of classes A and B are generally essential 
for the survival of bacteria, class C can often be genetically deleted without significant 
effects on cell growth or morphology. 
The transpeptidase active site contains three conserved motifs: SxxK, SxN, and 
KTG (where x denotes a variable residue)106 (Figure 1.5). The catalyzed reaction involves 
three steps: Michaelis-Menten binding of peptide substrate, acylation, and deacylation. It 
is proposed that the KTG lysine serves as an electrostatic anchor for the pentapeptide 
carboxy terminus to allow initial recognition of the substrate.107-112  In N. gonorrhoeae 
PBP2, there is evidence that the KTG threonine then rotates in response to carboxylate 
binding, acting as a trigger that initiates the acylation reaction by allowing β3 strand 
rotation for formation of the oxyanion hole.113 The SxxK lysine acts as a base, polarizing 
the hydroxymethylene sidechain of the SxxK serine to form a pseudo-alkoxide nucleophile 
that attacks the carbonyl carbon of the peptide substrate’s penultimate D-Ala.107-112 The 
resulting substitution reaction goes through a tetrahedral intermediate stabilized by an 
oxyanion hole made up of the backbone amides of the SxxK serine and a residue following 
the KTG motif.114-117  Upon resolution of the tetrahedral intermediate, the terminal D-
alanine is eliminated to form an activated L-alanyl-ɣ-D-glutamyl-L-diaminoacyl-D-alanyl 
acyl enzyme, at which time the carbonyl carbon undergoes nucleophilic attack by the 




































































































































































































β-lactam antibiotics mimic the D-Ala-D-Ala terminus of the peptidyl substrate.118-124  
In the presence of a β-lactam, the serine nucleophile instead attacks the carbonyl carbon 
of the cyclic amide, but upon resolution of the tetrahedral intermediate, the leaving group 
remains tethered to the acyl-enzyme, blocking deacylation125-127 (Figure 1.4). The reaction 
of β-lactams with PBPs is described by Equation 1, where E·S is the noncovalent 




The second-order rate constant (k2/Ks) is a direct measure of the reactivity of a β-
lactam with a PBP, and these rate constants can exceed 106 M-1s-1 against PBPs of 
susceptible strains.128 As described above, the rate of deacylation (k3) is slow, occurring 
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Four PBPs are encoded by the genome of N. gonorrhoeae.133  PBP1 (class A), 
and PBP2 (class B) are both essential and are potential targets for bactericidal activity; 
however, because PBP2 is inhibited at tenfold lower penicillin concentrations than PBP1, 
it is generally accepted to be the clinical target for susceptible strains. While PBP3 and 
PBP4 (class C) are nonessential, deletion of both in one strain results in pleiomorphy and 
slowed growth.111  
1.2.b. Factors affecting β-lactam acylation of PBPs 
As shown in Equation 1, there are two component steps to β-lactam acylation of 
PBPs: formation of the precovalent enzyme-lactam complex (Ks) and reaction of the serine 
nucleophile with the lactam ring to form the covalent acyl-enzyme (k2). The first step is 
determined by factors affecting affinity of the β-lactam for the active site of the PBP, 
including complementarity of size, shape, and charge; however, very little is known about 
how these features contribute to the binding of β-lactams. Isothermal titration calorimetry 
(ITC) and surface plasmon resonance (SPR) are not especially useful to this end, as they 
can only report an apparent association constant (Ka) due to the overall reaction being 
covalent. Mutation of the nucleophilic serine to alanine has been performed in our 
laboratory, however, and in ITC studies of this modified system, we have shown that 
affinity is important for acylation.134 Whereas Kd of ceftriaxone was measured to be 2.3 µM 
against PBP2 derived from a fully susceptible strain of N. gonorrhoeae, no heat exchange 
was seen upon titration of millimolar ceftriaxone into PBP2 derived from cephalosporin-
resistant strains. Previous studies have indicated that the common acylamino side chain 
of many β-lactams may be an important driver of affinity against PBPs, but more rigorous 
analyses were not done to determine which characteristics specifically enhance or hinder 
acylation.135-139  In one instance, a high-affinity penicillin analogue was designed with a 
specific acylamino group that rendered it orders of magnitude more active than other β-
lactams (k2/Ks = 1.5×107 M−1s-1).140,141 Finally, complex formation is largely dependent 
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upon the active site architecture of the specific PBP being studied. Each bacterial species 
has its own collection of PBPs, and beyond the conserved motifs, there is considerable 
sequence variation. Resistant mutants arising from target modification complicate this 
problem further.  
 In addition to side chains and overall topology of the molecule, another factor, the 
Cohen parameter c, describes the precovalent complementarity of β-lactams in the PBP 
active site.142,143 The Cohen parameter is defined as the distance between the carboxylate 
carbon and the amide oxygen in bicyclic β-lactam systems (Figure 1.6). Lower Cohen 
parameters are correlated with higher complementarity, likely due to a physical 
requirement created by the distance between the carboxylate-binding residues and the 









The acylation reaction by β-lactams is determined by factors governing 
nucleophilic attack of the lactam ring, including both target and ligand factors. Target 
factors involve the electronic environment of the serine and how this environment affects 
its ability to act as a nucleophile. From studies of the mechanistically analogous serine 
protease chymotrypsin, as well as studies assigning protonation states to active site 
lysines in several PBPs, it is widely accepted that the SxxK motif lysine polarizes the serine 
hydroxyl group, forming an activated pseudo-alkoxide.107-112 The acid-base chemistry of 
the SxxK serine and lysine has been shown to be key to this process and is influenced by 
the local environment of the active site. For a Brønsted-Lowry acid or base to function 
optimally in a catalytic cycle, its pKa must be near the effective pH at the reaction site so 
that its protonation state can be readily restored.144-147 In the case of the conserved SxxK 
residues of PBPs, there are three predominating factors influencing protonation states: 
local electrostatics, the presence of an extensive hydrogen bonding network, and the Born 
effect.148,149 The presence of additional nearby ionizable groups can influence the pKa of 
an ionizable residue in accordance with the thermodynamic tendency away from 
Coulombic repulsion.150 The presence of the KTG lysine adjacent the SxxK lysine in PBPs 
will, therefore, decrease the pKa of both toward surrounding pH. The active site of PBPs 
also contains an extensive hydrogen bonding network, including a direct SxxK serine-
lysine donor-acceptor pair. The favorable energy of this interaction results in an increase 
in the acidity of the serine hydroxyl group due to the stabilization of its conjugate base.151  
Finally, the Born effect prescribes that the ionized state of an acid or base exists more 
readily in a hydrophilic environment – when buried in a protein, the pKa is perturbed to 
favor the neutral species (i.e., the pKa of the SxxK lysine is decreased).152  In studies on 
the pH dependence of E. coli PBP5 activity, these general principles have been supported 
experimentally, with results showing that the SxxK lysine is in its free-base form at optimal 
catalysis.108 Further, disruption of the residue’s pKa by substitution with arginine’s 
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guanidine side chain results in a 600-fold decrease in the second order rate constant for 
penicillin binding.153  
The preeminent ligand factor affecting β-lactam binding to PBPs is the activation 
of the lactam ring itself to reaction with nucleophiles, a property determined by the p-orbital 
character of the lactam nitrogen. In monocyclic 2-azetidinone systems, the amide system 
is stabilized by resonance, decreasing the electrophilicity of the carbonyl group. In bicyclic 
systems, however, the amide nitrogen is geometrically constrained to an sp3 hybridized 
trigonal pyramidal geometry, decreasing this resonance effect.154-159 The result is that in 
bicyclic systems, the lactam ring exhibits much higher intrinsic reactivity to nucleophiles. 
The amount of nitrogen p-orbital character can be measured by the distance of the 
nitrogen from the base of the trigonal pyramid defined by its three bond-pair substituents, 
a parameter known as the Woodward height160-162 (Figure 1.6). 
1.2.c. Major classes of β-lactam antimicrobials 
Monobactams are the simplest class of β-lactam antimicrobials, possessing a 
monocyclic 2-azetidinone system with an N-sulfonic acid moiety (Figure 1.7) the base 
structure of which was first isolated from Chromobacterium violaceum.163-165 Due to their 
monocyclic structure, they are the least activated of the β-lactam antimicrobials, and their 
activity is thought to be a consequence predominantly of their ease of entry into PBP active 
site. However, there is evidence to suggest that the electron-withdrawing inductive effect 
of the N-sulfonic acid serves to disrupt amide resonance, albeit slightly, lending to partial 
p-orbital character of the nitrogen’s hybrid orbitals.166 There is currently only one 
monobactam in clinical use, aztreonam, which exhibits potent inhibition of Gram-negative 
PBPs.167-170 It finds limited utility clinically, however, as it has no activity against Gram-








Penams are a class of β-lactams possessing an azabicyclo[3.2.0]heptane ring 
system, a carboxylic acid moiety at C3, and a sulfur atom at position one (Figure 1.7). 
They exhibit a large Woodward height (h ~ 0.4 Å) due to strain imparted by 5-membered 
ring fusion, and as such, exhibit good intrinsic reactivity to nucleophiles. Interestingly, 
molecules of the penam class can exist in two distinct conformational states, one in which 
the C3 carboxylate is in an equatorial position in relation to the ring system and one in 
which it is axial171-187 (Figure 1.6). In the equatorial position, it contributes to a lower Cohen 
distance (c ~ 3.9 Å) and, thus, a better fit to the geometric requirements of the PBP active 
site. In the axial position, the structure is considered inactive (c ~ 4.3 Å). The existence of 
two equally populated states related by rotation results in lowered activity compared with 
lactams possessing constrained carboxylate α-carbons. The prototypic and most well-
known penam is penicillin G, or benzylpenicillin, discovered in cultures of Penicillium 
chrysogenum in the 1920s.188  The other natural product penam is penicillin V, or 
phenoxymethylpenicillin. In the absence of β-lactamases, the natural penicillins show 
good Gram-positive activity but fail to inhibit the growth of many Gram-negative 
organisms.189-193  A great deal of medicinal chemistry has been executed on the penam 
scaffold to modulate the spectrum of this class, resulting in many structural subclasses. 
The penicillinase-resistant penicillins (e.g., nafcillin, oxacillin, cloxacillin, dicloxacillin), as 
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spectrum β-lactamases and do not exhibit improved Gram-negative activity over the 
natural product compounds;194-204 the aminopenicillins (e.g., ampicillin, amoxicillin) show 
better Gram-negative activity but are generally outperformed by the natural penicillins 
against Gram-positive organisms;205-207 the carboxypenicillins (e.g., carbenicillin, 
ticarcillin) exhibit rather potent Gram-negative inhibition while retaining good Gram-
positive coverage;208-212 and the ureidopenicillins (e.g., piperacillin, mezlocillin, azlocillin) 
show similar spectrum to the carboxypenicillins but generally possess increased potency 
in comparison.208,209,211,213,214 
Cephems are a class of β-lactams possessing an azabicyclo[4.2.0]oct-2-ene ring 
system, a carboxylic acid moiety at C4, and a sulfur atom at position one (Figure 1.7) 
These systems generally exhibit low Woodward heights (h ~ 0.3 Å) due to conformational 
flexibility afforded by having a 6-membered ring fusion; however, there exists a 
competitive enamine resonance, resulting from the delocalization of the nitrogen’s lone 
electron pair into the π electron system of the dihydrothiazine ring, that contributes to 
disrupted amide resonance.155,159,215 A unique feature of cephem-based compounds is 
their chemistry at the C3 position, which can act as a leaving group upon ring opening due 
to the aforementioned enamine resonance. The departure of a C3 leaving group results 
in the formation of an exocyclic olefin that may enhance the thermodynamic stability of the 
acyl enzyme complex, thereby decreasing regeneration of apoenzyme.216 Whether or not 
it is a leaving group, C3 can participate in long range inductive effects with the β-lactam 
amide moiety, and strongly electron withdrawing groups are postulated to enhance the 
electrophilicity of the active carbonyl.159,217,218 A fixed, low Cohen parameter is 
characteristic of the class due to sp2 hybridization of C4 (c ~ 3.2 Å) (Figure 1.6).  
The first identified cephem, cephalosporin C, was isolated from 
Acremonium chrysogenum and showed only marginal antimicrobial activity;219-225 
however, its many semisynthetic derivatives have enjoyed great success as potent 
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therapeutics. The cephalosporins are categorized into “generations” based on medicinal 
chemistry and antimicrobial spectrum (Figure 1.8). First generation agents generally 
possess an aromatic acylamino side chain at C7 and possess potent Gram-positive 
activity.226-232 While second generation agents explore other aromatic acylamino groups 
at C7, much of the variation found in this generation is from the replacement of the acetoxy 
group with various nucleophiles (i.e., carbamates, heterocyclic mercaptans, and pyridines) 
(Figure 1.8). Second generation agents largely exhibit broader spectrum than their earlier 
counterparts, with some showing potent inhibition of Gram negatives with high intrinsic 
resistance.233-240 Among the key findings of this iteration of cephalosporin design was the 
alkoxyimino moiety, seen in cefuroxime, which confers resistance to degradation by serine 
β-lactamases.241-243 This functional group became a mainstay in the design of third 
generation agents, while the aryl group was modified to an aminothiazole, a change found 
to enhance Gram negative activity (Figure 1.8). One notable outlier is cefoperazone, 
which borrows its C7 acylamino group from the ureidopenicillin piperacillin. This group 
exhibits not only further expanded spectrum compared to previous generations, but also 
good stability to serine β-lactamases.244-259 In the fourth generation, various quaternary 
nitrogen-containing C3 were examined to enhance passive transport through the Gram 
negative outer membrane, decrease affinity for β-lactamases, and promote departure of 
the leaving group.260-266 Fifth generation agents are specifically engineered to combat 
various resistance problems while attempting to maintain spectrum.267-280 In general, these 
compounds maintain the alkoxyimino group, exchange the aminothiazole for an 
aminothiadiazole, and exhibit planarity in their C3 substituents.  
 18 



































Carbapenems are a class of bicyclic β-lactams possessing an 
azabicyclo[3.2.0]hept-2-ene ring system, a carboxylic acid moiety at C3, and a carbon 
atom at position one (Figure 1.7). The carbapenems are thought to be the most 
intrinsically active of known β-lactams – their rapid acylation of PBPs and potent 
antimicrobial activity have been ascribed to a highly activated lactam ring system, as 
shown by experiments examining the kinetics of base hydrolysis.156,162 Crystallographic 
structures reveal a high Woodward coefficient (h ~ 0.5 Å) attributable to the geometric 
constraints introduced by the unsaturation between C2 and C3 and the replacement of 
sulfur with carbon at position one. Similar to the cephems, the carbapenems exhibit a fixed 
Cohen distance due to an sp2 hybridized C3, but the bond angles imposed by a 5-
membered fused ring position the carboxylate slightly further from the lactam (c ~ 3.5 Å) 
(Figure 1.6). The C6 R-hydroxyethyl side chain possessed by molecules of this class 
represents a significant departure from penams and cephems, which generally exhibit 
large and variable aminoacyl side chains at this position. Differences in activity and 
spectrum among compounds of this class are, therefore, dictated almost exclusively by 
the side chain at C2. Since the isolation of thienaymycin from Streptomyces cattleya in the 
1970s,281,282 only four carbapenems have been approved for clinical use by the FDA: 
imipenem, doripenem, meropenem, and ertapenem.283-286 Given their broad spectrum, as 
well as their stability against β-lactamases afforded by their C6 R-hydroxyethyl side chain 
and trans C5-C6 geometry,287-289 the carbapenems have found most of their clinical utility 
as antimicrobials of last resort in infections with multidrug resistant organisms. 
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1.3. β-lactams in the treatment of Neisseria gonorrhoeae  
1.3.a. Overview of antimicrobial resistance  
The discovery of penicillin and other compounds capable of inhibiting bacterial 
growth revolutionized modern medicine and continues to shape its practice. These 
therapies not only provided a means of pharmacologically managing conditions and 
injuries that in the past killed or impaired many, but also provided avenues to prevent 
infection post-operatively and in immunosuppressed patients, including those undergoing 
solid organ transplant, those with advanced stage HIV / AIDS, and those receiving 
myelotoxic cancer therapies. However, with increased and sometimes improper use of 
antibiotics, resistance to these and other drugs has emerged in a number of common 
pathogens, thereby limiting treatment options. Prominent examples include methicillin 
resistant Staphylococcus aureus (MRSA),290 vancomycin resistant enterococcus (VRE),291 
multidrug resistant nosocomial pathogens (Pseudomonas aeruginosa, Klebsiella 
pneumonia, Stenotrophomonas maltophilia, etc.),292-294 and sexually transmitted infections 
(Neisseria gonorrhoeae, Mycoplasma genitalium).295,296 In 2014, the WHO began to warn 
of a post-antibiotic era, citing antimicrobial resistance as among the most dangerous 
current threats to public health.297 With the increasing prevalence of strains resistant to 
the existing armamentarium of antimicrobials, there is a great and manifest need for the 
development of new drugs to treat these infections.  
Antimicrobial resistance is classically ascribed to any combination of the following 
processes: decreased accumulation at the site of action, drug inactivation by degradative 
or modifying enzymes, overproduction of endogenous substrates, or target alteration by 
either chromosomal or enzymatic means (Figure 1.9). While N. gonorrhoeae employs 
multiple mechanisms in achieving β-lactam resistance, among its most powerful tools is 






























































1.3.b. Gonococcal β-lactam resistance not mediated by PBPs 
Because peptidoglycan crosslinking occurs in the periplasmic space, β-lactams must 
permeate the bacterial outer membrane to exert their cytotoxic effects. Hydrophilic small 
molecules require aqueous channels known as porins to cross this barrier, and bacteria 
have developed several mechanisms for restricting entry298 including global decreases in 
porin expression,299-302 shifts in expression from one porin type to another of smaller 
channel radius,303 and porin mutations resulting in impaired permeation through the 
channel.304 In Neisseria gonorrhoeae, changes in antimicrobial permeability are mediated 
in part by mutations in porB1B encoding the major outer membrane protein porin B1b, 
known as the penB resistance determinant.305 These mutations are located at positions 
120 and 121 on loop 3, which lies within the β-barrel in crystal structures of several porins 
(including N. meningitidis porin B).304,305 It is hypothesized that these mutations perturb 
the structure of the pore constriction, thereby disallowing entry of larger solutes; however, 
penB is phenotypically silent in the absence of efflux overexpression.306 Changes to other 
pore-forming elements may also diminish the periplasmic accumulation of β-lactams in N. 
gonorrhoeae, such as point mutations to the pilQ gene encoding secretin PilQ acquired 
by laboratory strains.307 This type of mutation, known as the penC resistance determinant, 
decreases β-lactam susceptibility, but its disruption of transformation and piliation make it 
unlikely to be found in clinical isolates.  
As illustrated by mutations to porB1b and pilQ, changes in outer membrane 
permeability alone frequently do not alter susceptibility significantly and are often 
associated with additional resistance mechanisms.308 Another mechanism responsible for 
diminished intracellular accumulation is the production of multiunit macromolecular 
machineries that extrude amphipathic xenobiotic compounds, including dyes, detergents, 
solvents, and antimicrobials. These efflux pump systems can be categorized structurally 
into the following families: the ATP-binding cassette (ABC) family, the resistance-
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nodulation-cell division (RND) family, the multidrug and toxic compound extrusion (MATE) 
family, and the small multidrug resistance (SMR) family.309,310 These families are 
distinguished from one another by species specificity, macromolecular structure, substrate 
range, and energy source. While baseline expression of efflux systems can afford survival 
in the presence of certain classes of antimicrobials (i.e., intrinsic resistance), their 
overexpression is of key concern in the development of marked or multidrug resistance.311 
N. gonorrhoeae possesses a tripartite multiple transferable resistance (Mtr) efflux pump 
system belonging to the RND family.312-316 The Mtr system has broad substrate specificity 
that includes many classes of antimicrobial drugs, cationic antimicrobial peptides, natural 
antibiotics, and detergents.312,317,318 It is encoded by the mtrCDE gene complex and 
regulated by the opposing actions of an activator (mtrA) and a repressor (mtrR).319-322 
Several mutations conferring resistance are observed this system, but the most common 
are single missense mutations to a 13 base-pair inverted repeat in the mtrR promoter 
region.320,323-326 Nonconservative mutations in the mtrR DNA binding region have also 
been reported.324,326,327 These loss-of-function mutations in mtrR result in the derepression 
of mtrCDE, allowing for the overexpression of efflux components and a concomitant 
increase in their assembly. 
A final, less ubiquitous mechanism by which bacteria hinder antimicrobial entry is 
the formation of biofilms.328,329 The biofilm state reduces the overall surface area of 
antimicrobial exposure, relative to the bacterium’s planktonic form. Permeation is also an 
issue, with thicker biofilms being generally more difficult to fully eliminate. The observed 
antimicrobial tolerance is likely influenced by more than simple diffusion mechanics, 
however. Studies of expression programs indicate cells in a biofilm go into a dormant 
“persister” state that renders them less susceptible to antimicrobial drugs targeting protein 
synthesis and cellular division.330,331 The gonococcus has developed means of hindering 
antimicrobial access by decreasing exposed bacterial surface area as well. Expression of 
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surface molecules (i.e., phase variable pili, opacity-associated proteins, and 
lipooligosaccharide) promotes gonococcal interactions in vitro, resulting in microcolony 
aggregation and, ultimately, in biofilm formation.332-335 Gonococcal aggregation has been 
shown to increase ceftriaxone tolerance in vitro, with cultivable bacteria being isolated 
after 24-hour exposure to 1 µg/mL.329 In the same set of experiments, residual gonococcal 
viability was found even in a 10 µg/mL treatment group, as measured by ATP production. 
This phenomenon is relevant in vivo as well, as there is evidence of gonococcal biofilm 
formation in cervical biopsies of patients with gonococcal cervicitis.336 
Another mechanism of resistance is production of enzymes that inactivate the 
molecule by addition or removal of chemical moieties or destroy it by hydrolysis.337 Several 
classes of modifying enzymes have been identified that catalyze the following reactions: 
acetylation of aminoglycosides, chloramphenicol, and streptogramins; phosphorylation of 
aminoglycosides and chloramphenicol; and adenylation of aminoglycosides and 
lincosamides.338-343 These reactions alter molecular moieties critical to interaction with 
antimicrobial targets, thereby diminishing binding. The predominating degradative 
enzymes are the hydrolytic β-lactamases, which cleave β-lactams at the active amide 
bond, rendering them incapable of participating in the covalent inhibition process 
characteristic to the class.344-348 High-level gonococcal resistance to penicillin can also be 
achieved through the acquisition of plasmids containing the blaTEM-1 gene, which encodes 
a TEM-1 β-lactamase capable of hydrolyzing penicillins, rendering them inactive.18,19,349 
Although no extended-spectrum β-lactamases (ESBLs) have yet been reported in 
gonococcal isolates, another plasmid containing blaTEM-135 has been identified.350-352 From 
structural and functional comparisons, it is proposed that the encoded TEM-135 
penicillinase may be a direct precursor to an ESBL capable of hydrolyzing 
cephalosporins.351 
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Less studied resistance mechanisms involve the modulation or evolution of 
pathways that compensate for loss of an essential cellular component or enzyme. Bacteria 
are capable of making sophisticated global adaptations to metabolism, including shifts 
between glycolytic and oxidative pathways, alterations in fructose utilization, or changes 
in fatty acid oxidation.353-357 Many of these changes are postulated to result in modulation 
of cell wall autolytic activity and other cell surface properties. In gonococcal strains 
exhibiting mosaic penA, whose gene products likely function suboptimally as 
transpeptidases, compensatory metabolic changes ameliorate fitness defects. It has been 
shown that introduction of mosaic penA41 to a wild-type strain results in the development 
of spontaneous mutations in the acnB gene encoding the TCA cycle enzyme aconitase B, 
as well as in other metabolism-related genes, and that these mutations increase the 
fitness of strains harboring mosaic penA alleles to near-wild-type levels.353 While the exact 
effect of these mutations remains unknown, there are large global shifts in the expression 
of genes involved in energy and carbon metabolism that occur in the presence of a specific 
acnB-G348D mutation, a change that slows the interconversion of citrate and isocitrate by 
the enzyme. 
There are yet additional resistance mechanisms in N. gonorrhoeae that have not 
yet been fully elucidated. Factor X, as it is termed, is a nontransformable determinant of 
unknown identity that can increase penicillin MICs as much as 6-fold.358   
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Table 1.1: Summary of non-PBP-mediated β-lactam resistance in N. gonorrhoeae. *Only seen in 
laboratory strains. **Plasmid-mediated. ***Observed in laboratory strains transformed with mosaic 
penA. Have not yet been confirmed in clinical isolates. 
 
 
1.3.c. Target modification involving gonococcal PBP2  
Target modification is a common mechanism of antimicrobial resistance in which 
the target active site is obscured or its topology altered to diminish binding of the 
antimicrobial. This can be accomplished by mutations to the gene encoding the target,359 
enzymatic addition of chemical moieties to critical contact atoms,360,361 or conformational 
changes resulting from interaction with other macromolecules.362,363 There exist several 
examples of pathogens with modified PBPs that exhibit diminished acylation by β-lactams. 
The MRSA mecA determinant is a notable example of target modification; this gene 
encodes a homolog of the S. aureus β-lactam target possessing a closed active site, such 
that β-lactams cannot gain access for inhibition.364-366 S. pneumoniae develops 
chromosomally-mediated high resistance to β-lactams through the acquisition of 
mutations in any or all of five of its PBPs.367-374 While point mutations can contribute to a 
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resistant phenotype, the hallmark of pneumococcal resistance is horizontal transfer of 
portions of the pbpx gene from resistant commensal streptococci with that of 
pneumococcus, generating a low-affinity mosaic PBP2x protein. E. faecium not only 
acquires point mutations in pbp5 under selective pressure, but it also begins to 
overexpress the low-affinity PBP5 mutant.375-377 Point mutations to the ftsl gene encoding 
PBP3 have been shown to commonly contribute to β-lactam resistance in H. influenzae,378-
381 and alterations in PBP1 have been reported in penicillin-resistant C. perfringens.382,383 
Biochemical and molecular studies have shown that a majority of the decrease in 
susceptibility seen in β-lactam-resistant strains of N. gonorrhoeae is due to chromosomal 
alterations resulting in the modification of PBP2.358,384 First, isolated membrane preparations 
from β-lactamase-negative penicillin-resistant gonococci show marked reduction in 
acylation of PBP2 by [3H]-penicillin G.385,386 These results have been replicated in purified 
protein assays, showing decreased acylation of PBP2 from penicillin- and cephalosporin-
resistant strains by a variety of β-lactams.384,387-390 Additionally, when penA genes from 
resistant strains are transformed into the fully susceptible standard FA19 (i.e., in the 
absence of other resistance determinants), susceptibility to β-lactams plummets.128,358,384,385 
In early studies of penicillin resistance, transformation of penA genes from chromosomally 
resistant strains isolated in Australia caused a 100- to 400-fold increase in the minimum 
inhibitory concentrations (MIC) of penicillin. More recently, transformation of the penA gene 
from a CephDS strain (penA35) into FA19 resulted in 20- and 40-fold increases in the MICs 
of ceftriaxone and cefixime, respectively, while transformation of the penA gene from a 
CephR strain (penA41) resulted in 300- and 500-fold increases. The MICs exceeded the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical resistance 
breakpoint of 0.125 μg/mL in both cases (0.31 μg/mL and 1.6 μg/mL for ceftriaxone and 
cefixime, respectively). These experiments establish mutations in PBP2 as the primary β-
lactam resistance determinant in N. gonorrhoeae.  
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1.3.d. PBP2 modifications resulting in penicillin resistance 
The first use of penicillin against gonococcal infection was in a case of gonococcal 
ophthalmia neonatorum in 1930.391 Due to its success in treating the affected infant, and 
with growing concerns of sulfonamide resistance at the time, penicillin was tested against 
gonococcal urethritis in the early 1940s. In several studies, therapeutic efficacies of 76-
100% were obtained in men after verified sulfonamide failure.11,13,393-397 Penicillin thus 
replaced sulfonamides as first-line treatment for gonococcal infections. Despite early 
success, the proportion of penicillin-resistant gonococcal strains climbed steadily over the 
coming years.15 In a longitudinal study of 5,700 isolates, conducted from 1959 to 1967, a 
marked temporal increase in resistance was observed.14 At the outset of the study, 63% 
of isolates were susceptible to 0.01 µg/mL, and all isolates were susceptible to 0.3 µg/mL. 
Eight years later, only 13% were susceptible to 0.01 µg/mL, and 83% were susceptible to 
0.3 µg/mL, with 9% showing resistance to concentrations greater than 1.0 µg/mL. During 
this period, prescribed doses were increased to maintain satisfactory cure rates, and an 
increasing number of treatment failures were reported.398-405 In 1976, the first gonococcal 
strains possessing plasmid-borne penicillinases were identified in California,17-20,406 but the 
growing prevalence of chromosomally mediated resistance is what eventually drove 
reevaluation of treatment guidelines and a search for more efficacious 
therapies.16,385,386,407-412 
Examination of the penA sequences of chromosomally mediated penicillin-
resistant N. gonorrhoeae (CMRNG) revealed that their PBP2 variants generally contain 5 
to 8 amino acid changes compared to wild-type enzyme from FA19.413,414 A key mutation 
is the insertion of an Asp (Asp346a) after position 346415,416  (Figure 1.10). This insertion 
is positioned in the transpeptidase domain immediately adjacent to another Asp (Asp346), 
which forms a functionally significant hydrogen bond with Ser363 of the SXN motif.388 The 
hydrogen bond is maintained in the Asp364a mutant, and the insertion appears to confer 
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increased flexibility to the β2c-β2d loop.397,389 Additionally, the side chain of Asp346a 
projects toward the β-lactam binding site, so while the precise mechanism of resistance is 
not entirely clear, it has been proposed that the insertion may sterically hinder antibiotic 
binding during Michaelis-Menten complex formation or electronically hinder breakage of 
the β-lactam ring during acylation.389 PBP2 variants of PenR strains generally possess 
additional mutations in the carboxy-terminal region, further decreasing the acylation rate 
and reducing susceptibility.387,389 Interestingly, these mutations do not greatly change the 
structure of the enzyme, even locally, indicating that the mechanism of resistance may be 
dependent upon protein dynamics. 
 
 
Figure 1.10: Changes to the active site of penicillin-resistant FA6140 as a result of an Asp346a 





1.3.e. PBP2 modifications resulting in cephalosporin resistance 
After the withdrawal of fluoroquinolones in the early-to-mid 2000s, cephalosporins 
were the only remaining drugs indicated for the treatment of gonococcal infections.39 
However, in the last two decades, cephalosporin resistance has emerged as well.41-59 
Among the first reported cases of reduced susceptibility (CephDS) was the Swedish 35/02 
strain in 2002.417 The 35/02 strain exhibits MIC values of 0.38 and 0.094 µg/mL for 
cefixime and ceftriaxone, respectively, corresponding to 25- and 60-fold increases 
compared to a wild-type reference strain 119/05. Many additional CephDS strains were 
isolated in Sweden, the UK, and the United States around this time, showing MICs of 0.19-
0.38 and 0.094-0.125 µg/mL for cefixime and ceftriaxone, respectively.417 
The primary difference between penicillin-resistant and ESC-resistant strains is the 
number and types of penA mutations present. Whereas PenDS/R strains contain relatively 
few mutations in PBP2, CephDS/R strains possess penA alleles encoding PBP2 variants 
with around 60 amino acid changes compared to the wild type protein (Figure 1.11). It is 
proposed that these penA genes are acquired by horizontal transfer events between N. 
gonorrhoeae and commensal Neisseria species (e.g., N. flavescens, N. cinerea, N. 
lactamica, etc.).45,46,418,419 The commensal species, occupying microbiological niches in 
the urogenital tract and pharynx, develop chromosomal resistance through frequent 
exposure to antimicrobials and subsequently act as reservoirs for antimicrobial resistance 
genes.420,421 When prolonged gonococcal infection occurs at these sites, these genes are 
readily acquired by the gonococci by transformation and subsequent homologous 
recombination, resulting in a “mosaic” allele encoding a PBP2 variant with lowered 
cephalosporin acylation.390,417 Three mutations in mosaic PBP235/02 (encoded by the 
penA35 allele), G545S, I312M, and V316T, are significant for decreased ESC 
susceptibility in 35/02,422 but when incorporated into wild type penA and transformed into 
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the PenSCephS FA19 strain, resistance to ESC increased only marginally.128 However, 
when these three mutations were reverted to wild-type in the penA35 background, they 
were found to have a prominent effect on resistance (Table 4.2). This result indicates that 
these resistance mutations require other mutations present in the penA35 mosaic to exert 
their effects, a phenomenon known as epistasis.  
 
 
Figure 1.11: Mosaic penA allele and PBP2 structure. A. Mosaic penA alleles are created by N. 
gonorrhoeae through homologous recombination of the penA allele of wild-type N. gonorrhoeae 
with those of β-lactam-resistant Neisseria commensal species. B. The PBP2 variants encoded by 
mosaic penA have around 60 mutations compared to wild-type enzyme (H041 shown, mutations 




By generating chimeric penA in which segments, or modules, of penA35 were 
reverted to the wild-type sequence, information was gained on which mutations in penA35 
contribute to β-lactam resistance. FA19 transformants with wild-type module 4 (comprising 
residues 489 to 528) on a penA35 background showed the greatest increase in 
susceptibility, indicating one or more mutations in this region are critical to resistance.128 
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Subsequent transformation experiments with penA35 alleles lacking individual module 4 
mutations showed that F504L, A510V, and N512Y also contribute to β-lactam resistance in 
the 35/02 strain, with A510V seeming to specifically affect penicillin susceptibility. 
Cephalosporin-resistant gonorrhea was first identified in 2009, as a single case 
involving a female Japanese sex worker with a pharyngeal infection.62,63 Pharyngeal cultures 
came back positive two weeks after standard therapy with ceftriaxone, and infection 
clearance was only achieved by a repeat dose upon follow-up. While cultures for the 
patient’s second presentation were not tested (indicating the potential for reinfection, rather 
than treatment failure), the isolated strain, known as H041, exhibits MIC values of 8 and 2 
µg/mL for cefixime and ceftriaxone, respectively, corresponding to 6,000- and 3,000-fold 
increases compared to PenSCephS strain FA19. Its notable resistance to many other 
antibiotics marks H041 as the first identified pan-resistant strain. This sentinel event in the 
timeline of antibiotic resistance led the WHO to declare N. gonorrhoeae a “superbug” in 
2012 and the CDC to update its designation to “urgent threat” in 2013.423 
The penA gene from the H041 strain (penA41) is a mosaic containing 13 additional 
mutations compared to penA35. When transformed into FA19, the penA41 allele increases 
the MICs  of ceftriaxone and cefixime by 300- and 570-fold, respectively.384 Three mutations, 
A311V, T316P, and T483S, were identified in the penA41 allele that, when incorporated into 
the penA35 allele, confer a majority of the increased resistance seen in H041 compared to 
35/02. A311V and T316P are located near the serine nucleophile (Ser310) and are expected 
to affect α2 in some yet unconfirmed way. T483 is predicted to recognize the carboxylate 
moiety of β-lactam antibiotics via its hydroxyl group, and while T483S is a conservative 
mutation, loss of the methyl group likely alters this interaction. An H541N mutation is present 
in many nonmosaic and mosaic penA from strains with decreased cephalosporin 
susceptibility as well.45,46,417,422,424-426 In all, the work revealed a total of eight mutations that 





Figure 1.12: Mutations identified as critical to β-lactam resistance in PBP2H041. Resistance 
mutations (yellow) highlighted within the active site of an acyl-enzyme structure of ceftriaxone 
(green) in complex with a transpeptidase-only construct of PBP2H041. Polar contacts are shown as 




Transformation of N. gonorrhoeae with a penA construct containing these eight 
mutations alone (8M) was unsuccessful, indicating an insurmountable loss of fitness from 
a decrease in PBP2 transpeptidase activity [unpublished]. Further experiments revealed 
that just one mutation, T483S, is responsible for this failure. A construct lacking this 
mutation (7M) successfully transformed N. gonorrhoeae, but to a much lesser level of 
resistance. It is thus apparent that background epistatic mutations are required for the 
T483S mutation to contribute to resistance without loss of transpeptidase activity. 
Transformation experiments have identified these mutations as substitutions within 
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hydrophobic cores of the protein distant from the active site – A437V, L447V, and F462I 
[unpublished]. A construct including 8M plus the three epistatics (11M) successfully 
transformed into N. gonorrhoeae, indicating restored transpeptidase activity. Reversal of 
T483S in 11M reduced MICs of transformed bacteria to the same values as for 7M, 
confirming the influence of this mutation, and the lack of influence of the epistatic 
mutations, on ESC resistance.  
Structural analysis of PBP2H041 reveals that several of these mutations act to restrict 
protein dynamics required for efficient acylation.134 First, the side chain of S545 participates 
in a hydrogen bonding interaction with the side chain of T498, disallowing its rotation upon 
recognition of the β-lactam carboxylate. This “locking” of T498 hinders β3 strand twisting 
and, thus, oxyanion hole formation. It also affects the final position of the β-lactam by 
presenting an alternative hydrogen bonding partner for the carboxylate moiety. Second, 
F504L and N512Y appear to prevent hinging of the β3-β4 loop toward the active site, altering 
key interactions with the β-lactam acylamino side chain. In fact, the β3-β4 loop occupies an 
“outbent” conformation in both apo  and acyl forms of PBP2H041. Finally, the α2 mutations 
A311V, I312M, and T316P cause no obvious structural changes in PBP2H041. However, the 
A311V and I312M mutations involve increased size of hydrophobic side chains and may 
increase hydrophobic packing around α2, decreasing its mobility in the acylation reaction.  
 CephR N. gonorrhoeae has now been reported several times since the emergence 
of H041. The first case of successful transmission occurred with the French strain F89, 
isolated in 2010. Initially reported in a man who has sex with men (MSM) with urethritis, 
the strain came back in a positive repeat urethral culture 3 weeks after cefixime therapy.70 
Clearance was attained with gentamicin on follow-up. The strain was subsequently 
reported in Spain in two sexually related MSM.64 It exhibits MICs of 4 and 2 µg/mL for 
cefixime and ceftriaxone, respectively, and also it possesses resistance to many other 
antimicrobials. The penA gene of F89 possesses only one additional mutation compared 
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to penA35, A501P. Interestingly, alterations at the 501 position had been hypothesized as 
contributing to cephalosporin resistance only two years prior to F89’s isolation. Tomberg 
et al., while conducting molecular studies of penA35, noted the frequency of A501V in 
nonmosaic penA from gonococcal strains with reduced cephalosporin 
susceptibility128,418,424,425 (Table 1.2). They found not only that transformation of penA35-
A501V into FA19 increased its MICs for cefixime and ceftriaxone 2.5-fold compared to 
penA35, but also that cefixime’s second order acylation rate against a purified PBP235/02-
A501V construct is half that seen with PBP235/02. The 501 position continues to be the 
subject of much investigation due to its differential effects on different classes of β-
lactams. Despite further increasing cephalosporin resistance, mutations at this position 
appear to restore some susceptibility to penams and carbapenems.128,427  
 
 
Figure 1.13: The impact of A501P on the structure of the β3 strand. P501 causes a displacement 




Transformation of FA19 with a diverse set of penA35-A501X genes revealed that 
only specific mutations could increase cephalosporin resistance while maintaining 
essential transpeptidase function.428 Among these, A501P (found in NgF89) and A501R 
(not yet observed in clinical strains) had the biggest impact, increasing  MICs for cefixime 
and ceftriaxone by 5-fold compared to a penA35-transformed control. Consistent with 
previous data from Bharat et al., every successful penA35-A501X transformant had some 
restoration of penicillin G susceptibility. The differential effect of mutations at the 501 
position on the various classes of β-lactams may have to do with perturbation of the 
oxyanion hole. Kinking of β3 strand by the introduction of a proline could displace the 
oxyanion hole more distally from S310. Because the distance between the C4 carboxylate 
and lactam carbonyl in the cephem framework is typically short, and assuming the SxN, 
SxxK, and KTG residues act as an electrostatic anchor for the carboxylate, the lactam 
oxygen may not make the appropriate contacts with both S310 and T500 when in its 
oxyanionic state, rendering the cephalosporins universally less able to acylate structures 
with the 501P mutation.  
More reports of full cephalosporin resistance are continuing to emerge at an 
accelerated rate worldwide, including strains from the following countries: China, Japan 
(GU140106, FC428, FC460, FC498), France (F90), England (G97687/G7944), Denmark 
(GK124), Australia (A8806, A7536, A7846), Argentina, and Canada (47707). The PBP2 
mutants harbored by most of these strains (excluding that reported in Argentina, which is 
nonmosaic) possess structural similarities, sharing A311V and T483S mutations known to 
contribute to resistance through studies of H041 (Table 1.2). The functional significance 
of additional mutations in penA alleles from these strains has not yet been examined. 
Interestingly, sufficient genetic relatedness was found in six of these strains to consider 
them clonal, providing the first evidence of sustained international transmission of 
cephalosporin-resistant N. gonorrhoeae. 
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Non-mosaic PBP2 can also result in ESC resistance, although so far they have 
done so to a lesser extent. As mentioned previously, A501V is seen in a variety of non-
mosaic penA alleles of strains with reduced ESC susceptibility.418,424,425 In addition to 
providing evidence for the role of potential mutations at the 501 position in a mosaic penA, 
Tomberg et al. also showed the impact of a variety of these mutations in a non-mosaic 
penA4 background.428 The resulting penA4-A501X transformants exhibited MICs 2- to 14- 
fold higher for cephalosporins compared to a penA4-transformed control. A statistical 
approach was used to determine if additional common mutations, G542, P551S, and 
P551L, have an effect on decreased ESC susceptibility in non-mosaic PBP2 variants. In 
this study, Whiley et al. determined that strains harboring non-mosaic penA with any of 
the three mutations exhibit a significant decrease in ESC susceptibility, with G542-, 
P551S-, and P551L-harboring strains exhibiting median MICs 7.5-, 3.8-, and 7.5-fold 
higher than pooled strains lacking the mutations.429 In 2014, a strain possessing a non-
mosaic PBP2 variant with P551S was isolated from a young man with purulent urethritis. 
Its ceftriaxone MIC was 0.5 µg/mL, marking it as the first reported strain of N. gonorrhoeae 
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1.3.f. PBP1 modifications contributing to β-lactam resistance 
While its primary mechanism of β-lactam resistance is the acquisition of mutations 
in the penA gene encoding PBP2, N. gonorrhoeae can also acquire mutations in ponA, 
the gene encoding the other β-lactam target PBP1, that diminish its acylation.430 A specific 
mutation in ponA, L421P (the “ponA1 determinant”), is common and reduces the rate of 
PBP1 acylation by a variety of β-lactams by 50-75%. Despite this significant reduction, 
ponA1 is not sufficient for clinically significant resistance alone because the ponA1 gene 
fails to transform FA19 to a higher level of β-lactam resistance. Moreover, it fails to 
transform a series of laboratory-generated intermediate-resistant strains to higher levels 
of resistance. However, reversion of ponA1 to wild-type in FA6140 reduces its penicillin 
MIC by two-fold, indicating that this mutation requires the presence of a number of other 
determinants in order to exert its effect. 
1.4. Use of additional antimicrobial classes as antigonococcal therapeutics 
1.4.a. FDA-approved therapies 
With the fall of β-lactams as useful antigonococcal agents, it may seem attractive 
to look toward FDA-approved therapies from other antimicrobial classes. However, as 
aforementioned, N. gonorrhoeae has developed marked resistance to a number of other 
classes of antimicrobials as well, including sulfonamides, spectinomycin, tetracyclines, 
and fluoroquinolones. Some approved therapies show continued activity against 
gonococcal isolates, but with each comes a drawback making it a suboptimal candidate 
for widespread use (Table 1.3).  
In vitro susceptibility to spectinomycin is currently high globally, with rare cases of 
resistance, but there is concern that, given rapid resistance development before, resistance 
is likely to be selected again. In several countries, gentamicin has been used in combination 
with doxycycline for the syndromic management of urogenital infections, and several studies 
had shown high microbiological cure rates with the regimen, but no specific data on 
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pharyngeal and anorectal infection existed until a study of gentamicin in combination with 
azithromycin showed that microbiological cure was achieved in 100% of subjects, including 
10 cases of pharyngeal infection.431 Moreover, according to a recent meta-analysis, the cure 
rate of single dose is 91.5% across 3 studies with 346 total participants.432,433 An additional 
meta-analyses comparing 23 oral and parenteral therapies found gentamicin to rank highly 
among them,434 but a third found cure rates with high variability.435 While this could be an 
option for cases of treatment failure with other agents, gentamicin is unfavorable as a first-
line agent because of the risk for ototoxicity and nephrotoxicity,436,437 and there exists no 
data on the relationship between gentamicin MIC and pharmacokinetics with clinical 
outcomes to establish evidence-based microbiological resistance breakpoints. Finally, a 
randomized control trial comparing 240 mg intramuscular gentamicin and 500 mg 
intramuscular ceftriaxone failed to demonstrate noninferiority of the regimen.438,439 The 
bacterial cell wall synthesis inhibitor fosfomycin shows good in vitro activity as well, 
exhibiting a median MIC of 8-16 μg/mL in several studies.440-444 Studies of acute and 
subacute gonococcal urethritis treated with fosfomycin yielded cure rates greater than 
90%,445,446 but rapid resistance selection in vitro raises concern for widespread use.447 
Nonetheless, a small clinical trial found 3 g oral fosfomycin trometamol (96.8% cure rate) to 
be noninferior to 250 mg intramuscular ceftriaxone (95.3% cure rate).448 Like gentamicin, 
fosfomycin suffers from a lack of data allowing the establishment of evidence-based 
microbiological resistance breakpoints. The glycylcycline tigecycline also shows in vitro 
activity against gonococcal isolates,444,449,450 but its primary biliary clearance raises concern 
that the drug will not accumulate sufficiently in the urine to treat gonococcal urethritis.451 
Carbapenems must bind PBPs in the same way as other β-lactams, and their 
activity is dictated by the ability to undergo the same nucleophilic substitution reaction to 
form the inactive acyl enzyme. With this mechanistic similarity, known carbapenems 
expectedly show decreased efficacy in penicillin- and ESC-resistant strains of N. 
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gonorrhoeae due to changes in the PBP2 active site. Due to the aforementioned structural 
differences between classes, however, carbapenem reactivity with the target is still much 
higher than that of penams or cephems, with meropenem and ertapenem exhibiting MICs 
against H041 of 0.125 and 0.064 µg/mL, respectively.63 In a study examining in vitro 
activity of ertapenem against clinical N. gonorrhoeae isolates, the antimicrobial potency of 
ertapenem was comparable to that of ceftriaxone, with a median MIC of 0.032 µg/mL for 
both compounds For isolates with mosaic penA alleles conferring ceftriaxone resistance 
(MIC = 0.5 to 4 μg/mL), however, resistance to ertapenem was much less pronounced 
(MIC = 0.016 to 0.064 μg/mL).452 While elevated MICs can be seen in strains possessing 
mosaic penA alleles,427,452,453 the A501P mutation in PBP2 conferring further 
cephalosporin resistance, as seen in strain F89, restores carbapenem susceptibility to 
near-wild-type levels.427 In 2018, after reported treatment failures with both ceftriaxone 
and spectinomycin, the English strain G97687/G7944 was ultimately cleared with a 3-day 
course of intravenous ertapenem, demonstrating its clinical promise as a treatment of last 
resort.76 
In addition to well-established antimicrobials, newly FDA-approved therapies are 
emerging as promising in the treatment of gonococcal infections. One such drug is the 
novel fluoroquinolone delafloxacin. In early studies of its in vitro activity, it was consistently 
found to inhibit the growth of N. gonorrhoeae clinical isolates more potently than 
ciprofloxacin.454-456 However, in a Phase 3 randomized control trial of 460 patients, oral 
administration of 900 mg delafloxacin resulted in only an 85.1% cure rate for urogenital 
gonorrhea (compared to 91.0% for 250 mg intramuscular ceftriaxone).457 Novel 
fluorocycline eravacycline also shows good activity in vitro,444 but its similar 
pharmacokinetic profile to tigecycline raises doubts about its ability to treat gonococcal 
urethritis.  
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Table 1.3: Summary of antigonococcal data for FDA-approved therapies. 
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1.4.b. Novel analogues of known antimicrobial classes 
In addition to considering existing drugs from diverse antimicrobial classes, the 
synthesis of novel, potent derivatives of these classes is another potential strategy (Table 
1.4). New broad-spectrum semisynthetic fluoroquinolones avarofloxacin and sitafloxacin 
exhibit good in vitro activity against gonococcal clinical isolates, with MIC values ranging 
from ≤ 0.001 to 1 μg/mL (compared to ≤ 0.001 to > 32 μg/mL for ciprofloxacin).466-468 
Macrolide derivatives known as bicyclolides (e.g., modithromycin, EDP-322) have had 
promising results in vitro as well, including activity against strains with decreased 
macrolide susceptibility.469 The MIC range of modithromycin and EDP-322 against 
gonococcal strains of varying resistance profiles were found to be 0.004 to 256 μg/mL and 
0.008 to 16 μg/mL, respectively. Unfortunately, high level azithromycin resistance (defined 
as an MIC ≥ 256 μg/mL) correlates with decreased susceptibility to these agents as well. 
Two newly developed 2-aryl carbapenems, SM-295291 and SM-369926, have shown 
variable in vitro antigonococcal activity against clinical isolates (MIC90 ≤ 1 μg/mL).470 The 
design and synthesis of novel carbapenem structures that show specifically enhanced 
affinity for the PBP2 transpeptidase domain in the presence of CephR mutations thus 




Table 1.4: Summary of antigonococcal data for experimental therapeutics belonging to classes of 
FDA-approved therapies. 
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1.4.c. Identification of new antimicrobial targets 
Several antimicrobial compounds with novel mechanisms of action have been 
designed or discovered in the last decade, many of which show in vitro activity against 
multi-drug resistant N. gonorrhoeae (Table 1.5). Some successful compounds utilize 
known strategies for antimicrobial activity, including novel mechanisms of protein 
synthesis inhibition (e.g., pleuromutilin BC-3781, fluoroketolide solithromycin, and 
boronate AN3365) and modes of topoisomerase inhibition (e.g., aminobenzimidazole 
VXc-486, spiropyrimidinetrione ETX0914, tricyclic 2-quinolone REDX05391, and 
triazaacenaphthylene gepotidacin). BC-3781, AN3365, VXc-486, and REDX05931 show 
early promise in vitro, with good antimicrobial potency against panels of gonococcal 
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strains. REDX05391 has been further tested in a murine model of gonococcal infection. 
In this study, significant reductions in gonococcal colonization load were seen with the oral 
administration of single 10, 30, or 60 mg/kg doses, and full infection clearance was seen 
in the group given 60 mg/kg.471 Solithromycin and ETX0914 have advanced to small 
clinical trials of urogenital gonococcal infection, with results indicating a 91% cure rate with 
oral administration of 1 g solithromycin and a 96% cure rate with 2 g ETX0914.472,473 
Interestingly, in strains exhibiting lowered macrolide susceptibility, solithromycin remains 
effective in vitro; however, similar to the bicyclolides, when tested against isolates with 
high-level azithromycin resistance, solithromycin begins to fail. 
Other compounds in the pipeline exhibit entirely novel mechanisms of antimicrobial 
action. One such mechanism is the depletion of essential lipids. FabI is an NADPH-
dependent trans-2-enoyl-acyl carrier protein reductase identified as a key enzyme in 
bacterial fatty acid synthesis. MUT056399, a specific FabI inhibitor, was originally 
developed as an anti-staphylococcal agent. Its measured IC50 against S. aureus FabI is 
12 nM, and its MIC90 against MRSA is 0.12 µg/mL. In studies of spectrum, MUT056399 
was shown to have activity against N. gonorrhoeae, exhibiting an MIC90 of 0.25 µg/mL.474 
LpxC is a UDP-3-O-acyl-N-acetylglucosamine deacetylase involved in lipid A 
biosynthesis. LPC-067, an LpxC inhibitor designed specifically to target N. gonorrhoeae, 
exhibits MICs of 0.1 µg/mL against FA19 and 1.0 µg/mL against 35/02.475 Further 
iterations of design, synthesis, and testing have yielded LPC-067 analogues with MICs of 
0.005 µg/mL and 0.05 µg/mL against the two strains, respectively.   
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Table 1.5: Summary of antigonococcal data for experimental therapeutics with mechanisms of 
action distinct from current FDA-approved therapies. 
 









MIC90 = 0.5 μg/mL  
(24 strains)476 
 




















MIC90 = 0.5 μg/mL  
(28 strains)479 
 
















MIC90 = 0.25 μg/mL  
(250 strains)481 
 
MIC90 = 0.125 μg/mL  
(37 strains)482 
 
MIC90 = 0.125 μg/mL  
(873 strains)483 
 





MIC(WHO L) = 4 µg/mL484 
 
MIC(ATCC49226) = 0.12 
µg/mL484 
 
MUT056399 FabI Depletion of essential lipids 
 
MIC90 = 0.25 μg/mL  
(10 strains)474 
 
LPC-067 LpxC Diminished lipid A synthesis 
 
MIC(FA19) = 0.1 µg/mL475 
 
















1.5. Development of non-β-lactam PBP inhibitors 
1.5.a. Tetrahedral intermediate mimics 
In addition to novel PBP-inhibiting compounds based on active β-lactam 
frameworks, non-β-lactam compounds can also be explored as antigonococcal agents, 
including other covalent inhibitors leveraging the nucleophilic serine. Electron-poor 
boronic acids have been known to inhibit serine proteases for several decades,486 and, 
after early work showing their utility as β-lactamase inhibitors,487-489 have more recently 
been examined as PBP inhibitors as well (Figure 1.14). In 2003, Pechenov et al. explored 
several electrophilic functional groups as potential mimics of the transient tetrahedral 
oxyanion intermediate generated in the PBP catalytic cycle, and among these, dipeptidic 
boronate 1 was found active against several low molecular weight PBPs, exhibiting its 
most potent inhibitory activity against N. gonorrhoeae PBP3 (Ki = 0.370 µM).490 Later, a 
1.6 Å crystal structure of tripeptide analogue 2 in complex with E. coli PBP5 (Ki = 13 µM) 
revealed a covalent adduct in which the Oɣ of Ser44 is bonded to the inhibitor boron and 
one boronic acid oxygen projects into the oxyanion hole comprising the backbone amides 
of Ser44 and His216, establishing this class of compounds as true tetrahedral intermediate 
mimics117 (Figure 1.15A). Another peptidic boronate 3, which possesses a diaminopimelic 
acid as its diaminoacyl group, has been shown to bind with high affinity to Actinomadura 
R39 DD-peptidase (Ki = 32 nM). In a 2.4 Å crystal structure, 3 was found to bind R39 DD-
peptidase in a mode similar to that seen in previous studies of boronates and E. coli PBP5, 
with the boron covalently bound to nucleophilic Ser49, and one boronate oxygen 











































































Figure 1.15: Crystal structures of boronic acid transpeptidase inhibitors in complex with their 
targets, showing their tetrahedral intermediate mimicry. A. Compound 2 (green) in complex with E. 
coli PBP5. B. Compound 3 (green) in complex with Actinomadura R39 DD-peptidase. C. Compound 
5 (green) in complex with Actinomadura R39 DD-peptidase. D. Compound 5 (green) in complex 






Structure-guided design strategies led to the development of 
acylaminoethylboronic acids such as 4, which inhibits both Actinomadura R39 DD-
peptidase (IC50 = 0.27 µM) and S. aureus PBP1b (IC50 = 20 µM).492,493 In further 
explorations of the class, acylaminomethylboronic acids were found to inhibit 
Actinomadura R39 DD-peptidase as well, and subsequent derivatization of this scaffold 
yielded 5, which has been shown to inhibit PBPs of classes A (S. pneumoniae PBP1b, 
IC50 = 26 μM), B (S. pneumoniae PBP2x, IC50 = 138 μM), and C (Actinomadura R39 DD-
peptidase, IC50 = 0.6 μM).494 Distinguishing the methylboronic acids, which mimic a C-
terminal glycine, from their alanine-like predecessors is the formation of a tricovalent 
complex within the transpeptidase active site, as shown by crystal structures of 5 and 
close analogues in complex with R39 DD-peptidase (Figure 1.15D).495 In these structures, 
the boronic acid oxygens have been displaced by Oɣ of nucleophilic Ser49, Oɣ of SxN 
Ser298, and Nε of KTG Lys410. However, a tetrahedral oxyanion-occupying state similar 
to prior published structures was seen in some molecules of the asymmetric unit (Figure 
15.C), leading the authors to hypothesize that the ligands bind similarly at the outset, but 
that a lack of bulk at Cα allows the ligand to move more freely after initial binding.  
A final set of boronic acid-containing scaffolds is the (dihydroxyboranyl)benzoic 
acids and [(hydroxyboranyloxy)]benzoic acids. Initial studies found that the m-
(dihydroxyboranyl)benzoic acid fragment inhibits R39 DD-peptidase, and subsequent 
design of 5-acylamino derivatives yielded mid-micromolar inhibitor 6 (IC50 = 23 µM).496 
Recent work presents bicyclic o-[(hydroxyboranyl)oxy]benzoic acids as potent inhibitors 
of E. coli PBP5, with 7 exhibiting an IC50 of 1.6 nM.497 Although these compounds were 
found to have surprisingly little antimicrobial activity alone, they were able to potentiate 
meropenem activity against highly resistant E. coli and K. pneumoniae in a dose-
dependent manner due to their potent metallo-β-lactamase inhibition. 
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Table 1.6: Activity of boronic acid compounds against bacterial transpeptidases. aThermodynamic 
equilibrium constant (Ki). bHalf-maximal inhibitory concentration (IC50). 
 
Compound Species Target Activity Reference 
1 
N. gonorrhoeae PBP3 0.37 μMa 
 490 N. gonorrhoeae PBP4 34 μMa 
E. coli PBP5 16 μMa 
2 E. coli PBP5 13 μMa 117 
3 Actinomadura spp. 
R39 DD-
peptidase 32 nM






b  492,493 












 494 S. pneumoniae PBP1b 26 μMb 
S. pneumoniae 
R6 PBP2x 138 μM
b 




7 E coli PBP5 1.6 nMb 497 
 
Additional tetrahedral intermediate analogues synthesized by Pechenov et al. 
include peptidic and peptidomimetic aldehydes 8, α-trifluoromethyl ketones 9, and α-
chloromethyl ketones 10 490 (Figure 1.16). However, these analogues are less potent than 
their boronate parent compound (Ki values of 60 μM for both 8 and 9 against N. gonorrhoeae 
PBP3, no measurable inhibition by 10), and activated carbonyl analogues of other boronic 
acid R39 DD-peptidase inhibitors identified by Woon et al. were found to be inactive up to 1 
mM.493 These data indicate that creation of a potent activated carbonyl inhibitor may prove 
a futile effort. That said, Dzhekieva et al. hypothesized that attachment of a specific 
peptidoglycan fragment was key to inhibition and synthesized compound 11, a direct α-
trifluoroketone analogue of 3, with Ki values of 0.37 µM and 13.5 µM against Actinomadura 
R39 DD-peptidase and B. subtilis PBP4a, respectively.498 A crystal structure of 11 in complex 
with R39 DD-peptidase reveals a tetrahedral adduct with Oɣ of Ser49 and the oxygen from 











Figure 1.17: Crystal structures of activated carbonyl transpeptidase inhibitors in complex with their 
targets, showing their tetrahedral intermediate mimicry. A. Compound 11 (green) in complex with 


























































The chemically similar cyclobutanones were originally synthesized for their 
potential as β-lactamase or transpeptidase inhibitors, with the rationale that they, like the 
α-trifluoromethyl and α-chloro ketones, would be able to form a stable enzyme-bound 
hemiketal. However, several early studies failed to produce agents with any inhibitory 
activity against either β-lactamases or transpeptidases499,500 until Lowe & Swain reported 
the synthesis of compound 12, capable of inhibiting both E. coli R-TEM and B. cereus I, 
as well as Streptomyces R61 DD-peptidase.501 Later, the 7,7-dichloro compound 13 was 
also found to inhibit both β-lactamases and R61 DD-peptidase.502,503 Structural studies on 
factors influencing hemiketal formation have led to compound 14, 98% of which exists in 
the hemiketal state at equilibrium in methanol.504 In addition to structure-activity 
relationships showing a correlation of methyl hemiketal formation with activity, crystal 
structures with serine lactamase OXA-10 show their tetrahedral intermediate mimicry, with 
nucleophilic Ser67 bound covalently to C6 and the hemiketal oxygen occupying the 
oxyanion hole created by Ser67 and Phe208 505  (Figure 1.17B). With these new insights 
into the synthesis of more electrophilic cyclobutanone scaffolds, as well as definitive 
evidence of their hemiketal-based mechanism, perhaps this class can be approached for 
new attempts at harnessing their PBP-inhibitory potential. 
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Table 1.7: Activity of activated carbonyl compounds against bacterial transpeptidases. 
aThermodynamic equilibrium constant (Ki) unless indicated otherwise. bMeasured Ki divided by two 
under the assumption that one enantiomer is inactive.  
 
Compound Species Target Activitya Reference 
8 
N. gonorrhoeae PBP3 60 μM 
490 N. gonorrhoeae PBP4 >1 mM 
E coli PBP5 >1 mM 
9 
N. gonorrhoeae PBP3 60 μM 
490 N. gonorrhoeae PBP4 >1 mM 
E. coli PBP5 >1 mM 
10 
N. gonorrhoeae PBP3 ~1 mM 
490 N. gonorrhoeae PBP4 >1 mM 
E. coli PBP5 >1 mM 
11 Streptomyces spp. 
R61 DD-








B. subtilis PBP4a 13.5 μMb 
13 Streptomyces spp. 
R61 DD-
peptidase ~1 mM  502, 503 
 
The phosphonates are another structural class initially examined as inhibitors of 
serine proteases, and later expanded to β-lactamases and PBPs due the enzymes’ 
mechanistic similarities (Figure 1.18). Designed with the rationale that a phosphonate 
should form a tetrahedral adduct with the nucleophilic serine similar to that observed with 
boronic acids, the acetamidomethylphosphonate 15 was the first of its class to show 
potent inhibition of a β-lactamase, capable of phosphonylating Enterobacter cloacae P99 
at a rate of 1,120 M-1s-1.506 Equally impressive was the stability of the complex, which 
underwent regeneration of the apo-enzyme (k3) at a rate of 2.32×10-6 s-1. However, this 
molecule failed to inhibit Streptomyces R61 DD-peptidase, as did its retro-amide 
analogue.507  Soon after, a p-nitro analogue of this compound (16) was shown to be a 
weak inhibitor of R61 DD-peptidase (k2/Ki = 0.07 M-1s-1), giving credence to the idea of 







Figure 1.18: Structures of phosph(on)ate transpeptidase inhibitors. 
 
Since then, a great deal of work has been done to elucidate the basic inhibitory 
mechanisms of this class. First, the phosphoester substituent acts as a leaving group, as 
evidenced by the formation of stoichiometric quantities of alcohol upon β-lactamase 
inactivation. Moreover, good leaving group ability is key for the covalent reaction to 
proceed.509 This was further illustrated by experiments with phosphonamidates, which 
exhibited much slower rates due to the relative instability of deprotonated amines.510,511 
The rate-determining step for this subclass is the acquisition of a proton, a requirement 
that may limit their utility in the absence of a general acid catalyst.510 Proof of covalent 
adduct formation with β-lactamases was eventually obtained by electrospray mass 
spectrometry,512 and later crystal structures showed the formation of covalent complexes 
mimicking the β-lactam tetrahedral intermediate state.513-515 In a 2.0 Å structure of TEM-1 
in complex with 16, the nucleophilic Ser70 is phosphonylated by the inhibitor, the oxyanion 





























































and the p-nitrophenol leaving group has departed515 (Figure 1.19A). Other studies have 
examined structure-activity relationships of the alkyl side chain, demonstrating that the 
incorporation of an (acetamido)methyl group increases the rate of β-lactamase 
inactivation by 10,000-fold.511 Complementarity (in this case, mimicry of the β-lactam R1 
acylamino group) is, therefore, requisite for fast β-lactamase inactivation. Li et al. 
established, however, that a sulfonamidomethyl isostere is suitable.516 Compound 17 is 
not only an inhibitor of E. cloacae P99 (1.2×103 M-1s-1), but was also identified as another 





Figure 1.19: Crystal structures of phosph(on)ate transpeptidase inhibitors in complex with their 
targets, showing their tetrahedral intermediate mimicry. A. Compound 16 (green) in complex with 
β-lactamase TEM-1. B. Compound 18 (green) in complex with Streptomyces R61 DD-peptidase. C. 
Compound 19 (green) in complex with Streptomyces R61 DD-peptidase. 
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Cyclic phosphonates like 18,517 while demonstrating improvement compared to 
their acyclic analogues (R61 DD-peptidase k2/Ki = 0.46 M-1s-1), still suffer from a lack of 
potency. However, they offer the benefit of generating a stable ligand-enzyme complex. 
As with the β-lactams, when the leaving group is ejected upon reaction with the target, it 
remains tethered to the phosphonate and hinders hydrolysis of the resulting complex (R61 
DD-peptidase k3 = 3.4×10-5 s-1). A phosphonate analogue of 18 was found to inactivate the 
E. cloacae P99 β-lactamase more rapidly (k2/Ki = 9.8×103 M-1s-1 versus 6.7×103 M-1s-1), 
albeit with a faster off-rate (k3 = 9.8×10-2 s-1 versus 1.1×10-3 s-1), but its activity against 
transpeptidases was never reported.518 Further derivatization of salicyloyl phosphate and 
cyclic benzoyl phosphonate led to compounds capable of inactivating P99 at rates of over 
104 M-1s-1,519 but only compound 19 was tested against transpeptidases. Its inactivation 
rate against Streptomyces R61 DD-peptidase was measured to be 24 M-1s-1 (k3 = 8.9×10-
5 s-1), a 50- to 400-fold improvement over previous phosphonates for which inhibition data 
is available.520 Crystal structures of 18 and 19 in complex with R61 DD-peptidase confirm 
tetrahedral intermediate mimicry, showing phosphonylation of nucleophilic Ser62, as well 
as occupancy of the oxyanion hole created by Ser62 and T301 by the anionic oxygen520 
(Figure 1.19B & C). The emergence of salicyloyl phosphate and cyclic benzoyl 
phosphonates led to the pursuit of acyl and diacyl phosph(on)ates as inhibitors of β-
lactam-recognizing enzymes.521-527 In general, these compounds are poor substrates of 
both β-lactamases and DD-peptidases, with low enough turnover to be considered 
irreversible inhibitors.521,528 Among these, benzoyl phosphonate 20 was identified as a 
poor inhibitor of transpeptidase activity, exhibiting a rate of inactivation of 0.005 M-1s-1 
against R61 DD-peptidase.528 Additional variations of the phosphonate have been 
attempted for β-lactamase inhibition, including mercaptophosphonates,529.530 2-aryl-2-
(methoxyimino)acetylamino phosphonates,531 but no activity data against transpeptidases 
is available for these scaffolds. 
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Other phosphonate and phosphate analogues take advantage of the moiety as an 
electrostatic anchor rather than an electrophilic center. The potential for acylation by acyl 
phosphonates was leveraged with the development of electron withdrawn 
ketophosphonates.532,533 While these molecules inhibited β-lactamases, no evidence was 
found for the formation of a covalent tetrahedral adduct. Moreover, no substantial inhibition 
of R61 DD-peptidase was seen. Inhibition of β-lactam-recognizing enzymes by citrate and 
isocitrate and their amino derivatives,534,535 as well as high-occupancy crystal structures 
showing their binding in the active sites of β-lactamases,534,536 led to the synthesis and 
testing of a series of phosphonic acid isosteres.535 One such compound, 21, is a 
bioisostere of aminocitrate that exhibits 53% inhibition of Actinomadura R39 DD-peptidase 
at 500 μM. Naturally occurring phosphates, including guanosine monophosphate and 
inosine monophosphate, are reported micromolar inhibitors of β-lactamases as well, but 
no data is available on potential transpeptidase inhibition.537 Phosphate analogues of 
active boronic acids synthesized by Woon et al. have also shown little inhibitory potency, 
with the most active (22) showing 35% inhibition of R39 DD-peptidase at 1 mM.493 
Dzhekieva et al. have had similar results, with the direct phosphate analogue of boronic 
acid 3 and α-trifluoroketone 11 showing no inhibition of R39 DD-peptidase up to 2 mM.498 
Heterocyclic methylphosphates have also shown promise as inhibitors of β-
lactamases,538,539 but no data on transpeptidase inhibition have been reported. 
Overall, while synthesized molecules of this class have shown promise in the 
inhibition of β-lactamases, all attempts to date have yielded quite poor inhibitors of 
transpeptidases. Most compounds of these classes suffer from a slow on-rate, a major 
determinant of covalent inhibitors’ potency, and a need for additional derivatization to 
increase complementarity with the transpeptidase active site. However, their properties as 
electrophiles allow them to inhibit both serine- and metallo-β-lactamases as well as PBPs, 
opening possibilities for the development of dual inhibitors. 
 60 
Table 1.8: Activity of phosphate and phosphonate compounds against bacterial transpeptidases. 
aSecond-order rate of reaction with the target (k2/Ki). bPercent inhibition of target activity at 500 µM. 
cPercent inhibition of target activity at 1 mM. 
 
Compound Species Target Activity Reference 
16 Streptomyces spp. 
R61 DD-
peptidase 0.07 M
-1s-1 a 508 
17 Streptomyces spp. 
R61 DD-
peptidase 0.06 M
-1s-1 a 511 
18 Streptomyces spp. 
R61 DD-
peptidase 0.46 M
-1s-1 a 517 
19 Streptomyces spp. 
R61 DD-
peptidase 24 M
-1s-1 a 520 
20 Streptomyces spp. 
R61 DD-
peptidase 0.005 M
-1s-1 a 528 









1.5.b. β-lactam mimics 
Other inhibitory chemotypes rely on mimicry of the substrate in a manner similar 
to the β-lactams, frequently through acylation of the target by an activated carbonyl 
electrophile (Figure 1.20). The first ɣ-lactam-based PBP inhibitors were attempted shortly 
after the discovery of penicillin. These molecules were close analogues of penams, such 
as penicillin G, but showed neither antimicrobial activity nor hydrolysis in aqueous 
solution.540-542 This lack of success continued with a variety of monobactam, penam, 
oxapenam, and carbapenam derivatives failing to show any antimicrobial activity.543-546 
It was known at the time that a bicyclic β-lactam’s ability to acylate its target is, in 
part, due to disrupted amide resonance, and that one valuable measurement of this 
disruption is the pyramidalization of the lactam nitrogen.154-162  In computational studies, 
1-azabicyclo[3.2.0]heptane systems were predicted to have high degrees of N-
pyramidalization; however, synthesized molecules of this scaffold still failed to exhibit any 
appreciable antimicrobial activity.547,548 It was not until the introduction of the 2-oxo-1-
azabicyclo[3.2.0]hept-6-enes (23), which combine a high degree of bicyclic strain with a 
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competing enamine resonance also known to contribute to amide destabilization,155,159,215 
that the ɣ-lactam class gained traction as antimicrobials.549 Subsequent penem and 
carbapenem derivatives (24 & 25), which incorporate the resonant olefin into less strained 
systems, also showed marginal antimicrobial activity with limited spectrum, indicating that 
for the ɣ-lactam to have utility as a potent PBP-acylating scaffold, additional activation of 
the ring system would likely be required.550-553  
Much of the work that followed was conducted to determine structure-activity 
relationships for the class. With the diminished carbonyl electrophilicity seen in ɣ-lactams 
compared to β-lactams, affinity for the transpeptidase active site becomes a much more 
critical aspect of target binding and biological activity. While penems and carbapenems 
lacking an acylamino group still possess antimicrobial activity, their ɣ-lactam analogues 
generally do not.554 Further computational studies examined the optimal placement and 
stereochemistry of the acylamino side chain, determining that 7R-substitution provides the 
most morphological resemblance to the β-lactams (Figure 1.21). These analyses also 
suggested that, like cephalosporins, the bicyclic olefinic ɣ-lactams can be activated by 
long-range electron-withdrawing inductive effects at the C3 position. The relationship 
between biological activity and the C3-substituent is supported by the increased potency 
of compounds possessing cyano, carboxylic, and sulfonyl moieties compared to those 





























































































































Figure 1.21: Structural alignments of ɣ-lactams with penicillin G. A. Alignment of penicillin G (grey) 
with ɣ-lactams 24 (magenta) and 25 (lime), showing good agreement of key features. B. Alignment 
of penicillin G with the 7S stereoisomer ɣ-lactam 24. There is still good agreement between 
features, consistent with the activity of both stereoisomers. C. Alignment of penicillin G with an 
inactive 1H-pyrrole-2,3-dione derivative. The inactivity of this scaffold suggests that the 3-oxo group 
projects into space unfavorable for productive binding to the transpeptidase active site. D. 
Alignment of penicillin G with pyrazolidin-5-one 27, showing retention of feature agreement from 
24, but with a more activated ring system. E. Alignment of penicillin G with an inactive δ-lactam 
derivative. The inactivity of this scaffold suggests that the larger, more flexible ring system group 
presents conformational uncertainty and projects into space unfavorable for productive binding to 
the transpeptidase active site. 
 
 
 Parallel efforts to increase the reactivity of the β-lactam ring itself led to the 
syntheses of 1,2-diazetidin-3-ones.556,557 The resulting scaffolds were too successful, 
however, because they lacked the stability to be useful in drug-like molecules. Seeing this 
work, and recognizing a need for more reactivity in the ɣ-lactam ring system, Jungheim et 
al. designed and synthesized a series of bicyclic pyrazolidin-5-ones (26) that, despite a 
bulky and ill-positioned gem-dimethyl group, exhibited good antimicrobial activity.558 
Development of novel synthetic schema, in combination with the structure-activity 
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relationship data available for ɣ-lactam derivatives of penems and carbapenems, allowed 
derivatization of this class to yield highly biologically active compounds 27 and 28.559-566 
Compound 27 exhibits good spectrum, and decreases cell wall synthesis and crosslinking 
without effects on the synthesis of other macromolecules. It binds E. coli PBP3 at 
concentrations as low as 0.1 µg/mL.567 Compound 28 has antimicrobial activity against a 
variety of Gram positive and Gram negative species, and exhibits high potency against E. 
coli PBP3 as well (IC50 = 0.25 µg/mL).568,569  
Further exploration of structure-activity relationships in this active scaffold has led 
to very few positive results. Modifications at C7 based on the 6R-hydroxyethyl side chain 
of carbapenems led to a reduction in activity,570 as did expansion to a more cephem-like 
[4.3.0] bicyclic system.566,571,572 Notably, removal of the C7 substituent altogether 
decreases antimicrobial potency but does not abolish it entirely.573  Monocyclic pyrazolidin-
5-ones suffer from a similar lack of potency.574 That these C7-unsubstituted and 
monocyclic pyrazolidin-5-ones retain antimicrobial activity while their monoaza analogues 
do not, indicates the marked activation of this scaffold, and demonstrates its promise in 
the development of PBP-acylating antimicrobials. 
Other attempts have been made to activate ɣ-lactam ring systems, including the 
introduction of electron-withdrawing groups to the ring itself. Synthesis of bicyclic 1H-
pyrrole-2,3-diones showed adduct formation with methanol, indicating successful 
activation and potential for PBP acylation;575 however, these compounds lack 
antimicrobial activity, and fit poorly into the transpeptidase active site (Figure 1.21). Other 
groups have surveyed additional ring strain through the synthesis of bridged ɣ-lactams. 
To this end, the 7-oxo-1-azabicyclo[3.2.1]oct-2-ene 29 was synthesized.576 The compound 
has an IC50 of 5 μM against both PBP3 and PBP4 of P. aeruginosa and exhibits modest 
antimicrobial activity against a variety of species. 
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In kinetics studies to determine which other cyclic amides, if any, hold promise in 
transpeptidase or serine protease acylation, hydrolysis of monocyclic lactams was 
measured to determine reactivity with nucleophiles. Surprisingly, δ-valerolactam 
underwent alkaline hydrolysis at a rate almost equivalent to that of β-propiolactam 
(second-order rate constants of 1.21×10-4 M-1s-1 and 2.37×10-4 M-1s-1, respectively), while 
all other ring sizes were 40- to 1,700-fold less reactive.577 However, early syntheses of 
direct δ-lactam penam analogues yielded no biological activity.578 Even in the context of 
the activated diaza scaffold discussed above, δ-lactams failed to show much potency 
despite high pseudo-first order rates of alkaline hydrolysis (k = 8.8×10-4 s-1).569 Through 
computational modeling and structural alignment of the synthesized compounds with 
known actives, it was concluded that the disparity between chemical reactivity and 
biological activity could be explained by three factors unique to the larger ring system that 
decrease productive binding to the transpeptidase active site: 1) the spatial arrangement 
of the acylamino side chain, 2) additional steric bulk, and 3) increased conformational 
freedom (Figure 1.21).  
 
Table 1.9: Activity of ɣ-lactams against bacterial transpeptidases. aHalf-maximal inhibitory 
concentration (IC50). bApproximation from PBP-binding shown for isolated membrane proteins.  
 
Compound Species Target Activitya Reference 
27 E. coli PBP3 ~1.5 μg/mLb 567 
28 E. coli PBP3 0.25 μg/mL 569 





Lactivicin (30), a cycloserine- and ɣ-lactone-containing natural product, has also 
been shown to inhibit a variety of PBPs at micromolar concentrations579 (Figure 1.22). It 
is highly active against Gram positive organisms, but its modest Gram negative activity 
revealed a need for derivatization. Early analogues employing acylamino side chains 
similar to third-generation cephalosporins (31) exhibited improved antimicrobial spectrum, 
likely due to enhanced outer membrane permeability, as well as improved interactions 
with the transpeptidase active site.580,581 Improved target inhibition by such modifications 
was later shown by phenoxylacetyl lactivicin 32, an analogue of penicillin V, which is 6- 
and 40-fold more potent against two different S. pneumoniae PBP2x variants than the 
parent compound.582 Further attempts to extend spectrum involved the use of specific, 
charged acylamino side chains employed in antipseudomonal cephalosporins. Compound 
33, which shares an acylamino group with ceftazidime, shows both increased potency 
against Gram negatives and enhanced inhibition of pseudomonal PBPs.583 Conjugation of 
this molecule to siderophoric 4,5-dihydroxyphthalimide (compound 34) improves its 
uptake into Gram negative bacilli without negatively affecting target inhibition, enhancing 
its antimicrobial activity by as much as 500-fold.583.584 
Through mechanistic studies conducted by Macheboeuf et al., it is now known that 
the lactivicins inhibit PBPs covalently via an acylation reaction distinct from β-lactams.582 
In a crystal structure of lactivicin in complex with S. pneumoniae PBP1b, Oɣ of nucleophilic 
Ser460 has formed a covalent bond with the cycloserine carbonyl carbon, causing the 
cycloserine ring to open and, by resonance, the ɣ-lactam as well (Figure 1.23). The 
oxygen of the resulting ester carbonyl is located in the oxyanion hole formed by Ser460 
and Thr654. The ɣ-lactone ɣ-carboxylate group makes polar contacts with the side chains 
of Thr652 (KTG) and Thr654, and the carbonyl oxygen of the cycloserine N-acetyl group 
contacts Asn518 (SxN). The structure has marked similarities with a PBP1b-cefotaxime 
acyl-enzyme structure,585 indicating a similarity of precovalent binding mode that allows 
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the acylation reactions to proceed. Like β-lactams, lactivicins probably act as C-terminal 
peptidomimetics, where the ɣ-lactone ɣ-carboxylate acts as the C-terminus, an 
electrostatic anchor that helps to position the electrophilic carbonyl for attack by the serine 
nucleophile, while the acetylamino group aids in complex formation by mimicking the 
peptide bond of a third amino acid.  
The reactivity of the lactivicin cycloserine (4-aminoisoxazolidin-3-one) moiety has 
led to the exploration of novel isoxazolidin-5-one compounds. While several of the initial 
compounds to come out of this work, including 35, had only marginal antimicrobial activity, 
they readily formed adducts with methanol, showing that they are reactive to nucleophilic 
species.586 It should be noted that many of these molecules are esterified and would likely 
be manifold more potent as carboxylic acids. Cao et al. subsequently designed and 
synthesized a series of 3-alkoxyisoxazolidin-5-ones possessing carboxylic acid moieties 
in accordance with the geometric requirements established for transpeptidase inhibition 
by β-lactams.587 These compounds represent a significant improvement over earlier 
efforts, with the 3-isopropoxyisoxazolidin-5-one 36 inhibiting B. subtilis growth at 0.2 
µg/mL. Target inhibition was confirmed via spectroscopic PBP labeling with a dansylated 




















































































































































Figure 1.23: Crystal structure of lactivicin in complex with S. pneumoniae PBP1b. A. Lactivicin 
(LTV, green) covalently bound in the transpeptidase active site of PBP1b. B. Overlay of covalently 
bound cefotaxime with lactivicin. C. Detailed view of lactivicin interactions (polar contacts are shown 





Table 1.10: Activity of lactivicins against bacterial transpeptidases. aHalf-maximal inhibitory 
concentration (IC50) unless otherwise denoted. bSecond-order acylation rate constant (k2/Ks).  
 
Compound Species Target Activitya Reference 
30 
B. subtilis PBP1 0.28 μg/mL 
579 
B. subtilis PBP2 1.0 μg/mL 
B. subtilis PBP3 12 μg/mL 
B. subtilis PBP4 0.05 μg/mL 
E. coli PBP1a 5.0 μg/mL 
E. coli PBP1b 14 μg/mL 
E. coli PBP2 22 μg/mL 
S. pneumoniae R6 PBP2x 380 M-1s-1 b 582 S. pneumoniae 5204 PBP2x 0.6 M-1s-1 b 
32 S. pneumoniae R6 PBP2x 2,150 M
-1s-1 b 582 S. pneumoniae 5204 PBP2x 25 M-1s-1 b 
33 
P. aeruginosa PBP1a 0.046 μM 
583 P. aeruginosa PBP1b 1.23 μM P. aeruginosa PBP2 33.3 μM 
P. aeruginosa PBP3 0.092 μM 
34 
P. aeruginosa PBP1a 0.03 μM 
583 P. aeruginosa PBP1b 0.27 μM P. aeruginosa PBP2 3.7 μM 
P. aeruginosa PBP3 0.046 μM 
 
A more recently identified class of β-lactam-mimicking compounds is the 1,6-
diazabicyclo[3.2.1]octan-7-ones (DBO), which possess a 5-membered diazacyclic system 
resembling that seen in pyrazolidinones 26-28 discussed above, as well as a bridged 
structure similar to 29 (Figure 1.24). The DBO carbonyl is activated by a disruption of urea 
resonance caused by geometric constraints of the bicyclic system on the bridgehead 
nitrogen side, and by an electron-withdrawing inductive effect on the N-sulfonic acid side, 
as shown in the prototypical compound NXL104 (avibactam, 35). Avibactam was originally 
developed as a covalent β-lactamase inhibitor with a fast on-rate (k2/Ki > 104 M-1s-1) 
against a variety of classes, as well as a slow off-rate (k3 < 10-3 s-1).588-591 Early crystal 
structures of avibactam with serine β-lactamases show carbamoylation of the serine 
nucleophile and occupancy of the oxyanion hole by the carbonyl oxygen.590,592-594 Unlike 
other β-lactamase inhibitors, however, avibactam exhibits intrinsic antimicrobial 
activity.595,596 In subsequent investigations of this activity, it was found to bind PBPs with 
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low- to mid-micromolar affinity, with a notable preference for PBP2 from a variety of 
species.597,598 From these data, the DBO scaffold has become a jumping off point for one 
of the first successful ventures into dual inhibition.  
Many derivatization efforts have focused on modification of the avibactam 2-
carbamoyl moiety. Synthesis and testing of direct N-alkyl and N-aryl derivatives was 
reported by Blizzard et al., who explored a series of carbocyclic and heterocyclic 
substitutions.599 Interestingly, N-(pyridin-2-yl) compounds exhibited nanomolar inhibition 
of class A, C, and D β-lactamases, but they failed to show much synergy with 
carbapenems against resistant Gram negative bacilli. The best synergy results were 
obtained with N-(pyrrolidin-3-yl) and N-(piperidin-4-yl) analogues, the latter of which has 
been pursued as MK7655 (relebactam, 36). While relebactam’s carbapenem-potentiating 
effects are well documented,600-603 it has relatively weak intrinsic antimicrobial activity,604 
and its PBP-binding profile has not been characterized. Further investigations of the 2-
carbamoyl group led to the N-alkoxycarboxamides FPI1459 (nacubactam, 37) and 
FPI1465 (38).  Nacubactam is an N-(2-aminoethoxy) derivative with potent β-lactamase 
inhibition and better intrinsic antimicrobial activity than either avibactam or relebactam 
against a variety of problematic Gram negative species.605 In keeping with its improved 
intrinsic activity, it also inhibits E. coli PBP2 more potently than avibactam, with an IC50 of 
0.12 μg/mL. FPI1465 is a ring-constrained N-(pyrrolidin-3-yloxy) analogue of nacubactam 
with similar antimicrobial activity.606 Although its reported IC50 against E. coli PBP2 is 
higher than that reported for nacubactam, the enzymatic assays reported by King et al. 
were done under conditions of simultaneous addition rather than preincubation. 
Comparing results from similar techniques, both compounds represent an ~5-fold 
improvement over avibactam. A 2.9 Å crystal structure of FPI1465 in complex with E. coli 
PBP1b reveals marked similarities between the PBP binding modes of DBOs and β-
lactams606 (Figure 1.25). The nucleophilic Ser510 is carbamoylated, and the ligand 
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carbonyl oxygen occupies the oxyanion hole created by Ser510 and Thr701. The sulfonic 
acid makes polar contacts with Thr699 (KTG) and Thr701, similar to what is seen in 
complex structures of aztreonam, ampicillin, and cephalexin, and it is also within hydrogen 
bonding distance of Ser572 (SxN).607 Neither the FPI1465 2-carbamoyl group nor the 
aztreonam C3 acylamino group contact Asn574 (SxN), a common point of interaction with 
6-acylamino and 7-acylamino groups of penams and cephems, respectively. A final 
subclass arising from modifications to the 2-carbamoyl group are the diacylhydrazines 
FPI1523 (39), FPI1602 (40), WCK5153 (41), and WCK5107 (zidebactam, 42). FPI1523 is 
a simple acetyl derivative with 20-fold better E. coli PBP2 inhibition than avibactam, as 
well as 8- to 16-fold better antimicrobial activity against E. coli transformed with a variety 
of β-lactamases.606 FPI1602, WCK5153, and zidebactam are a series of nitrogen 
heterocycle-substituted acyl hydrazines of increasing ring size. Of the compounds 
reported by King et al., FPI1602 is the most potent single agent antimicrobial, with MICs 
less than 0.5 μg/mL against E. coli transformed with a variety of β-lactamases and good 
activity against NDM-1-producing clinical isolates of E. coli and E. cloacae.606 It exhibits 
E. coli PBP2 inhibition similar to FPI1523. WCK5153 and zidebactam have been 
characterized largely for their considerable antipseudomonal properties.608 They exhibit 
submicromolar inhibition of P. aeruginosa PBP2, as well as antimicrobial activity against 
even metallo-β-lactamase-producing strains. While they are potent inhibitors of PBP2 from 
K. pneumoniae and A. baumanii as well, WCK5153 and zidebactam are only capable of 
























































































































































































Figure 1.25: Crystal structure of DBO FP1465 in complex with E. coli PBP1b. A. FPI1465 
covalently bound in the transpeptidase active site of PBP1b. B. Overlay of covalently bound 





Other groups have explored the chemistry of the 3- and 4-positions. One such 
example is ETX2514/durlobactam (43), a 3-unsaturated 3-methyl analogue of avibactam. 
Durlobactam shows good antimicrobial activity against a series of Gram negative bacilli, 
including K. pneumoniae and S. maltophila.612 However, despite its relatively rapid 
carbamoylation of A. baumanii PBP2 and its marked potentiation of carbapenem and 
sulbactam activity against metallo-β-lactamase-producing strains, durlobactam does not 
have significant intrinsic anti-acinetobacter activity itself.612,613 Durlobactam is a poor 
antipseudomonal agent, perhaps due to its poor carbamoylation of P. aeruginosa PBPs.  
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Additional 3-unsaturated DBOs include 2-decarbamoyl 4-(oxazol-4-yl) product 
CPD3 (44) and its 2-aminomethyl analogue CPD4 (45). In this work, Levy et al. explored 
a series of 4-substituted analogues and found that, with few exceptions, those with a 4-
heterocyclic moiety are more potent than the unsubstituted parent compound.614 CPD3 
and CPD4 are both nanomolar E. coli PBP2 inhibitors, but addition of the aminomethyl 
group seen in CPD4 improves its antimicrobial potency considerably, making it among the 
most intrinsically active of the DBOs reported to-date (mean MIC values of 0.031 μg/mL 
and 1 μg/mL against E. coli and P. aeruginosa clinical isolates, respectively). Fused 
pyrazolo[3,4-e] (NXL105, 46) and oxazolo[4,5-e] (47) products and derivatives show 
intrinsic activity against E. coli and a series of P. aeruginosa strains, but no further reports 
of spectrum or PBP inhibition could be found.615-618 However, resistance to these 
compounds in E. coli has been ascribed to mutations in the mrdA gene encoding PBP2, 
indicating significant binding in susceptible strains.615 ETX1317 (48) occupies unique 
chemical space, with a 2-fluoroacetic acid in place of the sulfonic acid seen in other DBOs. 
ETX1317 has potent intrinsic antimicrobial activity, with a median MIC of 0.25 μg/mL 
against a panel of 1,875 clinical isolates of Gram negative enterics, and has been shown 
to bind E. coli PBP2 from membrane preparations.619 
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Table 1.11: Activity of DBOs against bacterial transpeptidases. aHalf-maximal inhibitory 
concentration (IC50) unless otherwise denoted. bConducted with simultaneous addition of inhibitor 
and substrate, as opposed to an inhibitor preincubation period usually used for IC50 measurements. 
cSecond-order carbamoylation rate constant (k2/Ks). 
 
Compound Species Target Activitya Reference 
35 
E. coli PBP2 0.92 μg/mL 
597 
P. aeruginosa PBP2 1.1 μg/mL 
P. aeruginosa PBP3 1.8 μg/mL 
P. aeruginosa PBP4 11 μg/mL 
H. influenza PBP2 3.0 μg/mL 
S. pneumoniae PBP3 8.1 μg/mL 
S. aureus PBP2 51 μg/mL 
S. aureus PBP3 156 μg/mL 
E. coli PBP2 0.59 μM 614 
E. coli PBP2 63 μMb 606 
K. pneumoniae PBP2 2 μg/mL 598 
37 E. coli PBP2 0.12 μg/mL 605 
38 E. coli PBP2 14.8 μMb 606 
39 E. coli PBP2 3.2 μMb 606 
40 E. coli PBP2 3.6 μMb 606 
41 
P. aeruginosa PBP2 0.14 μg/mL 608 
A. baumanii PBP2 0.01 μg/mL 609 
K. pneumoniae PBP2 0.07 μg/mL 610 
42 
P. aeruginosa PBP2 0.26 μg/mL 608 
A. baumanii PBP2 0.01 μg/mL 609 
K. pneumoniae PBP2 0.08 μg/mL 610 
43 
A. baumanii PBP1a 180 M-1s-1 b 
612 
A. baumanii PBP2 1,800 M-1s-1 b 
A. baumanii PBP3 3.37 M-1s-1 b 
P. aeruginosa PBP1a 12 M-1s-1 b 
P. aeruginosa PBP2 24.3 M-1s-1 b 
P. aeruginosa PBP3 60 M-1s-1 b 
E. coli PBP1a 120 M-1s-1 b 
E. coli PBP2 17,000 M-1s-1 b 
E. coli PBP3 2.3 M-1s-1 b 
44 E. coli PBP2 25 nM 614 





1.5.c. Other reactive (presumed covalent) inhibitors 
There are several identified PBP inhibitors that possess functional groups reactive 
to nucleophiles, but which have not been fully characterized as covalent in mechanism. 
Two such classes are the arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-
ones, identified as inhibitory scaffolds in a high-throughput screen and subsequently 
derivatized to yield 49 and 50 620 (Figure 1.26). These compounds exhibit single-digit 
micromolar inhibition of S. aureus PBP2a and are active against a series of diverse 
transpeptidases, including S. pneumoniae PBP2x, E. coli PBP3, E. coli PBP5, 
Streptomyces R61 DD-peptidase, and Actinomadura R39 DD-peptidase. They were also 
shown to inhibit growth of several pathogens and confirmed to inhibit cell wall synthesis in 
[3H]-glycine incorporation assays. Arylalkylidene rhodanine 51 was identified in a high-
throughput screen, this time against PBP2 of N. gonorrhoeae.621 This compound was 
found to have much more potent antimicrobial activity (2 µg/mL) than expected from its 
modest target inhibition (153 µM), suggesting potential off-target effects. The 
arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones contain an electron 
withdrawing olefin motif that can act as a Michael acceptor, and the former have been 
shown to bind covalently to cysteine residues through nucleophilic attack by the side chain 
thiol.622 Moreover, they have been found to inhibit S. pneumoniae PBP2x 
noncompetitively.620 These molecules may, therefore, bind to the activated serine 
nucleophile of transpeptidases through a similar mechanism (Figure 1.27). The 
arylalkylidene rhodanine structure is considered a pan-assay interference (PAIN) 
compound substructure, but because derivatization can result in high selectivity for a given 























































Table 1.12: Activity of arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones against 
bacterial transpeptidases. aHalf-maximal inhibitory concentration (IC50). bPercent inhibition at 50 
µM. cPercent inhibition at 100 µM. 
 
Compound Species Target Activity Reference 
49 
S. aureus PBP2a 5 µMa 
620 
S. pneumoniae PBP2x, S 96%b 
S, pneumoniae PBP2x, R 90% c 
E. coli PBP3 87% b 
E. coli PBP5 94% b 
Streptomyces spp. R61 DD-peptidase 75%
 b 
Actinomadura spp. R39 DD-peptidase 95%
 b 
50 
S. aureus PBP2a 9 µMa 
620 
S. pneumoniae PBP2x, S 31% b 
S, pneumoniae PBP2x, R 90%c 
E. coli PBP3 86% b 
E. coli PBP5 83% b 
Streptomyces spp. R61 DD-peptidase 44%
 b 
Actinomadura spp. R39 DD-peptidase 55%
 b 
51 N. gonorrhoeae PBP2 153 µMa 621 
 
1.5.d. Noncovalent inhibitors 
Physical screening of molecules against PBPs has resulted in the discovery and 
development of many classes of noncovalent inhibitors, but very few have been pursued 
for optimization and development into preclinical leads. Some initial hits were found 
serendipitously in the course of other experiments, followed by more purposeful physical 
screening (Figure 1.28). In early studies of S. aureus PBP2a, it was noted that 
chromatographic stationary phase Cibacron blue (52) bound the protein tightly, such that 
it would not elute upon introduction of a salt gradient.624 Subsequent testing of Cibacron 
blue revealed that it is a mid-micromolar inhibitor of PBP2a, and screening of chemically 
similar compounds from a Merck collection allowed the identification of the more potent 
Erie yellow (53), which exhibits an IC50 of 13 µM. No antimicrobial data was reported for 
these hits, however. In another study, a PBP inhibitor was found by testing a hit from 
screens against a different enzyme. Physical screening of a cyclic heptapeptide 
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bacteriophage display library revealed 54 to inhibit activity of a synthetic catalytic antibody 
with β-lactamase-like activity.625 During biochemical characterization, 54 was found to 
inhibit TEM-1, as well as several high- and low-molecular weight PBPs to varying 
degrees.626 Although this scaffold was subject to some minor derivatization, the β-
lactamases were the primary focus of this work, and none of the analogues were tested 
























































Focused physical screening with the aim of discovering more drug-like small 
molecule PBP inhibitors followed these initial ventures (Figure 1.29). One class of such 
inhibitors was identified from small parallel physical screens against MRSA PBP2a, 
Streptococcus pneumoniae PBP2x, and Enterococcus faecium PBP5.627 The screen and 
subsequent analogue search, synthesis, and testing identified anthranilic acid-derived 
arylsulfonamides and their isosteric arylamide derivatives as mid- to high-micromolar 
inhibitors of the tested PBPs.627,628 The most potent inhibitors from each scaffold, 55 and 
56, exhibit half-maximal inhibition of MRSA PBP2a at 80 µM and 210 µM, respectively. 
Both compounds show only marginal suppression of staphylococcal growth, however. 
Shortly thereafter, high-throughput screening of a 50,000-compound library from the 
ChemBridge Corporation identified a number of compounds that exhibit activity against N. 
gonorrhoeae PBP2 in the micromolar range.621 While a few of the compounds from this 
study possess functional groups concerning for nonspecific binding (e.g., arylalkylidene 
rhodanine 51 above), arylsulfonamides 57 and 58 are promising hits, exhibiting half-
maximal inhibition of PBP2 at 50 µM and 56 µM, respectively, as well as comparable 
activities against penicillin-susceptible and -resistant strains of N. gonorrhoeae (MIC = 8-
16 µg/mL).621  
Screening for antimicrobial natural products has also successfully identified PBP-
inhibitory compounds. The endophytic fungus Aspergillus TJ23 was found to inhibit the 
growth of ATCC43300 (MRSA) in vitro.629 Subsequent separation of liquid culture 
components yielded the active species 59, a meroterpenoid metabolite with a 
dioxabicyclo[2.2.1]heptane skeleton. This compound, named aspermerodione, inhibits 




Figure 1.29: Structures of transpeptidase inhibitors identified through physical screening methods. 
 
In addition to physical screening, in silico tools have also been utilized for PBP 
drug discovery because this approach forgoes the need for large physical libraries, a high-
throughput transpeptidase assay or liquid handling robot, or large repositories of natural 
product sources (Figure 1.30). One early study employed a four-point pharmacophore 
model to conduct a high-throughput virtual screen of the NCI database (~260,000 ligands) 
against S. pneumoniae PBP2x.630 The screen successfully identified 2-((1,3,4-thiadiazol-
2-yl)amino)benzenesulfonic acid 60 and 2-ureidobenzenesulfonic acids 60 and 61 as 
inhibitors of PBP2x. While 61 and 62 show similar potency against PBP2x from penicillin-
resistant S. pneumoniae 5204 (IC50 = 71 µM and 72 µM, respectively), 62 shows 































In another study, a fragment-based docking protocol was used against the active 
site of E. coli PBP5.631 The computational analysis revealed the 4-quinolone scaffold as a 
putative binder of the active site, and upon synthesis of derivatized 4-quinolones, several 
were shown to inhibit high molecular weight PBPs of E. coli at mid-micromolar 
concentrations. While the best inhibitor reported, 63, demonstrates affinity for every PBP 
from E. coli, this compound showed no suppression of E. coli growth up to 1 mM.  
Among the most successful noncovalent PBP inhibitors discovered to date are the 
1,2,4-oxadiazoles (Figure 1.30). The prototype of this class, 64, was identified from a 
high-throughput virtual screen of the ZINC database against MRSA PBP2a, with energy 
scoring performed by four separate algorithms.632 The hydroxyl derivative 65 is a 
micromolar-range inhibitor of PBP2a with antimicrobial activity against a series of Gram 
positive organisms (MIC = 1-2 µg/mL against a series of staphylococci and enterococci). 
The compound was also observed to be on-target, inhibiting [3H]-alanine incorporation into 
peptidoglycan without effects on the synthesis of protein or polynucleotides. From 
extensive exploration of the scaffold through medicinal chemistry, 66 has emerged as a 
promising antimicrobial candidate, exhibiting favorable pharmacokinetic properties as well 
as efficacy in a murine model of staphylococcal peritonitis.633-635 While the 1,2,4-
oxadiazoles have excellent activity against staphylococci and other Gram positives,634-636 
no antimicrobial data against Gram negative organisms has been published. Additional 
computational work has been done to determine quantitative structure-activity 
relationships (QSAR) for the class using comparative molecular field analysis (CoMFA), 
comparative molecular similarity indices analysis (CoMSIA), and field-based 3D-QSAR, 































































While many of the noncovalent PBP inhibitors mentioned here are in need of 
additional testing and medicinal chemistry to achieve standards of potency and selectivity 
required of a preclinical lead, these studies suggest that novel classes of PBP-targeted 
drugs may provide a workable route toward antimicrobials that 1) circumvent the changes 
associated with resistance that affect β-lactam binding, and 2) proactively avoid the 
potential issue of ESBL acquisition by N. gonorrhoeae. Moreover, because there are so 
few examples of successful compounds from which to draw, this is an area of need in 
antigonococcal therapeutic discovery.  
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Table 1.13: Activity of noncovalent inhibitors against bacterial transpeptidases. aHalf-maximal 
inhibitory concentration (IC50) unless otherwise noted. bPercent inhibition at 1 mM. 
cThermodynamic equilibrium constant (Ki) 
 
Compound Species Target Activitya Reference 
52 S. aureus PBP2a 24 µM 624 
53 S. aureus PBP2a 13 µM 624 
54 
E. coli PBP1b 28.6 µM 
626 
E. coli PBP3 62.5 µM 
E. coli PBP5 6.3 µM 
E. faecium PBP5 21.6 µM 
Streptomyces spp. R61 DD-peptidase 26.8 µM 
55 
S. aureus PBP2a 80 µM 
 628 E. faecium PBP5 0%b 
S. pneumoniae PBP1b 60%b 
56 
S. aureus PBP2a 210 µM 
627 E. faecium PBP5 32%b 
S. pneumoniae 5204 PBP2x 59%b 
57 N. gonorrhoeae PBP2 50 µM 621 
58 N. gonorrhoeae PBP2 56 µM 621 
59 S. aureus PBP2a 18.4 µM 629 
60 S. pneumoniae 5204 PBP2x 219 µM 630 
61 
S. pneumoniae 5204 PBP2x 71 µM 
630 S. pneumoniae R6 PBP2x 336 µM 
S. pneumoniae PBP1b 259 µM 
62 
S. pneumoniae 5204 PBP2x 72 µM 
630 S. pneumoniae R6 PBP2x 255 µM 
S. pneumoniae PBP1b 88 µM 
63 
E. coli PBP1a/1b 27 µMc 
631 
E. coli PBP2 26 µMc 
E. coli PBP3 27 µMc 
E. coli PBP4 4.8 µMc 
E. coli PBP5/6 220 µMc 





1.6. Goal and Significance  
With the emergence and spread of multi-drug resistant strains, the therapeutic 
landscape for Neisseria gonorrhoeae has become increasingly barren. The bacterium has 
demonstrated a strong proclivity for development of resistance against each FDA-
approved therapy tried in the last 90 years. Furthermore, any existing FDA-approved 
alternatives suffer from some weakness, and other experimental therapies that show 
promise are still in the early stages of their development. For this reason, continued efforts 
to identify antigonococcal compounds using all avenues of drug discovery (e.g., 
repurposing of FDA-approved therapies, in silico tools, physical screening, etc.) are 
necessary to ensure a future in which disease caused by this pathogen is still treatable.  
Much work has been done in our laboratory regarding the structural mechanisms 
of PBP2-mediated β-lactam resistance in Neisseria gonorrhoeae. In the past several 
years, our efforts have been focused on determining how specific amino acid changes in 
mosaic PBP2, including that expressed by strain H041, affect its structure, function, and 
ability to bind various β-lactams. In this project, the focus was reframed toward the ligand 
to examine what features are shared among active compounds with the goal of designing 
new compounds, or unearthing existing ones, capable of inhibiting PBP2 variants from 
both β-lactam-susceptible and -resistant strains. Here, we report data from three studies. 
The first is an analysis of the structure-activity relationships for inhibition of PBP2H041 by 
cephalosporins, as well as for antimicrobial activity against the strain itself. The second 
applies the knowledge gained from the structure-activity relationships to discover several 
novel scaffolds capable of inhibiting PBP2. Finally, the third explores the chemical space 
surrounding one of the identified scaffolds using medicinal and synthetic chemistry in order 





























Fifth Generation cephalosporins were kindly provided by Basilea (ceftobiprole), 
Merck (ceftolozane), and Allergan (ceftaroline). Other cephalosporins were purchased 
from TCI America Inc, Sigma Aldrich Inc, and Alfa Aesar Inc, and Bocillin-FL was 
purchased from ThermoFisher Scientific Inc. Compounds coded NSC in the text were 
kindly provided by the Developmental Therapeutics Program at NCI from their Open 
Chemicals Repository. Compounds coded Z/EN, CB, and STK/STL were purchased from 
Enamine Ltd, ChemBridge Corp, and Vitas-M Chemicals Ltd, respectively. 
2.2. Biochemical and microbiological methods 
2.2.a. Cloning, expression, and purification of truncated N. gonorrhoeae PBP2 
constructs 
Truncated constructs comprising only the transpeptidase domain of PBP2 (tPBP2) 
were generated as previously described.389 The expression construct was transformed 
into Escherichia coli BL21 (DE3) cells; 2 L of cell culture were grown at 37 °C, and protein 
expression was induced by addition of 0.3 mM isopropyl β-D-thiogalactoside, followed by 
overnight incubation at 20 °C. Cells were harvested by centrifugation, lysed in 20 mM Tris-
HCl (pH 8.0), 500 mM NaCl, and 10% glycerol (TNG), and the MBP-PBP2 fusion protein 
was purified on a 5 mL HisTrap FF Ni2+ affinity column (GE Healthcare, Piscataway, NJ). 
The fusion protein was pooled, mixed with His6-tagged TEV protease at a molar ratio of 
50:1, and dialyzed overnight at 4 °C against TNG to allow cleavage of the fusion protein 
and to remove imidazole. The resulting digest was then passed over a 5 mL HisTrap HP 
column equilibrated with TNG. Purified tPBP2 did not elute in the flow-through but instead 
was eluted by a TNG/15 mM imidazole step gradient. Uncleaved fusion protein, His6-TEV, 
and His6-maltose-binding protein remained bound to the column and were eluted with a 
TNG/250 mM imidazole wash step. The purified protein was pooled, dialyzed into 20 mM 
Tris (pH 8.0), 500 mM NaCl, and 10% glycerol, and concentrated by ultrafiltration. 
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2.2.b. Site directed mutagenesis of tPBP2H041 
A K361E mutation was introduced into tPBP2H041 using the QuikChange Lightning 
Kit (Agilent, Santa Clara, CA). The forward 5’-CATTATGCAAGAATCTTCCAACGTCG-3’ 
and reverse 5’-CCGCGCACATCCAAAGTA-3’ primers were used to amplify the plasmid 
DNA containing penA41 as per the manufacturer’s recommended protocol. The amplified 
PCR product was treated with Dpn1 enzyme and then used to transform in E. coli BL21 
(DE3) cells. The mutant was confirmed by sequencing. 
2.2.c. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)-
based binding assay for Bocillin-FL  
 
The rate of acylation of PBP2 by the  fluorescent Bocillin-FL638 was determined by 
time-course kinetics experiments in which 1 μM tPBP2 was incubated with Bocillin-FL 
under pseudo-first order conditions. Aliquots were removed at specified time points 
between 2 seconds and 1 hour, and the reaction quenched by 4X SDS-PAGE sample 
buffer. Samples were heated at 95°C for 2 minutes, and acylated protein was separated 
from free Bocillin-FL using 12% Mini-Protean TGX SDS-PAGE gels. Gels were scanned 
using a Kodak EDAS 290 UV imaging system, followed by staining with Coomassie R-250 
to confirm equal loading. Bocillin-FL-bound PBP2 was quantified by densitometry using 
ImageJ.639 Data were normalized to the maximum fluorescence intensity and fit to a one-
phase association curve to determine pseudo-first order rate constants, which were 
plotted against Bocillin-FL concentration and fit to a linear regression to give the second-
order acylation rate as the slope.  
2.2.d. SDS-PAGE-based competition binding assay for β-lactams 
 
Acylation rates for β-lactam compounds were derived by determining the 
concentration of β-lactam required to inhibit half the binding of a known amount of Bocillin-
FL. tPBP2 was co-incubated with a specified concentration of Bocillin-FL (10 or 100 μM) 
and increasing concentrations (1 μM to 1 mM) of β-lactam for 1 hour. Samples were 
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denatured, separated by SDS-PAGE, and imaged as above. Data were normalized to the 
maximum fluorescence intensity and fit to a four-parameter inhibitor-response curve to 
determine half-maximal inhibitory concentrations (IC50), and the acylation rates of the β-
lactams were determined by the following relationship: 
𝑘%
𝐾&. (𝐵𝑂𝐶) ∙
[𝐵𝑂𝐶] = 	𝑘% 𝐾&. (𝛽𝐿) ∙ 𝐼𝐶'((𝛽𝐿) 
 
2.2.e. SDS-PAGE-based binding assay for noncovalent inhibitors 
 
Potency of noncovalent inhibitors was measured by determining the concentration 
of compound required to inhibit half the binding of a known amount of Bocillin-FL. PBP 
was incubated with 1 µM to 1 mM test compound for one hour, followed by the addition of 
1 µM Bocillin-FL. The reaction was allowed to proceed for a time period corresponding to 
the linear phase of Bocillin-FL binding for the PBP used. Samples were denatured, 
separated by SDS-PAGE, and imaged as above. Data were normalized to the maximum 
fluorescence intensity to give fractional residual activity. For IC50 determinations, data 
were then fit to a four-parameter inhibitor-response curve. 
2.2.f. Crystallization of tPBP2H041 in complex with cefoperazone 
tPBP2H041  was concentrated to 13 mg/mL, and crystallization conditions were set 
using a Gryphon liquid dispensing system (Art Robbins, Sunnyvale, CA, USA) in a 96-well 
sitting drop format in which 200 nL protein solution was mixed with 200 nL well solution. 
Crystals were obtained at 18°C over wells containing 37-40% PEG 600, buffered with 0.1 
M CHES at pH 9.1-9.3. Crystals appeared after 3-4 days and exhibited a plate-like 
morphology. 
To generate an acylated complex of tPBP2H041, crystals were soaked in a 60 mM 
solution of cefoperazone for 30 minutes at room temperature, followed by flash freezing 
without adding cryo-protectant. Diffraction data were collected at a wavelength of 1.00 Å 
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on a MX300-HS detector at the SER-CAT 22-BM beamline at the Advanced Photon 
Source in Argonne, IL, USA. 360° of data were collected in 1° oscillations, with an 
exposure time of 2 s/frame and a crystal-to-plate distance of 220 mm, and were processed 
using HKL2000.640 The structure was solved by refinement of the tPBP2H041 structure. 
Cefoperazone was modeled using the |Fo|-|Fc| difference electron density map, followed 
by iterative cycles of model building and refinement using the graphics programs O641 or 
COOT642, and REFMAC.643 The stereochemistry of models was analyzed with 
PROCHECK.644 
2.2.g. Disc diffusion against Neisseria gonorrhoeae 
N. gonorrhoeae (FA19 and H041) was streaked onto gonococcal medium base 
(GCB) agar plates and incubated overnight at 37°C under 5% CO2. The next day, N. 
gonorrhoeae growth was collected from the overnight plates, resuspended in GCB+ 
(composed of GCB broth, supplements I and II, 20 mM NaHCO3, and 10 mM MgCl2), and 
diluted to a final OD600 of 0.18. Aliquots of dilute gonococcal cells (200 µL, ~50,000 CFU) 
were added to 3 mL GCB top agar (GCB broth + 0.7% agar), and the mixtures were gently 
poured onto new GCB plates and allowed to set. For each compound tested, 5 µL of a 2 
mg/mL solution in DMSO (10 µg total) was pipetted onto a disc, and each disc was placed 
on a prepared plate. Plates were then incubated at 37°C under 5% CO2 for 24 hours, at 
which time the diameter of the zone of inhibition was measured. These experiments were 
conducted in the laboratory of Robert Nicholas, PhD, at the University of North Carolina 
Chapel Hill.  
2.2.h. Minimum inhibitory concentrations against Neisseria gonorrhoeae 
Neisseria gonorrhoeae H041 was passaged on GCB plates and resuspended at 
an OD600 of 0.18. GCB plates containing 2-fold changes in concentrations of test 
compound were poured on the day of the experiment, and agar dilution minimum inhibitory 
concentrations (MIC) were determined by the spot method. Briefly, aliquots (~50,000 
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CFU) of each clone were spotted onto the antimicrobial-containing plates, and the plates 
were incubated overnight. The next morning, the plates were examined, and the MIC was 
reported as the lowest concentration of antimicrobial suppressing growth (growth is 
defined as > 5 colonies growing in the spot of inoculation). MIC determinations were 
repeated a minimum of two times. These experiments were conducted in the laboratory of 
Robert Nicholas, PhD, at the University of North Carolina Chapel Hill. 
2.3. Computational methods 
2.3.a. Pharmacophore-constrained docking of β-lactams against tPBP2 variants 
Structures used in pharmacophore-constrained docking experiments can be 
accessed through the Protein Databank. PDB accession codes: 6P53 (tPBP2WT 
apoenzyme), 6P54 (tPBP2WT-ceftriaxone), 6VBC (tPBP2H041 apoenzyme), 6VBD 
(tPBP2H041-ceftriaxone). tPBP2 coordinates were prepared by protonation at pH 7.4, 
explicit solvation with water, and minimization under the AMBER12 forcefield.645 The 
minimized structure was then allowed to relax by with a short (1,000 ps) molecular 
dynamics simulation at 2 fs resolution using the Nosé-Poincaré-Andersen (NPA) 
algorithm.646 A pharmacophore model was then generated to constrain the β-lactam ring 
to the area surrounding Ser310 of PBP2, including the oxyanion hole formed by Ser310 
and Thr500. Selected β-lactams were then docked to the receptor using an induced-fit 
protocol in which compounds were first placed in the active site using the pharmacophore 
and scored using the London dG algorithm. The top 50 scored conformers were then refined 
against the AMBER12 forcefield with flexible rotation of receptor side chains and rescored 
using GBVI/WSA dG algorithm. All rescored conformers were retained for analysis by 
energy score amplitude, as well as protein-ligand interaction fingerprint (PLIF). All 
calculation used Molecular Operating Environment 2018.01.   
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2.3.b. Quantitative-structure activity relationship (QSAR) for cephalosporins 
against N. gonorrhoeae H041  
 
Partial least squares (PLS) analysis was used to examine the relationship between 
activity measurements, reported as log(k2/Ks), and descriptor variables, including 
structural and molecular properties of the cephalosporins tested. The generated PLS 
model was validated using the square of the correlation coefficient obtained by the leave-
one-out cross-validation method. The resulting model was also validated using y-
randomization, as well as application to a small test set of null cephalosporins. All 
analyses, including descriptor calculations and PLS model generation, were conducted in 
MOE 2018.01.  
 To examine the relationship between MICs and molecular descriptors, a 
classification QSAR model was developed, with an activity cutoff set at median MIC ≤ 4 
μg/mL. Cefdinir consistently modeled as an outlier, as it exhibits a low rate of PBP2 
acylation and yet has high antimicrobial potency, and likely has a different mechanism of 
action (e.g., rapid PBP1 acylation). For this reason, it was excluded from the model. The 
generated classification model was validated using the leave-one-out cross-validation 
method, as well as by y-randomization. All analyses, including descriptor calculations and 
model generation, were conducted in MOE 2018.01.  
2.3.c. Homology modeling and rigid alignment of class B PBPs 
To generate homology models of class B penicillin-binding proteins, amino acid 
sequences were obtained from the NCBI Protein database and used as templates in the 
SWISS-MODEL server.647 Template searching and target-template sequence alignment 
were then performed by BLAST and HHBlits analysis of the PDB repository to identify 
structural models of highly similarity. The best templates were selected according to 
sequence identity, quality of the available structural data, and the Global Model Quality 
Estimation (GMQE). Models were exported to the Structural Analysis and Verification 
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Server (SAVES) v5.0, and their overall stereochemical quality was checked in 
PROCHECK. Crystal structures of additional class B PBPs were accessed (PDB 
accession codes can be found in Table 3.6), and all models were subjected to sequence 
alignment and rigid-body superposition to examine conservation of residues. 
2.3.d. tPBP2-ceftriaxone structure-guided docking of JEK-42 and JMT-1 to tPBP2 
variants 
 
Using tPBP2-ceftriaxone complex coordinates (tPBP2WT-ceftriaxone: 6P54, 
tPBP2H041-ceftriaxone: 6VBD), pharmacophore constraints were placed around the 
cephem C4 carboxylate (CO2- centroid, radius 2.0 Å) and the acyl carbonyl oxygen 
(hydrogen bond acceptor, radius 1.0 Å). The receptor was prepared for docking by the 
deletion of ceftriaxone from the active site and subsequent protonation at pH 7.4. 
Prototype PBP2 inhibitors (amide JEK-42 and sulfonamide JMT-1) were then docked to 
the receptor using an induced-fit protocol in which ligands were first placed in the active site 
using the pharmacophore and scored using the London dG algorithm. The top 10 scored 
conformers were then refined against the AMBER12 forcefield with flexible rotation of 
receptor side chains and rescored using the GBVI/WSA dG algorithm, and the top rescored 
conformer was retained. The tPBP2-JMT complex was prepared for molecular dynamics 
by explicit solvation with water and minimization under AMBER12 forcefield. The 
minimized structure was then allowed to equilibrate with a short (100 ps) molecular 
dynamics simulation (NPA algorithm, time step = 2 fs) with constraints placed on bond 
length. After equilibration, the solvated complex underwent 5 ns of molecular dynamics 
without constraints, and the overall structure of the complex, energies of ligand-receptor 
interaction, and trajectories of ligands were analyzed. These experiments were conducted 
in MOE 2018.01.  
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2.3.e. Virtual screening of fragments against a three-point pharmacophore 
 The base structures of JEK-42 and JMT-1, N-acetylanthranilic acid and N-
(methylsulfonyl)anthranilic acid, were flexibly aligned to the bicyclic penam, carbapenem, 
and cephem systems using a stochastic conformational search. From the alignment, a 
consensus pharmacophore was generated using a 100% threshold and 1.0 Å tolerance, 
yielding a model with three features: anionic (radius = 0.7 Å), hydrophobic/aromatic (radius 
= 0.9 Å), and hydrogen bond accepting (radius = 1.0 Å). This model was used to screen 
a custom ZINC library of 790,417 molecular fragments, defined as having a molecular 
weight < 250, for matching structures. This experiment  was conducted in MOE 2018.01. 
2.3.f. Validation of in silico methods for Pseudomonas aeruginosa PBP3  
β-lactam antibiotic structures were uploaded to the Database of Useful Decoys: 
Enhanced (DUD-E) server,648 and physicochemically matched decoy structural files were 
generated. All structures, true ligands and decoys, were combined into a single file for 
docking. The transpeptidase domain of PBP3 (PDB accession code: 3PBN) was prepared 
for docking using by protonation at pH 7.4, addition of partial charges, and the 
identification of potential binding sites by the calculation of alpha spheres. True ligands 
and decoys were then docked flexibly to the receptor using the rigid-receptor DOCK6.5 
protocol with 1,000 orientations.649 The compounds were scored against the AMBER 
forcefield and ranked. Receiver operator and enrichment curves were generated from the 
docking scores and ranks, and an area under the curve (AUC) was calculated for each. 
 Using MOE 2018.01, coordinates for the transpeptidase domain of PBP3 prepared 
by removal of crystallographic waters and ions, correction of structural incompletions, 
addition of partial charges, and protonation at physiologic pH. The structure was then 
energy minimized and allowed to relax with a short (500 ps) molecular dynamics 
simulation at 2 fs resolution using the NPA algorithm. The active site was defined by the 
cluster of alpha spheres containing the active serine residue (Ser294), and the database 
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of β-lactams and decoys was then docked flexibly to the defined site using triangle matching. 
Top conformers were refined against the AMBER12 forcefield with flexible rotation of 
receptor side chains, and conformers were ranked via GBVI/WSA dG scoring. Receiver 
operator and enrichment curves were generated from the docking scores and ranks, and an 
AUC was calculated for each. 
2.3.g. In silico virtual screen against Pseudomonas aeruginosa PBP3 
A custom library of 100,000 ligands derived from the ZINC database650 was docked 
to previously prepared P. aeruginosa PBP3 coordinates using the rigid-receptor DOCK6.5 
protocol above. Ranked ligands with docking scores two standard deviations below the 
mean of all docked compounds (Z < -2) were selected for consensus analysis via an 
induced-fit docking protocol in MOE2018.01 as done for the database of β-lactams and 
decoys above. Molecules were scored according to their overall binding by both protocols 
(i.e., sum of ranks), as well as agreement between protocols (i.e., difference between ranks).  
2.4. Synthetic methods  
2.4.a. Synthesis of 5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-carboxamido)benzoic acid 
(JEK-42) 
 
To a solution of 4’-methyl-[1,1’-biphenyl]-4-carboxylic acid (1.0 eq) in DCE were 
added oxalyl chloride (1.1 eq) and DMF (cat.) with stirring. Acyl chloride formation was 
allowed to proceed for 12 hours at room temperature. Volatiles were removed under 
reduced pressure to give 4’-methyl-[1,1’-biphenyl]-4-carbonyl chloride, which was used 
without further workup. A solution of methyl 2-amino-5-fluorobenzoate (1.0 eq) in 
anhydrous DCM was added, followed by pyridine (1.0 eq) portionwise, and the reaction 
was allowed to proceed at room temperature for 8 hours. After completion, as determined 
by TLC, the reaction was acidified to pH 2 with 1 M HCl, and the product was extracted 
with dichloromethane. The combined organic phases were washed with saturated 
NaHCO3 and brine, dried over Na2SO4, and filtered. Solvent was then removed under 
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reduced pressure, and the crude reaction mixture was purified by trituration using 
dichloromethane and hexanes. 
To a stirred solution of product methyl 5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-
carboxamido)benzoate in tetrahydrofuran, 1 M aqueous LiOH (2 eq) was added. The 
reaction was allowed to proceed with stirring at room temperature overnight. Solvent was 
then evaporated under reduced pressure, and the residue was subsequently diluted with 
water and acidified to pH 2 using 1 M HCl. The mixture was then extracted using EtOAc, 
and the combined organic phases were washed with brine, dried over Na2SO4, and filtered. 
Solvent was then removed under reduced pressure to provide 5-fluoro-2-(4'-methyl-[1,1'-
biphenyl]-4-carboxamido)benzoic acid as a white solid. The product was purified by normal 
phase flash chromatography using a dichloromethane / methanol mobile phase. Products 
needing additional purification were recrystallized from ethyl acetate and hexanes. 
2.4.b. General procedure I: Synthesis of 2-(arylsulfonamido)benzoic acids 
Arylsulfonyl chloride (1.0 eq) and methyl 2-aminobenzoate (1.0 eq) were dissolved 
in anhydrous dichloromethane and stirred for 10 minutes, at which time pyridine (1.0 eq) 
was added dropwise. The reaction was allowed to proceed with stirring at room 
temperature for 12 h. After completion, as determined by TLC, the reaction was acidified 
to pH 4 with 1 M HCl, and the product was extracted with dichloromethane. The combined 
organic phases were washed with brine, dried over Na2SO4, and filtered. Solvent was then 
removed under reduced pressure, and the crude reaction mixture was purified by 
trituration using dichloromethane and hexanes. 
To a stirred solution of product methyl 2-(arylsulfonamido)benzoate in 
tetrahydrofuran, 1 M aqueous LiOH (2 eq) was added. The reaction was allowed to 
proceed with stirring at room temperature overnight. Solvent was then evaporated under 
reduced pressure, and the residue was subsequently diluted with water and acidified to 
pH 2 using 1 M HCl. The mixture was then extracted using EtOAc, and the combined 
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organic phases were washed with brine, dried over Na2SO4, and filtered. Solvent was then 
removed under reduced pressure to provide the corresponding 2-
(arylsulfonamido)benzoic acid as an off-white solid. The product was purified by normal 
phase flash chromatography using a dichloromethane / methanol mobile phase. Products 
needing additional purification were recrystallized from ethyl acetate and hexanes. 
2.4.c. General procedure II: Synthesis of N-(2-(1H-tetrazol-5-
yl)phenyl)benzenesulfonamides 
 
Arylsulfonyl chloride (1.0 eq) and methyl 2-aminobenzonitrile (1.0 eq) were 
dissolved in anhydrous dichloromethane and stirred for 10 minutes, at which time pyridine 
(1.0 eq) was added dropwise. The reaction was allowed to proceed with stirring at room 
temperature for 12 h. After completion, as determined by TLC, the reaction was acidified 
to pH 5 with HCl, and the product was extracted with dichloromethane. The combined 
organic phases were washed with brine, dried over Na2SO4, and filtered. Solvent was then 
removed under reduced pressure, and the crude reaction mixture was purified by 
trituration using dichloromethane and hexanes. 
To a stirred solution of product 2-(arylsulfonamido)benzonitrile (1.0 eq) in DMSO, 
sodium azide (1.0 eq) and copper(II) sulfate (0.02 eq) were added. The reaction was 
heated to 150 °C and allowed to proceed with stirring for 1 h. After cooling, the reaction 
mixture was diluted with water and acidified to pH 2 using 1 M HCl. The mixture was then 
extracted using EtOAc, and the combined organic phases were washed with brine, dried 
over Na2SO4, and filtered. Solvent was then removed under reduced pressure to provide 
the corresponding N-(2-(1H-tetrazol-5-yl)phenyl)benzenesulfonamide as an off-white 
solid. The product was purified by normal phase flash chromatography using a 
dichloromethane / methanol mobile phase. Products needing additional purification were 
























CHAPTER 3: Structure-Activity Relationships of Cephalosporins against 
Penicillin- and Cephalosporin-Resistant Neisseria gonorrhoeae H041  
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3.1. Introduction 
The cephalosporins are a structurally diverse class of antibiotics divided into 
generations based on their timeline of development, as well as specific medicinal chemical 
modifications that affect activity and antimicrobial spectrum. While the 3rd generation 
agents cefixime and ceftriaxone have been the most commonly prescribed cephalosporins 
for gonorrhea over recent years, few members of this class have been tested against ESC-
resistant (ESCR) strains. This is especially the case for 4th and 5th generation 
cephalosporins such as ceftaroline and ceftobiprole that have been approved relatively 
recently. Building structure-activity relationships (SAR) for cephalosporins against their 
PBP2 target and an ESCR strain of N. gonorrhoeae offers the potential to address ESCR 
N. gonorrhoeae in two ways: it may reveal existing FDA-approved cephalosporins that 
exhibit efficacy against such strains, and suggest ways in which the efficacy of specific 
cephalosporins can be improved by chemical modification.  
Here, we report a quantitative structure-activity relationship (QSAR) of 22 
cephalosporins for inhibition of PBP2 from H041 and antimicrobial activity against N. 
gonorrhoeae. The data reveal key features of cephalosporins that enhance formation of the 
precovalent PBP2-cephalosporin complex, as well as those that may independently hinder 
or enhance antimicrobial activity. The study also reveals that FDA-approved agents 
cefoperazone (Cefobid, Pfizer), ceftaroline (Teflaro, Allergan), and ceftobiprole (Zevtera, 
Basilea) acylate mosaic PBP2 at higher rates than ceftriaxone, and that cefoperazone 
exhibits higher antimicrobial activity against H041. Overall, our data reveal there is 
considerable potential in adopting and/or adapting these cephalosporins as anti-gonococcal 
agents to address ESCR N. gonorrhoeae.  
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3.2. Computational predictions of precovalent cephalosporin-PBP2 interactions  
 
3.2.a. Pharmacophore-constrained docking of cephalosporins against tPBP2H041 
In order to identify residues of PBP2 involved in the recognition of cephalosporins 
in the precovalent complex, cephalosporins were docked to the active site of tPBP2H041. A 
pharmacophore constraint (shown in Appendix A) was used to confine the β-lactam ring 
system to the area around the Ser310 nucleophile and the oxyanion hole formed by the 
amide nitrogens of Ser310 and Thr500, and the refined poses for all compounds remained 
largely within the volume specified. Protein-ligand interaction fingerprints (PLIF) of all 
poses were generated for each molecule, their interactions with individual residues were 
analyzed by frequency and type of interaction (Figure 3.1), and the predominant 
interactions were used to generate a consensus pharmacophore (Figure 3.2).  
For all cephalosporins, S310 and T500 contact the β-lactam carbonyl oxygen with 
side chain and main chain hydrogen bonding interactions, respectively, while K313 and 
K497 are predominantly involved in side chain ionic interactions with the cephem C4 
carboxylate group. In addition, most of the cephalosporins contact T347, K361, S483, and 
S545. The C4 carboxylate moiety participates in additional hydrogen bonding interactions 
with the hydroxyl group of S483, and in most poses, S1 of the cephem dihydrothiazine 
ring participates in weak hydrogen bonding with the side chain hydroxyl group of T347. 
Electronegative elements of many of the cephalosporin R2 groups make side chain and 
main chain polar contacts with K361, including the thiotriazinone (TTN) moiety of 
ceftriaxone (Figure 3.3A). Finally, the common amide moiety of all R1 groups makes 
variable polar contacts within the active site. In some poses, the amide nitrogen 
participates in hydrogen bonding with S545 and the carbonyl oxygen with N364, while in 
others, the C7-N bond is rotated such that the carbonyl oxygen interacts with S545. This 
rotation also affects the position of the R1 aromatic ring systems of several cephalosporins, 
leading to two distinct conformational states: one in which the rings reach toward the 
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hydrophobic pocket formed by Y422 on the α8-β2f loop, and one in which they project 
toward Y544 on the β5-α11 loop (Figure 3.3B). The aromatic rings do not make 
substantial formal contacts with the active site in either of these conformations, however. 
Closer inspection of the poses reveals two possible binding modes for all 
cephalosporins examined: a “major pose” is observed for approximately 60% of poses 
(131/220), and a “minor pose”  for 40% (89/220) (Figure 3.4). While there appear to be to 
no differences in docked energy scores for the major pose (-6.39 ± 0.56 kcal·mol-1) over 
the minor pose (-6.54 ± 0.79 kcal·mol-1, p = 0.17), compounds with faster acylation rates 
tend to occupy the minor pose (OR = 0.38, p = 0.01). Representative examples of each 
pose for ceftriaxone and cefoperazone are shown in Figure 3.5. In the major pose, the C4 
carboxylate of the cephalosporin interacts with Oɣ of S483, and the β-lactam ring is 
positioned away from the nucleophile (Figure 3.5A and C). In the minor pose, the 
carboxylate is situated within the hydrogen bonding network created by K313 and S310, 
bringing the β-lactam ring in closer proximity to S310 (Figure 3.5B and D). Interestingly, 
neither pose overlaps with ceftriaxone observed in the crystal structure of tPBP2H041 
acylated by this antibiotic134 (Figure 3.6). Of the two binding modes, the minor pose 
appears more favorable for initiation of the acylation reaction. The β-lactam carbonyl is 
well-situated for attack by the Oɣ of S310 and for subsequent stabilization of the resulting 
tetrahedral intermediate by the oxyanion hole created by the amides of S310 and T500 






Figure 3.1: Protein-ligand interaction fingerprints (PLIFs) for pharmacophore-constrained induced-fit 
docking of cephalosporins to tPBP2H041. A. Heat map of cephalosporin-tPBP2H041 interactions colored 
by number of poses interacting with a given residue. B. Heat map of cephalosporin-tPBP2H041 
interactions, colored by the cephalosporin moiety interacting with a given residue. Key: cefoperazone 
(CFP), ceftaroline (CPT), ceftobiprole (BPR), ceftriaxone (CRO), ceftizoxime (ZOX), cefotaxime (CTX), 
ceftazidime (CAZ), cefixime (CFM), cefepime (FEP), cefpodoxime (CPD), ceftolozane (TOL), cefdinir 
(CDR), cefaclor (CEC), ceftibuten (CTB), cefuroxime (CXM), cefmetazole (CMZ), cefoxitin (FOX), 

























































































































Figure 3.3: Positioning of the R1 and R2 groups of ceftriaxone within the active site of tPBP2H041. 
A. The thiotriazinone (TTN) R2 of ceftriaxone (CRO, orange) makes contact with K361 (yellow) in 
a majority of docked poses. B. The 2-(aminothiazol-4-yl)-2-(alkoxyiminoacetyl) (ATAO) R1 group of 
CRO (orange) adopts two conformations in the docked poses, consistent with electron density seen 
in the published crystal structure of tPBP2H041 acylated by ceftriaxone.134 In each conformation, R1 






Figure 3.4: Statistical analysis of docked poses, showing two distinct predicted binding modes. A. 
Pie chart showing relative abundance of the two predicted binding modes. B. Predicted binding 
mode abundance stratified by second-order acylation rate constant. C. Pooled energy scores for 






Figure 3.5: Representative poses of ceftriaxone and cefoperazone docked to tPBP2H041. A. In the 
major pose predicted by the pharmacophore-constrained docking protocol, the C4 carboxylate of 
ceftriaxone interacts with S483, its R2 side chain interacts with K361, and the β-lactam ring system 
is not optimally oriented for nucleophilic attack by S310. Ceftriaxone (CRO) is shown in orange, 
and potential hydrogen bonds made by the antibiotic are indicated by dashed lines. B. In the minor 
pose for CRO, the C4 carboxylate interacts with the side chains of K313 and S310, and the β-
lactam ring is available for attack by S310. C. Cefoperazone (CFP) in the major pose. D. CFP in 





Figure 3.6: Overlay of docked ceftriaxone poses with tPBP2H041-CRO complex structure. Docked 
precovalent poses of ceftriaxone (major in orange, minor in purple) show marked differences from 
the acylated structure (green). In the minor pose, in which the β-lactam ring is well-positioned for 
attack by nucleophilic Oɣ of S310, the aromatic thiazole ring has moved further from its final position 
near α8.  
 
3.2.b. Pharmacophore-constrained docking of cephalosporins against tPBP2WT 
 
In order to draw more direct comparisons between  tPBP2H041 and tPBP2WT,  the 
panel of cephalosporins was docked to the active site of tPBP2WT using the same 
pharmacophore-constrained docking protocol as above. Because T498 rotation has been 
shown as critical for triggering the acylation reaction, the protocol was run for both apo 
and ceftriaxone-bound (T498-rotated) forms of tPBP2WT. PLIF analysis for each ligand 
docked to apo-tPBP2WT is shown in Figure 3.7. In this system, the side chains of S310 
and T500 contact the β-lactam carbonyl oxygen with side chain hydrogen bonding 
interactions, and T483 and S362 are predominantly involved in side chain hydrogen 
bonding interactions with the cephem C4 carboxylate group. In most poses, S1 of the 
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cephem dihydrothiazine ring participates in weak hydrogen bonding with the side chain 
hydroxyl group of T347. The common C7 acylamino moiety on R1 of all cephalosporins 
forms a hydrogen bond with N364 in some poses, and some R1 aromatic ring systems 
make contact with R502 and H514 of the β3-β4 loop. Large R2 groups adopt two distinct 
conformations in the dataset: one in which electronegative elements make side chain and 
main chain polar contacts with K361 on α4 and one in which they are rotated toward 
residues on α11. A representative pose is shown in Figure 3.9A.  
The picture is significantly different for the poses of cephalosporins docked to a 
structure of tPBP2WT in which the T498 side chain is rotated toward the active site (Figure 
3.8). First, the C4 carboxylate is in direct contact with the side chains of K497, T498, and 
T500 in a majority of poses, consistent with the post-covalent crystal structures of cefixime 
and ceftriaxone in complex with tPBP2WT (Figure 3.10). In these poses, the β-lactam ring 
is in a more favorable position for attack by Oɣ of Ser310. Similar to what is seen in docking 
against the apo structure, S1 of the dihydrothiazine ring participates in weak hydrogen 
bonding interactions with the side chain of T347. The R1 adopts a position in which the C7 
acylamino forms consistent hydrogen bonding interactions with the side chain of N364, 
and aromatic systems generally come in close enough proximity to Y422 to form H-𝜋 or 
𝜋-𝜋 interactions with its side chain. While there is a small subset of poses in which R2 
groups interact with K361, a majority occupy the cleft between the α10-β3 loop and α11, 
consistent with a crystal structure of tPBP2WT-ceftriaxone in which the leaving group is 
trapped before departure. A representative pose for this analysis is shown in Figure 3.9B. 
Together, the results of our docking experiments suggest that the initial recognition of the 
C4 carboxylate is similar for tPBP2WTand tPBP2H041. Subsequent rotation of T498 in 
tPBP2WT may result in a dramatic change in ligand position preparing it for acylation, a 
repositioning that does not occur in tPBP2H041 due to locking of T498 by a hydrogen bond 
with S545.  
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Figure 3.7: Protein-ligand interaction fingerprints (PLIFs) for pharmacophore-constrained induced-fit 
docking of cephalosporins to apo tPBP2WT. A. Heat map of cephalosporin-tPBP2WT interactions colored 
by number of poses interacting with a given residue. B. Heat map of cephalosporin-tPBP2WT 
interactions, colored by the cephalosporin moiety interacting with a given residue. Key: cefoperazone 
(CFP), ceftaroline (CPT), ceftobiprole (BPR), ceftriaxone (CRO, ceftizoximine (ZOX), cefotaxime (CTX), 
ceftazidime (CAZ), cefixime (CFM), cefepime (FEP), cefpodoxime (CPD), ceftolozane (TOL), cefdinir 
(CDR), cefaclor (CEC), ceftibuten (CTB), cefuroxime (CXM), cefmetazole (CMZ), cefoxitin (FOX), 




Figure 3.8: Protein-ligand interaction fingerprints (PLIFs) for pharmacophore-constrained induced-fit 
docking of cephalosporins to tPBP2WT with T498 rotated toward the active site, as is seen in the 
ceftriaxone-bound structure . A. Heat map of cephalosporin-tPBP2WT interactions colored by number of 
poses interacting with a given residue. B. Heat map of cephalosporin-tPBP2WT interactions, colored by 
the cephalosporin moiety interacting with a given residue. Key: cefoperazone (CFP), ceftaroline (CPT), 
ceftobiprole (BPR), ceftriaxone (CRO, ceftizoximine (ZOX), cefotaxime (CTX), ceftazidime (CAZ), 
cefixime (CFM), cefepime (FEP), cefpodoxime (CPD), ceftolozane (TOL), cefdinir (CDR), cefaclor 
(CEC), ceftibuten (CTB), cefuroxime (CXM), cefmetazole (CMZ), cefoxitin (FOX), cefsulodin (CFS), 






Figure 3.9: Representative poses of ceftriaxone docked to tPBP2WT. A. When docked to apo  
tPBP2, the C4 carboxylate of ceftriaxone interacts with T483, and the β-lactam ring system is not 
optimally oriented for nucleophilic attack by S310. Ceftriaxone (CRO) is shown in orange, and 
potential hydrogen bonds made by the antibiotic are indicated by dashed lines. B. When docked to 
tPBP2WT in which T498 is rotated toward the active site, the C4 carboxylate interacts with the side 






Figure 3.10: Overlay of docked ceftriaxone poses with tPBP2WT-CRO complex structure. Docked 
precovalent poses of ceftriaxone with apo tPBP2WT (orange) show marked differences from the 
acylated structure (green). When T498 is rotated toward the active site, however, the docked poses 
(purple) better resemble the post-covalent state. 
 
3.3. Activity data for cephalosporins against N. gonorrhoeae strain H041 and its 
PBP2 
 
3.3.a. Second-order acylation rate constants against tPBP2H041 
As a prerequisite to determining the second-order rates of acylation for the panel 
of cephalosporins against tPBP2H041, we first measured the second-order acylation rate of 
Bocillin-FL against tPBP2H041 using a time-dependent gel-based assay (Figure 3.11). The 
obtained value, 275 ± 9 M-1s-1, is consistent with values previously reported for 
[14C]penicillin G against PBP2 from H041.384 k2/Ks was then determined for each 
cephalosporin with a gel-based competition assay using Bocillin-FL (untransformed 
inhibition data shown in Appendix B). The 22 cephalosporins exhibit a wide range of 
activities against tPBP2H041(Table 3.1), with acylation rates ranging from 0 to over 10,000 
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M-1s-1. Three of the cephalosporins exhibit 2-7 fold faster rates of acylation than third-
generation ceftriaxone (1,710 ± 320 M-1s-1). These are the third-generation agent 
cefoperazone (11,800 ± 1,300 M-1s-1) and the fifth-generation agents ceftaroline (10,900 
± 1,700 M-1s-1) and ceftobiprole (3,230 ± 190 M-1s-1). Ceftizoxime (third-generation) 
exhibits activity comparable to that of ceftriaxone (1,000 ± 210 M-1s-1), whereas several 
other third-generation cephalosporins exhibit slightly slower rates of acylation, including 
cefotaxime (880 ± 120 M-1s-1), ceftazidime (780 ± 150 M-1s-1), cefixime (720 ± 60 M-1s-1), 
and cefpodoxime (590 ± 90 M-1s-1). The remaining cephalosporins exhibit very slow 
acylation rates; in fact, for four of these, cephalexin, cefazolin, cephalothin, and 




Figure 3.11: Second-order rate of acylation of Bocillin-FL against tPBP2H041. A. Time-dependent 
acylation of tPBP2H041 at various Bocillin-FL concentrations. Each curve was used to derive the 
pseudo first-order rate constant, ka. B. Plot of ka against the concentration of Bocillin-FL, where the 
slope is the second order acylation rate constant (k2/Ks). A minimum of three kinetics experiments 




Table 3.1: Second-order acylation rates and minimum inhibitory concentrations for the selected 
panel of cephalosporins. aThe acylation rate constant for each cephalosporin was derived from 
kinetic measurements of the formation of the acyl-enzyme complex, as described in Chapter 2. The 
rates were determined by a competition assay with Bocillin-FL. Values were derived from a 
minimum of three separate determinations. Error is expressed as standard deviation. bThe 
minimum inhibitory concentration (MIC) for each cephalosporin was determined using an agar 
dilution protocol, as described in Chapter 2. Values were derived from a minimum of two separate 
determinations. †Inhibition plot could not be fit due to lack of a plateau at the highest concentration 
used; however, approximately 50% inhibition was seen at 10 mM. ‡Inhibition plot could not be fit 
due to minimal inhibition seen at the highest concentration used. *Cephamycin – possesses a C7-
OMe group. All IC50 curves are shown in Appendix B. 
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880 ± 120 6 [4-8] 
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630 ± 50 32 [16-32] 
CPD 
 




200 ± 20 >32  
CDR 
 
 82 ± 7 1.5 [1-2] 
CEC 
 
Cl 29 ± 4 >32  
CTB 
 




6.8 ± 0.2 16 [16] 
FOX* 
  
3.3 ± 0.6 3 [2-4] 
CMZ* 
  
3.6 ± 0.1 32 [32] 
CFS 
  
0.8 ± 0.1 >32  
LEX 
 






































































































~ 0‡ 12 [8-16]  
LOT 
  
~ 0‡ 32 [32] 
LOR 
  
~ 0‡ 16 [16] 
 
Examining the acylation data qualitatively, it appears that the R1 side chain has a 
significant impact on tPBP2H041 acylation rate, as seen in pairwise comparisons of 
compounds with identical R2 side chains (Table 3.2). These pairings exhibit up to 3,000-
fold differences in activity (e.g., cefoperazone versus cefmetazole). By contrast, the R2 
side chain has a much lower impact on acylation rate, as evidenced by the narrow range 
of values obtained for cephalosporins containing the 2-(2-aminothiazol-4yl)-2-






















Table 3.2: Pairwise comparisons of cephalosporins with identical R2. aSecond-order acylation rate 
constants taken from Table 1. bQuotient of second-order acylation rate constants for fast- versus 
slow-acylating cephalosporin. †Cephamycin – possesses C7-OMe group. ‡Inhibition plot could not 
be fit due to minimal inhibition seen at the highest concentration used. 
 

















19.1 ± 0.2 
CTX 
  











































































































3.3 ± 0.6 
 
 
3.3.b. Antimicrobial activity against N. gonorrhoeae H041 
Minimum inhibitory concentrations (MICs) were determined for the panel of 
cephalosporins using agar dilution (Table 3.1). The tested compounds exhibit varying 
degrees of antimicrobial potency against H041, ranging from 1 to >32 μg/mL. Consistent 
with the acylation data, cefoperazone shows slightly more inhibition of bacterial growth 
than ceftriaxone (1 vs 2 μg/mL), albeit within the error of dilution. Despite their rapid target 
acylation rates against tPBP2H041, the MICs for ceftaroline and ceftobiprole are similar or 
slightly higher compared to ceftriaxone. By contrast, cefdinir and cefoxitin, which both 
exhibit relatively low acylation rates against tPBP2H041, inhibit the growth of H041 at 
concentrations comparable to ceftriaxone (MIC = 1.5 and 3 μg/mL, respectively). The anti-
gonococcal activity of the remaining cephalosporins is generally weaker, falling in the 
range of 8 to 16 μg/mL. Cephalothin, ceftazidime, cefaclor, cefsulodin, and cephalexin are 
exceptionally poor antimicrobials, and cannot inhibit growth of the H041 strain except at 
concentrations of 32 μg/mL or more. In general, antimicrobial potency correlates relatively 
poorly with acylation rate because MICs are also influenced by the degree of permeation 














3.4. Quantitative structure-activity relationship for cephalosporins against N. 
gonorrhoeae strain H041 and its PBP2 
 
3.4.a. Partial least squares QSAR for second-order acylation rate constant against 
tPBP2H041 
 
Correlation of acylation data for the 18 cephalosporins with measurable acylation 
rates with their molecular descriptors yielded a partial least squares model with an r2 of 
0.995 and a cross-validated r2 of 0.957 (Fig. 3.12A). In addition to its high degree of 
predictability within the training set, the model successfully predicts near-zero activity for 
four cephalosporins not in the training set that have unmeasurable acylation rates against 
tPBP2H041 (Table 3.3). To assess the probability of chance correlation, y-randomization 
was performed, in which activity values were randomly assigned to a structure. This 
yielded an r2 of 0.937 and a cross-validated r2 of 0.067 (Figure 3.12B), indicating that 
correlations seen in the model are not random. Definitions of descriptors used in QSAR 
models can be found in Appendix C. 
From the PLS model, it can be seen that the second-order acylation rate of 
tPBP2H041 by cephalosporins is greatly affected by the van der Waals surface area and 
lipophilicity of the R1 substituent, with large, modestly lipophilic groups being favored. 
Other features of the R1 substituent were also found to correlate with high activity, 
including overall shape, connectivity, and topology. The contributions of these variables 
indicate that active molecules possess a high degree of unsaturation and cyclicity, with 
modest heteroatom counts and branching. The R2 side chain makes relatively less 
contribution to acylation compared to R1 but does have some effect. R2 groups containing 
a large number of hydrogen bond acceptors appear to confer higher acylation rates. The 
model also points to partial positive charge and hydrophobicity of R2 as being favorable, 
the former of which may be an indirect result of inductive effects by electronegative atoms 




Figure 3.12: Partial least squares quantitative structure activity relationship of cephalosporins 
against tPBP2H041. A. PLS QSAR model of tPBP2H041 acylation rate constant data, generated using 
the physicochemical and structural descriptors shown in Table 3.3. The model exhibits high internal 
validity by direct application to the training set (r2 = 0.995) and by leave-one-out cross validation 
(X-r2 = 0.957). B. QSAR validation by y-randomization. Random assignment of second-order 
acylation rate constants to physicochemical and structural descriptors shown in Table 3.3 yields a 
poor PLS model of tPBP2H041-inhibitory activity (X-r2 = 0.067).  
 
 
Table 3.3: Partial least squares QSAR model of tPBP2H041 acylation rate constant data. aDescriptor 
definitions can be found in Appendix C. 
 
Descriptora Moiety Coefficient Importance 
vdw_area R1 + 4.8926 1 
Kier1 R1 - 4.5005 0.9198 
zagreb R1 - 0.8829 0.1804 
KierA2 R1 + 0.6690 0.1367 
chi0v R1 + 0.5917 0.1209 
BCUT_SLOGP_0 R1 - 0.5145 0.1052 
BCUT_SLOGP_1 R1 - 0.3783 0.0773 
a_ICM R1 + 0.3723 0.0761 
SlogP_VSA7 R2 + 0.3679 0.0752 
BCUT_SLOGP_3 R1 - 0.3626 0.0741 
BCUT_SMR_3 R1 - 0.1991 0.0407 
a_acc R2 + 0.1939 0.0396 
BCUT_PEOE_3 R1 - 0.1797 0.0367 
GCUT_PEOE_2 R2 + 0.1737 0.0355 
BCUT_PEOE_0 R1 + 0.1693 0.0346 
PEOE_VSA_FPNEG R1 + 0.1104 0.0226 





Table 3.4: Application of PLS QSAR to a test set of null cephalosporins. aSecond-order acylation 
rates for tPBP2H041, as reported in Table 3.1. bSecond-order acylation rates computed using the 
model reported in Table 3.3 and Figure 3.12. Test set computations exhibit an overall root mean 
square error of 12.4 M-1s-1 compared to true acylation rate. 
 
Cephalosporin k2/Ks (M-1s-1)a Predicted k2/Ks (M-1s-1)b 
cephalexin (LEX) ~ 0.3† 2.6 
cefazolin (CFZ) ~ 0‡ 0.1 
cephalothin (LOT) ~ 0‡ 1.4 
cephaloridine (LOR) ~ 0‡ 24.6 
 
 
3.4.b. Classification QSAR for antimicrobial activity against Neisseria gonorrhoeae 
H041 
 
 Since MIC values obtained were in discrete, two-fold increments, classification 
QSAR was used to examine the relationship between MIC and the cephalosporin molecular 
descriptors rather than PLS QSAR. Using a median MIC cut-off of ≤4 μg/mL, we defined 5 
cephalosporins as active and 16 as inactive. The resulting model has an overall predictive 
accuracy of 100% (p = 0.0005) and cross-predictive accuracy of 100% (p = 0.0005) (Figure 
3.13A). As for the acylation-based QSAR, the validity of the model was checked by y-
randomization to assess the probability of chance correlation (Figure 3.13B). While the 
structural features driving acylation rate are largely the lipophilicity and topology of R1, 
antimicrobial activity is enhanced by overall hydrophilicity of the molecule. Features shown 
to contribute to greater activity include more hydrogen bonding elements, increased water 
solubility, and formal charge. Similar to acylation, the model also indicates that antimicrobial 
activity is enhanced by specific cephalosporin shape and topology, consistent with this 




Figure 3.13: Classification quantitative structure activity relationship of cephalosporins against N. 
gonorrhoeae H041. A. Classification QSAR model of antimicrobial activity against Neisseria 
gonorrhoeae H041, generated using the descriptors shown in Table 3.5. The model exhibits high 
predictive power (100% accuracy upon direct application to the test set, as well as cross-validation). 
B. QSAR validation by y-randomization. Random assignment of MIC values to physicochemical 
and structural descriptors shown in Table 3.5 yields a poor classification model of N. gonorrhoeae 
H041 antimicrobial activity (X-A = 0.81). 
 
 
Table 3.5: Classification QSAR model of Neisseria gonorrhoeae H041 antimicrobial activity data. 

























3.5. Importance of Lys361 to tPBP2H041-cephalosporin complex formation 
3.5.a. Homology modeling of class B PBPs and alignment with published crystal 
structures 
 
As noted above, the docking data reveal a potential hydrogen bond between K361 
of α4 in tPBP2H041 and polar R2 side chains. Examination of crystal structures and 
homology models of class B PBPs from several species shows that a positively charged 
residue is highly conserved at this position in many Gram-negative pathogens (Figure 
3.14, Table 3.5), including several belonging to the multi-drug resistant ESKAPE group, 
suggesting that it may be important for the transpeptidase activity of class B PBPs. By 
contrast, this residue is not conserved in class B PBPs of Gram-positive bacteria.  
 
 
Figure 3.14: Alignment of ⍺4 of class B PBPs showing conservation of a lysine residue in several 
important Gram negative pathogens. N. gonorrhoeae PBP2 shown in teal, E. coli PBP3 shown in 





Table 3.6: Superimposition of class B PBPs. aResidues from rigid structural alignment that 
generate a receptor surface analogous to the shallow cleft containing K361 in PBP2 of N. 
gonorrhoeae. bPredominant formal charge of the cleft. *No structural data available – homology 
model constructed using SWISS-MODEL. 
 
Morphology Organism Class B PBP Residuesa Chargeb 
Gram negative 
N. gonorrhoeae PBP2H041 H348, Y350, K361 ++ 
N. gonorrhoeae PBP2WT (3EQU) H348, Y350, K361 ++ 
N. meningitidis PBP2* V382, H386, V397 + 
P. aeruginosa PBP3 (3PBN) S334, K348 + 
P. aeruginosa PBP3a* A329, R331, N342 + 
E. coli PBP3 (4BJP) A345, Y347, K358 + 
A. baumanii PBP3 (3UE3) H376, Y378, K389 + 
H. influenzae PBP2* W378, K379, H383, 
E394 
++/- 
H. influenzae PBP3* A365, R367, N378 + 
H. pylori PBP2 (5LP4) W349, K350, H354, 
E365 
+/- 
H. pylori PBP3* F367, Q381 ∅ 
Gram 
positive 
S. aureus PBP2a (5M1A) E447, S461 - 
S. pneumoniae PBP2x (5OAU) W374, D375, H394 +/- 
S. pneumoniae PBP2x (1PYY) D375, E378, H394 +/- 
S. pneumoniae PBP2x (1QME) W374, D375, H394 +/- 
S. pneumoniae PBP2b (2WAE) W424, Y425, Y442 ∅ 
E. faecalis PBP4 (6BSQ) K468, N481 + 
E. faecium PBP5 (6MKA) S466, Y479 ∅ 
B. subtilis PBP2a* D398, E402, Y413 - - 
B. subtilis PBP2b* W352, R363, K493 ++ 
B. subtilis PBP3* E455, T468 - 
Atypical 
M. tuberculosis PBPA (3LO7) G263, K280 + 






Table 3.7: Homology model template-target matching parameters for class B PBPs. aData 
acquisition method and resolution for template molecule. bPrimary structure sequence identity 
between template and target molecules, reported as a percentage. cGlobal Mean Quality Estimate 
for the generated homology models. 
 
Target Template Methoda Identityb GMQEc 
B. subtilis PBP2a  
(SIQ60944.1) 
S. aureus PBP2 (2olv.1) X-ray, 2.8 Å 32.6 0.59 
B. subtilis PBP2b  
(ARW31327.1) 
S. thermophilus PBP2x 
(5u47.1.A) 
X-ray, 2.0 Å 33.5 0.64 
B. subtilis PBP3 
(KIU10857.1) 
E. faecium PBP2’ 
(5e31.1) 
X-ray, 2.3 Å 38.7 0.70 
H. influenzae PBP2  
(KPH67935.1) 
H. pylori PBP2/MreC 
(5lp5.1) 
X-ray, 2.7 Å 31.1 0.58 
H. influenzae PBP3  
(BAF48352.1) 
P. aeruginosa PBP3 
(4kqr.1) 
X-ray, 2.0 Å 41.4 0.63 
H. pylori PBP3 
(CAX30260.1) 
P. aeruginosa PBP3 
(4kqr.1) 
X-ray, 2.0 Å 28.1 0.57 
P. aeruginosa PBP3a 
(CAA64770.1) 
P. aeruginosa PBP3 
(4kqr.1) 
X-ray, 2.0 Å 49.8 0.74 
N. meningitidis PBP2 
(RGB21187.1) 
H. pylori PBP2/MreC 
(5lp5.1) 
X-ray, 2.7 Å 32.9 0.56 
B. burdorferi PBP2 
(ARS33437.1) 
 H. pylori PBP2/MreC 
(5lp5.1) 




Table 3.8: Homology model quality measures for class B PBPs. aPercent of residues with 
geometries in favorable or acceptable regions of the Ramachandran plot. bPercent of residues with 
geometries in favorable or acceptable regions of χ1- χ2 plot. cLog-odds score for overall homology 
model geometry. 
 
Model Ramachandran (%)a χ1- χ2 (%)b G-factorc 
B. subtilis PBP2a  96.8 98.8 -0.14 
B. subtilis PBP2b  97.9 98.7 -0.15 
B. subtilis PBP3  97.9 99.0 -0.12 
H. influenzae PBP2  99.2 99.7 -0.16 
H. influenzae PBP3  99.1 99.0 -0.09 
H. pylori PBP3 98.4 98.9 -0.25 
P. aeruginosa PBP3a 99.5 98.9 -0.11 
N. meningitidis PBP2 99.0 98.8 -0.17 




3.5.b. Second-order acylation rate constants of select cephalosporins against a 
tPBP2H041-K361E mutant 
 
To determine its influence on cephalosporin binding to tPBP2H041, Lys361 was 
mutated to Glu, and the acylation rates of several cephalosporins with representative 
electronegative or electropositive R2 side chains were determined. The second-order 
acylation rate of Bocillin-FL against tPBP2H041-K361E is 57 ± 1 M-1s-1, a 5-fold decrease 
compared to the native enzyme (Figure 3.15). The second-order acylation rates of 
ceftriaxone (290 ± 70 M-1s-1) and cefoperazone (370 ± 60 M-1s-1) are both markedly lower 
against the K361E mutant, with reductions of 83% and 97%, respectively (Table 3.8). 
Ceftazidime (560 ± 180 M-1s-1) and cefepime (410 ± 130 M-1s-1) also exhibit lower acylation 
rates, although less pronounced. These data indicate that in tPBP2H041, the R2 side chain 
binds the shallow cleft between the β2c-β2d loop and the α10-β3 loop containing K361 in 
the pre-covalent state.  
 
 
Figure 3.15: Second-order rate of acylation of Bocillin-FL against tPBP2H041-K361E. A. Acylation 
of tPBP2H041-K361E by Bocillin-FL was detected under pseudo-first order conditions using various 
ligand concentrations to determine rate constant ka. B. The pseudo-first-order rates of acylation (ka) 
were plotted against the concentration of Bocillin-FL to yield a plot whose slope is the second order 
acylation rate constant (k2/Ks). A minimum of three kinetics experiments were completed for each 




Table 3.9: Second-order acylation rates for select cephalosporins against tPBP2H041-K361E. 
aSecond order acylation rate constants against native tPBP2H041, as reported in Table 3.1. bThe 
acylation rate constant for each cephalosporin was derived from kinetic measurements of the 
formation of the acyl-enzyme complex, as described in Chapter 2. The rates were determined by a 
competition assay with Bocillin-FL. Values were derived from a minimum of three separate 
determinations. Error is expressed as standard deviation. cThe fractional acylation rate compared 
to that with native tPBP2H041.  
 
Ceph R2 k2/Ks  (M-1s-1)a 






11,800 ± 1,300 370 ± 60 0.03 
CRO 
 
1,710 ± 320 290 ± 70 0.17 
CAZ 
 
790 ± 150 560 ± 180 0.70 
FEP 
 
630 ± 50 410 ± 130 0.64 
 
 
3.5.c. Docking of select cephalosporins to a tPBP2H041-K361E mutant 
 
When this mutation is modeled in silico and the above docking protocol repeated, 
the generated poses for ceftazidime and cefepime position R2 toward the mutated residue 
due to electrostatic attraction, whereas the R2 side chains of ceftriaxone and cefoperazone 
become oriented away from this region (Figure 3.16). The repulsion of electronegative R2 
by E361 seen in these models may be the basis for differential effects of the mutant on 


















































































































































































































































































































































































































































































































3.6. Further evaluation of cefoperazone as a potential antigonococcal agent 
3.6.a. Crystallographic analysis of a tPBP2H041-CFP complex structure 
The rapid acylation of tPBP2H041 by cefoperazone compared to ceftriaxone, as well 
as its more favorable energetics of binding in the docked models, suggests it may bind 
more favorably in the transpeptidase active site compared to other cephalosporins. To 
examine this, the crystal structure of tPBP2H041 acylated by cefoperazone was determined 
at 2.2 Å resolution, obtained by soaking crystals of tPBP2H041 with antibiotic (Table 3.9).  
Overall, the structure is very similar to the reported tPBP2H041-CRO structure (C𝝰 
rmsd = 0.123 Å), including the “outbent” conformation of the β3-β4 loop (Figure 3.17). 
The unbiased |Fo|-|Fc| difference electron density map shows cefoperazone covalently 
bound to Ser310 (Figure 3.18). Electron density is observed for a majority of the 
cefoperazone molecule, with the exception of C3 of the dihydrothiazine ring, C6 of the 2,3-
dioxopiperazine ring, and the p-phenol substituent on R1. The lack of density at 
dihydrothiazine C3 and 2,3-dioxopiperazine C6 is consistent with the presence of a 
mixture of conformational states for these flexible ring systems. Cefoperazone forms a 
number of polar contacts with active site residues of tPBP2H041 (Figure 3.18). These 
include hydrogen bonds between the acyl carbonyl oxygen and the oxyanion hole 
comprising the main chain amides of Ser310 and Thr500, and between the C7 acylamino 
carbonyl oxygen and the side chain of Asn364 from the SxN motif. The C4 carboxylate 
forms hydrogen bonds with the main chain of Ser545 and the side chain of Thr500. The 
hydrophobic 2,3-dioxopiperazine ring system is positioned over the Y422 side chain, and 
the p-phenol system is solvent exposed. The tPBP2H041-CFP structure does not show a 
great deal of overlap with either the major or minor pose of cefoperazone from our docking 
models (Figure 3.19).  
  
 132 
Table 3.10: X-ray diffraction data and model refinement statistics for a preliminary crystal structure 
of tPBP2H041 in complex with cefoperazone. 
Data collection:  
Space group P212121 
Cell dimensions:  
a, b, c (Å) 50.2, 60.6, 109.1 
α, β, γ (o) 90.0, 90.0, 90.0 
Resolution range (Å) 40.56 - 2.17 
Rmerge* (%) 23.6 (60.9) 
Completeness (%) 100 (99.8) 
Redundancy 13.6 (13.9) 
<I>/<σI> 22.4 (6.1) 
No. of unique reflections 17,766 (1,688) 
Refinement:  
Resolution (Å) 40.56 - 2.17 
No. of non-hydrogen protein 
atoms 
2,457 
No. of antibiotic atoms 37 
No. of water oxygen atoms 108 
Rcryst/Rfree (%) 0.179/0.225 
RMS deviations from ideal 
stereochemistry 
 
bond lengths (Å) 0.003 
bond angles (o) 0.8 
B factors:  
Mean B factor (main chain) 
(Å2) 
23.4 
RMS. deviation in main chain 
B factors (Å2) 
1.0 
Mean B factor (side chains & 
waters) (Å2) 
28.3 
RMS deviation in side chain 
B factors (Å2) 
1.8 
 Ramachandran plot:  
Residues in most favored 
region (%) 
93.4 
Residues is generously 
allowed region (%) 
6.6 
Residues in additional 
allowed region 
0.0 







Figure 3.17: Overlay of ceftriaxone- and cefoperazone-acylated structures of tPBP2H041. 
Superimposition of tPBP2H041 in complex with ceftriaxone (aqua) and cefoperazone (pink) shows 
that the structures are nearly identical. Ceftriaxone and cefoperazone are shown as teal and 





















































































































































































Figure 3.19: Overlay of docked cefoperazone poses with tPBP2H041-CFP complex structure. 
Docked precovalent poses of cefoperazone (major in orange, minor in purple) show marked 
differences from the acylated structure (green sticks). In the minor pose, in which the β-lactam ring 
is well-positioned for attack by nucleophilic Oɣ of S310, the hydrophobic 2,3-dioxopiperazine ring 





3.6.b. In vivo testing of cefoperazone in a gonococcal model of infection 
As noted above, cefoperazone exhibits an acylation rate against tPBP2H041 higher 
than ceftriaxone, suggesting it may have therapeutic potential to treat gonorrhea. To 
examine this, cefoperazone (60 or 120 mg/kg TID) was administered intraperitoneally to 
two groups of BALB/c mice infected with N. gonorrhoeae H041 (Figure 3.20). A 120 mg/kg 
TID dosing regimen results in 100% culture negativity by day 3, with a mean time-to-
clearance of 2.1 days (n = 9), and shows equivalent efficacy to an identical regimen of 
ceftriaxone (n = 10, mean time-to-clearance 1.6 days, log-rank p = 0.15). By contrast, a 
gentamicin control regimen results in 100% culture negativity by day 4, with a mean time-
to-clearance of 3.1 days (n = 8, log-rank p = 0.02 versus CFP, log-rank p = 0.0004 versus 
CRO). Quantitative differences in colonization load are seen beginning at 1 day for 
cefoperazone- and ceftriaxone-treated groups compared to vehicle control (two-way RM 
ANOVA p < 0.01), while no such differences are seen until day 2 for the gentamicin-treated 
group (two-way RM ANOVA p < 0.01). While a general trend toward decreased colonization 
load is seen with administration of 60 mg/kg cefoperazone TID or 60 mg/kg ceftriaxone TID, 
neither regimen is able to attain full infection clearance by day 8.
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Figure 3.20: Evaluation of cefoperazone in a murine model of gonococcal infection. A. Kaplan-
Meier curve for culture positivity in mice treated with 120 mg/kg intraperitoneal (IP) cefoperazone 
or ceftriaxone three times daily (TID). *Historical data from the Jerse laboratory. **Positive control 
group was given 48mg/kg gentamicin IP once daily (QD). B. Colonization load by day for groups 
treated with 120 mg/kg IP cefoperazone or ceftriaxone TID. C. Kaplan-Meier curve for culture 
positivity in mice treated with 60 mg/kg IP cefoperazone or ceftriaxone TID. D. Colonization load 




The goal of the current work is to elucidate which features of the cephalosporin 
class of β-lactam antibiotics are important for antimicrobial activity against cephalosporin-
resistant Neisseria gonorrhoeae H041 through inhibition of PBP2. We find that the 
structure of the R1 (C7 acylamino) side chain of cephalosporins has a profound effect on 
the second-order rate of tPBP2H041 acylation, while the R2 (C3) side chain plays a subtler 
role. Through molecular docking simulations of the precovalent ligand-receptor complex, 
we show that aromatic and hydrophobic groups on R1 extend toward a hydrophobic patch 
of the tPBP2H041 active site, and electronegative elements of R2 interact with K361. We 
also show that antimicrobial activity correlates somewhat with tPBP2H041 inhibition, but is 
complicated by a need to evade additional resistance mechanisms present in the 
organism. Finally, we observe that cefoperazone acylates tPBP2H041 at a rate 7-fold faster 
than ceftriaxone, and it exhibits comparable activity to ceftriaxone against N. gonorrhoeae 
H041 both in vitro and in vivo. 
3.7.a. Contributions of R1 to  tPBP2H041-cephalosporin complex formation.  
In this study, we found evidence of a key role for R1 structure and properties in the 
second-order rate of acylation of tPBP2H041. The unfavorable contributions of several 
atomic lipophilicity descriptors indicate that the R1-binding region of the PBP2H041 active 
site is not tolerant of highly hydrophobic moieties. However, the atomic molar refractivity 
descriptors show that this region cannot be extremely polar either. It therefore appears 
that while there may be areas where hydrogen bonding is advantageous (e.g., interaction 
of the acylamino moiety in mimicry of the peptide substrate), the R1 side chain should 
contain groups of modest hydrophobicity, such as aromatic- and heteroaromatic ring-
containing systems. In addition, the total van der Waals surface area of the R1 group 
contributes positively to acylation rate, suggesting a critical role for size of the 
cephalosporin in tPBP2H041 acylation. Hence, while the ATAO side chains (van der Waals 
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volume V ~ 200 Å3 , distribution coefficient  logD7.4 = -0.7) seen in many third-generation 
cephalosporins, as well as the chemically similar thiadiazolyl variants possessed by fifth-
generation agents, generally confer some activity, the larger (V > 400 Å3) and more 
lipophilic (logD7.4 = 0.6) 2,3-dioxopiperazinyl moiety of cefoperazone dramatically 
increases acylation rate.  
Shape and topology also play critical roles, with high degrees of unsaturation and 
cyclicity being associated with higher rates of acylation. Illustrating this trend is the vast 
difference in acylation rates between cefmetazole, which has a negligible acylation rate 
and is the only cephalosporin in our study lacking a ring system on R1, and cefoperazone, 
which has two ring systems and exhibits the highest rate among the cephalosporins 
tested. Also apparent in the R1 topological parameters is a preference for modest numbers 
of heteroatoms, as well as a moderate degree of branching. The former is illustrated by 
the low activity conferred by the tetrazolyl R1 of cefazolin, and the latter is apparent from 
differences in acylation rates between compounds with 2-unsubstituted acylamino groups 
(e.g., cephalothin and cephaloridine) and those with a single branch point at this position 
(e.g., ceftriaxone and cefoperazone). The exception is that several compounds with 2-
substituted acylamino groups have very poor activity, including cephaloridine, cephalexin, 
and cefaclor. These, however, are suboptimal for tPBP2H041 acylation because they 
possess a small R1 with sulfonic acid or primary amine moieties. Energy score analysis of 
docking data for R2-paired compounds suggests that these R1 groups impact precovalent 
Michaelis complex formation by altering affinity for tPBP2H041 rather than acylation (Figure 
3.21). With the exception of ceftizoxime and ceftibuten, the faster acylating compound of 
each pair shows a more favorable binding energy with the tPBP2H041 active site. 
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Figure 3.21: Energy score analyses for docking of cephalosporins against tPBP2H041. A. Overall 
energy scores for the cephalosporins tested, rank ordered by second-order acylation rate (n = 10 
poses), show a correlation of computational affinity with activity. B. Comparisons of energy scores 
for cephalosporins with different R1 and identical R2. “High-affinity” indicates the molecule of the 
pair exhibiting more rapid acylation (e.g., cefoperazone). “Low-affinity” indicates the molecule of 
the pair exhibiting slower acylation (e.g., cefmetazole). N-methyltetrazole (NMTT), pyridyl (pyr). C. 
Comparisons of energy scores for cephalosporins with similar R1 and different R2 show a 






Previous studies have also indicated that the R1 side chain may be an important 
driver of affinity against PBPs. In a qualitative structure-activity relationship of penicillin 
analogues against E. faecium PBP5, it was found that azlocillin (k2/Ks = 15 M-1s-1) exhibits 
much more rapid acylation of the target than piperacillin (k2/Ks = 2.2 M-1s-1), ampicillin 
(k2/Ks = 1.8 M-1s-1), or Bocillin-FL (k2/Ks = 1.1 M-1s-1).135 In a separate study of 
Streptomyces R61 DD-peptidase, penicillin G (k2/Ks = 10,300 M-1s-1) was shown to be 
manifold more potent than penicillin V (k2/Ks = 1,500 M-1s-1), carbenicillin (k2/Ks = 830 M-
1s-1), and ampicillin (k2/Ks = 107 M-1s-1).136  Since the β-lactams examined in these 
experiments are all penicillin analogues, which possess geminal dimethyl groups at the 
R2 position, one can conclude that differences in activity are imparted by R1. This idea is 
further supported by the differing specificities of compounds with identical R2 for various 
transpeptidases. For example, in membrane preparations of E. coli, cefoperazone exhibits 
very different apparent affinities for PBPs (PBP3 > PBP1b > PBP2 > PBP1a > PBP4) from 
cefmetazole (PBP4 > PBP1a = PBP1b > PBP3 > PBP2).651,652   
The strong influence of the R1 group on the activities of cephalosporins is important 
to consider in light of recent new understanding of how PBP2 is acylated by ESCs. Structures 
of tPBP2WT acylated by cefixime or ceftriaxone reveal significant movement of the β3-β4 loop 
toward the active site, where several residues form a cluster around the aminothiazole ring, 
and such interactions may contribute to the affinity of ESCs for PBP2 .113 The situation is very 
different in tPBP2H041 because movement of the loop appears restricted by mutations 
conferring resistance to ESCs, resulting in fewer interactions involving the aminothiazole in 
the acylated complex.134 Interestingly, the electron density obtained for tPBP2H041 in 
complex with ceftriaxone shows a potential dual conformation of R1, which can also be 
seen in our docking data (Figure 3.3). Such a dual conformation indicates a lack of a 
preferred, high-affinity binding mode for ceftriaxone with tPBP2H041. While the β3-β4 loop 
is still locked in an “outbent” conformation in the tPBP2H041-CFP structure reported here, 
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the modeled R1 assumes an unexpected position in the modeled binding mode that may 
help to explain part of the increase in cefoperazone’s tPBP2H041 acylation rate. Instead of 
the aromatic p-phenol group participating in π-π interactions with Y422, the 2,3-
dioxopiperazine moiety lies flat in the active site, making considerable van der Waals 
contacts with Y422 and the surrounding residues (Figure 3.22). Perhaps, then, the ideal 
cephalosporin for acylation of tPBP2H041 is one whose R1 can either 1) induce the hinging 
in the β3-β4 loop to form more extensive contacts with the transpeptidase active site or 2) 





Figure 3.22: Contact of the 2,3-dioxopiperazine moiety of cefoperazone with tPBP2H041 in a 
preliminary complex crystal structure. While the 2,3-dioxopiperazine does not make any polar 
contacts with active site residues, it creates a large area of van der Waals contact with Y422 and 
surrounding residues. tPBP2H041 and its surface are shown in cyan, and cefoperazone and its 





3.7.b. Contributions of R2 to  tPBP2H041-cephalosporin complex formation.  
We also found that structural variations in R2 can have effects on tPBP2H041 
acylation, albeit to a lesser extent than R1. First, planar R2 groups are correlated with faster 
acylation rates. In fact, the four fastest acylating compounds (i.e., cefoperazone, 
ceftaroline, ceftobiprole, and ceftriaxone) all have planar R2 groups with extended ring 
systems, conferring several-fold increases in acylation when compared with compounds 
of similar R1 group (e.g., ceftobiprole versus cefdinir). Second, the hydrogen bonding 
capacity of R2 also appears to affect acylation, as exemplified by the thiotriazinone (TTN) 
moiety conferring a 1.5- to 3-fold enhancement over other ATAO-containing 
cephalosporins. Our docking data suggest that the electronegativity and hydrogen 
bonding capability of R2 enhances affinity for the tPBP2H041 active site (Figure 3.21). In 
addition to influencing precovalent ligand-receptor complex formation, the R2 group can 
also participate in long-range inductive effects through the conjugated cephem 
system.217,218 Thus, atoms in R2 may also exert an electron-withdrawing inductive effect, 
thereby activating the β-lactam carbonyl for more rapid acylation. This is best illustrated 
by the differences in acylation rate between cefaclor (29 ± 4 M-1s-1) and cephalexin (~0.3 
M-1s-1), which have identical R1 groups but R2 groups with opposite inductive effects.  
Finally, we found no correlation between the presence or absence of a C3 leaving 
group on the dihydrothiazine ring of the cephalosporin and tPBP2H041 acylation. These C3 
substituents are expelled by resonance upon acylation, and cephalosporins containing 
leaving groups are thought to form more stable acyl-enzyme complexes, thereby 
decreasing the rate of deacylation (k3) and regeneration of the PBP in apo form.653 Our 
data are in keeping with the idea that departure of a C3 leaving group affects k3 but not 
the rate of acylation. Nevertheless, given that tPBP2H041 has an enhanced rate of 
deacylation compared to tPBP2WT,134 the leaving group should be taken into consideration 
when selecting or designing antigonococcal therapeutics. 
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In recent years, there have been several attempts to utilize the R2 side chain of 
cephalosporins to reduce susceptibility to β-lactamases, and to enhance cell-wall 
permeability and PBP-binding affinity.654-656 As an example, the planar vinylpyrrolidinone 
side chain of ceftobiprole was designed to bind a narrow groove within the active site of 
S. aureus PBP2a.656 Although there have been no design efforts of this nature against N. 
gonorrhoeae PBP2 to date, our model can be used to make predictions about the structure 
of an R2 side chain that would be expected to increase acylation rate. Generally, 
tetravalent nitrogen-containing leaving groups lead to poor acylation against tPBP2H041, 
as in the case of ceftolozane, cefsulodin, and cephaloridine. This is consistent with 
previous studies showing that, although zwitterionic cephalosporins are distinguished by 
their superior transport through porins and decreased affinity for β-lactamases, they suffer 
from a loss of affinity for PBPs.266 By contrast, ceftaroline and ceftobiprole, which also 
contain nitrogen cations, acylate tPBP2H041 rapidly. Their formal positive charges are more 
distal to the bicyclic cephem core compared to others, suggesting a specific spatial 
discrimination against such a feature.  
In the docked models, larger heterocyclic R2 groups are shown to interact 
predominantly with K361 and surrounding residues, a finding corroborated by 
compromised acylation of a tPBP2H041-K361E mutant by cefoperazone and ceftriaxone. 
By contrast, a crystal structure of tPBP2WT acylated by ceftriaxone with the C3 leaving 
group intact shows R2 interacting with residues immediately prior to α11, similar to the 
structure of S. aureus PBP2a in complex with ceftobiprole.657 Surprisingly, very few poses 
from our docking studies adopt this conformation. These differences may indicate a 
different binding mode between PBP2WT and PBP2H041, or they may suggest a shift in 




3.7.c. Interactions of the C4 carboxylate with S483 
In addition to providing structural insight into the trends above for R1 and R2, the 
docking data also model how the bicyclic cephem scaffold might fit into the active site 
during formation of the tPBP2H041-cephalosporin precovalent complex. In the docking 
models, most of the cephalosporins interact directly with S483, which is mutated in 
PBP2H041 compared to PBP2WT (from threonine) and contributes to cephalosporin 
resistance.384 Previously, Tomberg et al. postulated that S483 is important for recognition 
of the C4 carboxylate. In tPBP2H041, a small pocket comprising S362, T/S483, and K497 
binds the carboxylate (Figure 3.23), orienting the cephem in a position where the β-lactam 
carbonyl is inaccessible to the serine nucleophile (Figure 3.5). This binding mode differs 
significantly from what is seen in acylated structures of either tPBP2WT or tPBP2H041. In 
post-covalent crystal structures of tPBP2WT acylated by cefixime or ceftriaxone, the C4 
carboxylate interacts instead with the Oɣ of T498, which has rotated to accommodate the 
ligand, bringing the β-lactam ring into optimal position for reaction with S310.113 In the acyl-
enzyme structure of tPBP2H041 with ceftriaxone, the C4 carboxylate interacts with S545 in 















































































































































































































































































Repetition of the cephalosporin docking analyses with tPBP2WT shows that the C4 
carboxylate interacts with T483 in the apo form, occupying a very similar position to what 
is seen in the major pose of our tPBP2H041 docking data. This suggests a similar initial 
binding mode for both tPBP2WT and tPBP2H041 in which T/S483 plays a critical role in 
carboxylate recognition (Figure 3.24). Additional experiments, in which the 
cephalosporins were docked against the T498-rotated form of tPBP2WT, yield binding 
modes showing the carboxylate occupying a position closer to that seen in the acyl 
structure (Figure 3.25). However, in tPBP2H041, the T498 side chain participates in a 
hydrogen bonding interaction with the S545 side chain, preventing its rotation to contact 
the β-lactam carboxylate during acylation.134 As a result, it appears that the cephalosporin 
receives no enzymatic guidance toward a reactive position (represented in our dataset as 
the minor pose) when bound to tPBP2H041, slowing the acylation rate. Our data do not 
explain the final position of the carboxylate in acylated structure of tPBP2H041, however. 
Although this final position may be achieved during the course of the acylation reaction, 





Figure 3.24: Overlay of ceftriaxone docked to apo tPBP2WT with the major pose of ceftriaxone 
docked to tPBP2H041. Docked precovalent poses of ceftriaxone with apo tPBP2WT (orange) are very 




Figure 3.25: Overlay of ceftriaxone docked to T498-rotated tPBP2WT with the minor pose of 
ceftriaxone docked to tPBP2H041. T498 rotation toward the active site in response to carboxylate 
binding orients the β-lactam ring in preparation for acylation, and also orients the aromatic thiazole 
toward its final position near α8 (tPBP2WT complex shown in orange). In the absence of this rotation, 





3.7.d. Correlations between acylation rate and antimicrobial activity 
There is some correlation between acylation rate and antimicrobial activity for the 
set of cephalosporins. For example, cefoperazone and ceftriaxone, which acylate 
tPBP2H041 rapidly, exhibit the most potent antimicrobial activity, while cefaclor, cefsulodin, 
cephalexin, and cephalothin, which do not acylate tPBP2H041, exhibit the least. Some 
cephalosporins, however, deviate significantly from this trend. One reason for these 
discrepancies can be seen in the antimicrobial activity model, the descriptors of which 
reflect the ability of a molecule to access the periplasm by traversing the predominant porin 
in N. gonorrhoeae PorB1b , as well as their propensity to be substrates for efflux by the 
MtrCDE system. In fact, the same amphipathic features of cephalosporins that favor rapid 
acylation of tPBP2H041 (i.e., large, lipophilic R1 and polar R2) also result in decreased 
diffusion through porins and increased efflux.317,318 Examples of cephalosporins susceptible 
to such factors include ceftaroline and ceftobiprole, whose rapid acylation rates contrast 
with relatively weak antimicrobial potency. This is especially the case for ceftaroline, which 
is relatively hydrophobic compared to other cephalosporins (logD7.4 = 1.03), and is 
relatively ineffective against H041 in vitro.444 The picture is less clear for ceftobiprole, 
whose relative hydrophilicity (logD7.4 = -2.33) suggests it less likely to be removed from 
the gonococcal cell by efflux pumps. However, MtrCDE confers resistance to a number of 
cationic species and may also transport ceftobiprole.312 Strategic addition of anionic 
groups to cephalosporins exhibiting rapid tPBP2H041 acylation may therefore increase 
antimicrobial activity by increasing aqueous solvation and avoiding efflux mechanisms.  
Another reason for the weak correlation between k2/Ks and antimicrobial activity is 
that some cephalosporins may acylate PBP1 more rapidly than PBP2. For example, 
cefdinir and cefoxitin exhibit very slow acylation rates versus tPBP2H041, but high 
antimicrobial activity (MICs are 1.5 and 3 μg/mL, respectively), consistent with them 
targeting PBP1 rather than PBP2. In fact, cefdinir and cefoxitin generally show preferential 
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binding to class A and class C PBPs from a number of bacterial species,658-665 and early 
studies of PBPs from N. gonorrhoeae show that cefoxitin acylates PBP1 more rapidly than 
PBP2 in penicillin-susceptible and -resistant strains.666  
3.7.e. The potential of cefoperazone to treat ESC-resistant gonorrhea 
This work has revealed the third-generation compound cefoperazone is nearly 7-
fold more active against tPBP2H041 than ceftriaxone, is comparably potent against the 
H041 strain, and performs similarly in a mouse model of infection. This is consistent with 
previous studies of gonococcal PBPs that showed cefoperazone bound to PBP2 in 
membrane preparations at concentrations of less than 10-3 µg/mL.666 It is also consistent 
with the high activity of ureido penicillins and cephalosporins against class B PBPs from 
several Gram negative pathogens.589,651,667-669 To date, cefoperazone has been reported 
as being highly effective against infections by both penicillin-susceptible and -resistant 
gonococci.670-672 Its activity against the H041 strain reported here suggests cefoperazone 
has potential to address ESC-resistant N. gonorrhoeae conferred by mosaic penA due to 
its higher acylation activity against PBP2 compared to ceftriaxone. Cefoperazone is FDA-
approved and safe for use in most patients, with tolerated daily doses up to multiple grams 
and a similar side effect profile to other β-lactam antimicrobials.673 Cephalosporins with N-
methyltetrazole (NMTT) leaving groups at R2, such as cefoperazone, have been 
associated with an increase in prothrombin time (PT) via the inhibition of vitamin K 
dependent ɣ-carboxylases by NMTT and its symmetric disulfide oxidation product; 
however, the IC50 is quite high for each species (~200 and 600 µM, respectively).674 
Generally, this inhibition results in increases in PT without increases in clinically significant 
bleeding.675 One study shows increased risk with cefoperazone specifically, but cases and 
controls are poorly matched (i.e., the exposed group had many more comorbidities 
associated with bleeding).676 While the pharmacokinetics of cefoperazone may be less 
favorable than ceftriaxone for treating urogenital infections, with a t1/2 of 1-2 hours (versus 
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6-8 hours for CRO) and primarily biliary excretion (versus primarily renal for CRO),677 it 
may have utility in the treatment of mucosal infections due to its relative lipophilicity. In the 
murine model of gonococcal infection, 120 mg/kg cefoperazone administered TID 
exhibited similar efficacy to an identical regimen of ceftriaxone. With optimized dosing 
guided by pharmacokinetics, cefoperazone may offer another clinical option for highly 
resistant gonococcal infections in a relatively barren therapeutic landscape.  
3.7.f. Significance 
The overall picture emerging from our studies is that rapid tPBP2H041 acylation is 
promoted by a large R1 (C7 acylamino side chain) with modestly lipophilic properties, and 
an electronegative R2 (C3 side chain) with a planar structure. Unfortunately, these 
properties render cephalosporins less permeable to the Gram negative outer membrane 
and more prone to efflux, but strategic placement of anionic groups may help to overcome 
these barriers. Finally, we have shown that cefoperazone holds promise as an 































Due to their status as critical antibacterial targets, and given the rising number of 
bacteria resistant to existing β-lactams, the PBPs have become the subjects of numerous 
drug discovery ventures. Many efforts have centered on the modification of the β-lactam 
or lactivicin framework, adding novel side chains predicted to show enhanced interaction 
with the active site. Others have focused on tetrahedral intermediate mimicry via the 
reaction of phosphonates, boronates, and cyclobutanones with the serine nucleophile. 
However, if the mutations in PBP2 conferring cephalosporin resistance do so in part by 
decreasing reactivity to electrophiles, these strategies may prove fruitless.  
Another, perhaps more urgent, reason to explore non-β-lactam agents as PBP 
inhibitors is the emergence of highly efficient hydrolytic enzymes. Nearly 1,000 unique β-
lactamases have been identified in clinical isolates across species, and extended-
spectrum β-lactamases (ESBLs) have emerged in many Gram negative bacteria, 
including the highly resistant ESKAPE pathogens (Enterococcus, Staphylococcus, 
Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter), necessitating the 
identification of alternatives to the current therapies.345 While strains of Neisseria 
gonorrhoeae capable of producing β-lactamases have been isolated, they are rarer than 
strains harboring chromosomal resistance determinants. Moreover, only penicillinases have 
been reported in the gonococcus to date.18,19,349 Recently, however, plasmids containing 
blaTEM-135 have been identified,350-352 several of which possess an M182T mutation seen in 
many ESBL.351 It is proposed that this mutation stabilizes the active site and may allow 
additional mutations to the encoded TEM-135 penicillinase that broaden its spectrum.  
For these reasons, high throughput methods (e.g., in silico and physical screening) 
have been employed with the goal of discovering novel chemotypes that inhibit PBPs 
noncovalently. Although several investigations have identified a number of chemical 
scaffolds as inhibitors of various class B PBPs, such molecules tend to lack potency and 
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require a great deal of optimization by medicinal chemistry. The identification of new PBP-
inhibitory scaffolds should be continued, as it may increase the number of eventual 
successful molecules against the target by affording diverse candidates for development. 
While the specific QSAR models developed in Chapter 3 were constructed using activity 
data from cephalosporins, the general trends they reveal about features necessary for 
PBP2 inhibition can be applied to the identification of novel inhibitors. In this chapter, the 
discovery of two novel N. gonorrhoeae PBP2 inhibitors (JEK-42 and JMT-1) possessing 
a common 1,1’-biphenyl moiety is described. These compounds are capable of inhibiting 
PBP2 of both β-lactam-susceptible (tPBP2WT) and -resistant (tPBP2H041) strains, and they 
show antimicrobial activity against N. gonorrhoeae FA19 and H041 in disc diffusion 
assays. Interestingly, they also show inhibition of P. aeruginosa PBP3. Through modeling 
of their PBP2 binding modes by docking and molecular dynamics, we show the potential 
for interaction with a number of residues conserved across class B PBPs, as well as 
possible β-lactam mimicry. Finally, we present a three-point pharmacophore model 
constructed from the structural similarities between these molecules and β-lactams to aid 
in the identification of additional scaffolds. Overall, our data reveal that JEK-42 and JMT-1 









4.2. Identification of 2-(biphenylamido)benzoic acids and isosteres as PBP2 inhibitors 
 
4.2.a. Physical screen of (biphenylamido)benzoic acids against tPBP2WT 
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  16, 23-26, 29-24, 36-39, 41-46: R1 = COOH



























From the ligand binding data (i.e., cephalosporin docking data and structure-
activity relationships) described in Chapter 3, we found that large, somewhat lipophilic 
groups of high cyclicity are favored in the direction of the cephalosporin R1 side chain. This 
information, in combination with the knowledge that active β-lactam antimicrobials require 
a specific spatial arrangement of their carboxylate and carbonyl groups for binding to 
PBPs,142 led to the selection of a group of (biphenylamido)benzoic acids as possible PBP2 
binders (Figure 4.1), 24 of which were synthesized and provided by Joy Kirkpatrick. 
Testing of these compounds against tPBP2WT revealed 2-(4’-methyl-[1,1'-biphenyl]-4-
amido)-5-fluorobenzoic acid (JEK-42) and 2-(4’-methyl-[1,1'-biphenyl]-3-amido)-5-
fluorobenzoic acid (JEK-45) as active in a competition assay with Bocillin-FL, exhibiting 
89 ± 5% and 86 ± 4% inhibition at 100 μM, respectively (Figure 4.2A). The beginnings of 
a structure-activity relationship can be seen from comparisons within this dataset (Figure 
4.2B). First, a switch from anthranilic acid to its meta- or para-benzoic acid analogues 
results in little to no PBP2 inhibition. The substitution pattern of the anthranilic acid moiety 
also affects inhibition, with 3-substituted and fully unsubstituted systems showing greatly 
diminished activity compared to 4- and 5-substituted analogues. Next, a [1,1'-biphenyl]-4-
amido or [1,1'-biphenyl]-3-amido structure is preferred, as [1,1'-biphenyl]-2-amido 
analogues of these compounds suffer a stark loss of potency. Finally, a 4’-methyl 
substitution appears to enhance inhibition considerably, as the only 4’-desmethyl 
analogue with any activity is the weak inhibitor JEK-30 (27 ± 10% inhibition). Due to its 
reasonable inhibition of tPBP2WT at the concentration assayed, as well as the commercial 





Figure 4.2: Inhibition data for JEK compounds against tPBP2WT. A. Values were determined in a 
purified protein assay in which tPBP2WT was preincubated with 100 µM compound, followed by 
addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO control. Error bars are 




JEK-42 was resynthesized from 4'-methyl-[1,1'-biphenyl]-4-carboxylic acid and 
methyl 5-fluoroanthranilate using the method shown in Scheme 4.1. The compound was 
tested for inhibition of tPBP2H041 at 100 µM and showed 99 ± 1% suppression of activity 
(Figure 4.3A). Further evaluation in a disc diffusion assay against N. gonorrhoeae FA19 
and H041 revealed that JEK-42 inhibits growth of these strains with 18.0  ± 0.9 mm and 
15.3  ± 0.4 mm zones of inhibition, respectively (Figure 4.3B). This inhibition is 
comparable to a ceftriaxone control disc, which shows zones of inhibition measuring 19.3 
± 1.3 mm against FA19 and 14.6 ± 3.8 mm against H041. To assess the possibility for 
broad-spectrum activity, the compound was also assayed against Pseudomonas 




Scheme 4.1: Synthesis of JEK-42 from 4’-methyl-[1,1’-biphenyl]-4-carboxylic acid. a. DMF, DCE, 


























Figure 4.3: Activity data for JEK-42. A. PBP inhibition was determined in a purified protein assay 
in which a given PBP was preincubated with 100 µM compound, followed by addition of 1 µM 
Bocillin-FL. Data are presented as a fraction of DMSO control. B. Antimicrobial activity was 
determined in a disc diffusion assay against susceptible reference gonococcal strain FA19 and 
multi-drug resistant H041 at 10 µg per disc. Data for a ceftriaxone control disc (CRO) are shown. 
Error bars are standard deviation. 
 
4.2.b. Synthesis and testing of a sulfonamide derivative of JMT-1 
To examine the effect of modifications to the carbonyl group of JEK-42, simple 
isosteric substitution of the amide with a sulfonamide was performed to give 5-fluoro-2-
(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-1), obtained from 4'-methyl-
[1,1'-biphenyl]-4-sulfonyl chloride and methyl 5-fluoroanthranilate using the synthetic 
method shown in Scheme 4.2. JMT-1 was screened at 100 µM against both tPBP2WT and 
tPBP2H041, against which it showed 93 ± 7% and 84 ± 2% inhibition, respectively (Figure 
4.4A). The compound was found to have antimicrobial activity as well, albeit slightly less 
than that of JEK-42. In disc diffusion assays, JMT-1 exhibits a 16.7 ± 1.2 mm zone of 
inhibition against N. gonorrhoeae FA19 and a 10.8 ± 0.4 mm zone of inhibition against N. 
gonorrhoeae H041 (Figure 4.4B). The compound is also active against P. aeruginosa 






Scheme 4.2: Synthesis of JMT-1 from 4’-methyl-[1,1’-biphenyl]-4-sulfonyl chloride. a. pyridine, 




Figure 4.4: Activity data for sulfonamide derivative JMT-1. A. PBP inhibition was determined in a 
purified protein assay in which a given PBP was preincubated with 100 µM compound, followed by 
addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO control. B. Antimicrobial 
activity was determined in a disc diffusion assay against susceptible reference gonococcal strain 
FA19 and multi-drug resistant H041 at 10 µg per disc. Data for a ceftriaxone control disc (CRO) 





















4.3. Prediction of the binding modes of JEK-42 and JMT-1 
4.3.a. In tandem docking and molecular dynamics against tPBP2WT and tPBP2H041 
Important for inhibition by the amides and sulfonamides is the presence of an 
anthranilic acid motif, and not its meta- or para-aminobenzoic acid analogues. This is 
perhaps due to the same constraints placed on β-lactam antimicrobials for their mimicry 
of the D-Ala-D-Ala substrate of peptidoglycan. Depending upon the C1-C2-N-C dihedral 
(or C1-C2-N-S in the case of sulfonamides), the distance between the carboxylate carbon 
and the amide oxygen in these molecules (analogous to the Cohen distance in β-lactams) 
ranges from 2.5 Å to 5.0 Å. Thus, in certain conformations, the reported scaffolds may be 
capable of mimicking β-lactams in their binding to PBPs. A comparison of the structural 
similarities among cephems, JEK-42, and JMT-1 is shown in Figure 4.5. 
 
 
Figure 4.5: Structural similarities between cephems and the base scaffolds of JEK-42 and JMT-1. 
The examined PBP2 inhibitors share a triad of features, including an acidic group, a hydrogen bond 
acceptor, and a hydrophobic/aromatic group.  
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Initial attempts to crystallize these compounds in complex with tPBP2 variants 
were unsuccessful, perhaps due to their limited affinity and aqueous solubility. For this 
reason, in silico tools were employed to model their potential binding modes. Using 
constraints informed by structures of PBP2 variants in complex with ceftriaxone, ligands 
JEK-42 and JMT-1 were flexibly docked into the active sites of tPBP2WT and tPBP2H041, 
followed by 5 ns molecular dynamics simulations to assess the stability of the generated 
poses. While substantial movement of the ligand anionic group is observed in the first 500 
ps for simulations of JEK-42 and JMT-1 in complex with tPBP2WT (Figures 4.6 and 4.7), 
the modeled complexes are stable for the remaining 4.5 ns according to measurements 
of ligand-tPBP2 interaction energy, ligand internal energy, and root mean square deviation 
(rmsd) of the ligand from its initial position (Figures 4.6 and 4.9). The tPBP2H041 complexes 
are stable for the entirety of the simulation by these same measures (Figures 4.6, 4.8, 
and 4.10). Overall, the consistency of energy scores and ligand positions indicate that the 
in silico analyses generated reasonable hypotheses for the ligands’ true binding modes at 
equilibrium.  
In the modeled poses, JMT-1 shows a more favorable interaction energy with both 
tPBP2WT and tPBP2H041 compared to JEK-42, due in large part to improved electrostatics 
(Table 4.1). However, while the sulfonamide may provide better contact with the active 
site, it appears to do so at the expense of ligand internal energy, as JMT-1 must assume 
a higher energy conformation for binding to the transpeptidase active site. A majority of 
this energy comes from angle bending and intramolecular electrostatic repulsion. 
Interestingly, while JMT-1 exhibits a significant reduction in interaction energy with 
tPBP2H041 compared to tPBP2WT, there is no such reduction for JEK-42. This is a possible 
explanation for the relative activities of the compounds against tPBP2H041 in the in vitro 
competition assay with Bocillin-FL.  
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Table 4.1: Summary data for molecular dynamics simulations of JEK-42 and JMT-1 in complex 
with tPBP2. aAverage energy calculated from the state of the system in intervals of 500 ps (n = 11). 
bOverall variation in tPBP2 complex structure, as calculated by the alignment and superimposition 
of 11 states representing the system at 500 ps intervals. cTotal ligand displacement from its initial 
position. 
 
 Receptor tPBP2WT tPBP2H041 






Overall -155.3 ± 11.8 -234.7 ± 9.8 -123.2 ± 4.9 -158.4 ± 12.6 
van der 
Waals -26.1 ± 4.3 -26.4 ± 4.6 -29.1 ± 3.7 -32.2 ± 3.7 







Overall 60.5 ± 7.2 131.9 ± 6.4 56.0 ± 8.2 152.4 ± 4.7 
Strain 8.1 ± 3.7 10.1 ± 4.5 9.1 ± 4.3 9.9 ± 4.5 
Angle Bend 21.6 ± 4.3 37.8 ± 5.3 19.5 ± 3.7 41.3 ± 3.3 
Out of Plane 3.7 ± 1.8 2.8 ± 1.5 4.2 ± 1.6 5.0 ± 1.9 
Torsion 29.2 ± 4.0 21.9 ± 3.9 23.4 ± 3.8 27.0 ± 4.3 
van der 
Waals 11.0 ± 2.1 11.6 ± 2.2 13.4 ± 2.5 9.1 ± 1.3 
Electrostatics -16.1 ± 4.0 47.4 ± 4.7 -15.0 ± 6.4 57.7 ± 3.4 
Complex rmsd (Å)b 0.920 1.114 0.554 1.013 







Figure 4.6: Energy and position analyses for molecular dynamics simulations of JEK-42 and JMT-
1 in complex with tPBP2WT and tPBP2H041. A. Potential energy of interaction was calculated for the 
tPBP2WT-JMT complexes at intervals of 250 ps. Data beyond 500 ps were fit to linear regressions 
to determine change in attractive/repulsive forces in the active site over time. All slopes are 
statistically insignificant. B. Ligand potential energy was calculated for poses in complex with 
tPBP2WT at intervals of 250 ps. Data beyond 500 ps were fit to linear regressions to determine 
change in pose energetic favorability over time. All slopes are statistically insignificant. C. Ligand 
displacement from its initial pose was calculated at intervals of 500 ps. Data beyond 500 ps were 
fit to linear regressions to determine ligand movement over time. All slopes are statistically 
insignificant. D. Potential energy of interaction analysis for tPBP2H041-JMT complexes. All slopes 
are statistically insignificant. E. Ligand potential energy analysis for tPBP2H041-JMT complexes. All 





Figure 4.7: Change in positions of JEK-42 (A) and JMT-1 (B) in the active site of tPBP2WT over the 
first 500 ps of molecular dynamics simulations. A. In the first 500 ps of the molecular dynamics 
simulation, JEK-42 moves to an rmsd of 2.4 Å, much of which is accounted for by the flipping of 
the anthranilic acid moiety. At the start of the simulation (ligand and receptor shown in yellow), the 
carboxylic acid faces T498, and the aromatic ring is angled such that it faces S310. At the end of 
the initial phase of the simulation (ligand shown in purple, receptor shown in pink), it has rotated 
approximately 90° such that the carboxylic acid now faces S310 and S362. B. JMT-1 moves to an 
rmsd of 1.5 Å in the first phase of the simulation. Like JEK-42, its carboxylic acid faces T498 at the 
start of the simulation (shown in orange), and by 500 ps (ligand shown in teal, receptor shown in 
cyan), the aromatic ring has rotated approximately 60° such that the carboxylic acid faces S310 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































For all complexes examined, a carbonyl or sulfonyl oxygen is positioned within the 
oxyanion hole created by the main chain nitrogens of Ser310 and Thr500, a position that 
is well-maintained throughout all molecular dynamics simulations (Figure 4.11A). An 
additional hydrogen bond is observed between the second sulfonyl oxygen of JMT-1 and 
the side chain of Thr500. Also consistent across models is the position of the 1,1’-biphenyl 
system, which projects into a hydrophobic patch comprising Phe420 and Tyr422 (Figure 
4.11B). In the distribution of states seen over the course of the simulations, these 1,1’-
biphenyl systems assume two predominant positions related by rotation: one in which the 
secondary aromatic ring forms H-π interactions with Asn364, and one in which it 
participates in π-stacking with Phe420. There is another less abundant state in which the 
ring participates in π-stacking with Tyr422. 
 
 
Figure 4.11: Common interactions of JEK-42 and JMT-1 with tPBP2. A. The carbonyl or sulfonyl 
oxygens of the ligands fits into the oxyanion hole created by the main chain nitrogens of S310 and 
T500 over the course of the molecular dynamics simulations. Polar contacts with the main chain 
are shown as black dashed lines. B. The biphenyl moieties of all three ligands sit in a hydrophobic 
patch of tPBP2 surface created by the side chains of F420 and T422 and can participate in either 




Differences among the modeled complexes are apparent in the positioning of the 
acidic moieties of the ligands. For models of JEK-42 and JMT-1 in complex with tPBP2WT, 
the anthranilic acid moieties adopt different orientations, perhaps due to differences in the 
geometries of their carbonyl (sp2) and sulfonyl (sp3) functional groups (Figure 4.9). JEK-
42 is positioned such that the anthranilic acid ring is angled toward β3 and α11, with its 
carboxylate contacting the side chains of Ser310, Ser362, and Lys497. In the JMT-1 
complex, the anthranilic acid moiety occupies a more central position in the active site, 
and its carboxylate makes contacts with the side chains of Lys313, Thr483, Lys497, and 
Thr498. By contrast, in tPBP2H041-bound poses, the anthranilic acid moieties of JEK-42 
and JMT-1 are nearly identical (Figure 4.10). In the absence of Thr498 rotation toward a 
bound acidic group, the carboxylate participates in hydrogen bonding with Ser545 and 
Thr500, and the aromatic ring lies flat along the floor of the active site.  
4.3.b. Homology modeling and rigid alignment of class B PBPs 
As noted above, the docking and molecular dynamics data reveal potential 
interactions of the 1,1’-biphenyl systems of JEK-42 and JMT-1 with N364 and F420 of 
PBP2. As part of the SxN motif, N364 is highly conserved in bacterial transpeptidases. 
Examination of crystal structures and homology models of class B PBPs (model statistics 
for which are shown in Chapter 3) reveals that F420 is also highly conserved, with an 
aromatic residue being present at this position in many Gram-negative and Gram-positive 
pathogens (Figure 4.12, Table 4.2). If the proposed binding modes for JEK-42 and JMT-
1 are correct, conservation of both N364 and F420 indicates promise for inhibition of a 





Figure 4.12:  Alignment of ⍺8 of class B PBPs showing conservation of an aromatic residue in 
several important Gram negative and Gram positive pathogens. A. In Gram negative pathogens, 
aromatic residues are conserved at the positions of F420 and Y422, creating an aro-x-aro motif. N. 
gonorrhoeae PBP2 (teal), E. coli PBP3 (chartreuse), P. aeruginosa PBP3 (magenta), P. aeruginosa 
PBP3a (pink), A. baumanii PBP3 (light orange), H. influenzae PBP3 (blue), H. pylori PBP3 (grey). 
B. In Gram positive pathogens, an aromatic residue at the position of F420 is frequently conserved, 
but there is generally a glutamine at the position of Y422. S. aureus PBP2a (green), S. pneumoniae 
PBP2x (purple), E. faecalis PBP4 (maroon), E. faecium PBP5 (pink), B. subtilis PBP2b (yellow), B. 





Table 4.2: Superimposition of class B PBPs. aResidues from rigid structural alignment that occupy 
the same position as F420 in PBP2 of N. gonorrhoeae. bResidue type. *No structural data available 
– homology model constructed using SWISS-MODEL. 
 
Morphology Organism Class B PBP F420a Typeb 
 N. gonorrhoeae PBP2-H041 F420 aromatic 
 N. gonorrhoeae PBP2-WT (3EQU) F420 aromatic 
 N. meningitidis PBP2* I462 hydrophobic 
 P. aeruginosa PBP3 (3PBN) Y407 aromatic 
 P. aeruginosa PBP3a* F401 aromatic 
Gram E. coli PBP3 (4BJP) F417 aromatic 
negative A. baumanii PBP3 (3UE3) Y448 aromatic 
 H. influenzae PBP2* I461 hydrophobic 
 H. influenzae PBP3* Y438 aromatic 
 H. pylori PBP2 (5LP4) I432 hydrophobic 
 H. pylori PBP3* Y441 aromatic 
 S. aureus PBP2a (5M1A) Y519 aromatic 
 S. pneumoniae PBP2x (5OAU) F450 aromatic 
 S. pneumoniae PBP2x (1PYY) F450 aromatic 
 S. pneumoniae PBP2x (1QME) F450 aromatic 
Gram S. pneumoniae PBP2b (2WAE) F450 aromatic 
positive E. faecalis PBP4 (6BSQ) Y540 aromatic 
 E. faecium PBP5 (6MKA) Y538 aromatic 
 B. subtilis PBP2a* I523 hydrophobic 
 B. subtilis PBP2b* Y420 aromatic 
 B. subtilis PBP3* Y526 aromatic 




4.4. Virtual screen of a molecular fragment library for putative PBP2 inhibitors. 
 
 The design of compounds applying the 4’-methyl-[1,1’-biphenyl] system to other 
C-terminal peptidomimetic functionalities may yield additional, more potent inhibitors of N. 
gonorrhoeae PBP2. To this end, a three-point pharmacophore comprising the common 
characteristics of bicyclic β-lactams (i.e., penams, carbapenems, and cephalosporins) 
together with JEK-42 and JMT-1 was generated from a flexible alignment of the scaffolds 
using a stochastic conformational  search (Figure 4.13). This pharmacophore was then 
employed to search an ~800,000-ligand fragment-like subset of the ZINC virtual database 




Figure 4.13: Pharmacophore model developed from the flexible alignment of JEK-42 and JMT-1 
with bicyclic β-lactam scaffolds. Common features were identified using a threshold of 100% and a 
tolerance of 1.0 Å. The resulting model consists of three features: anionic (red mesh, radius = 0.7 
Å), hydrophobic/aromatic (green mesh, radius = 0.9 Å),  hydrogen bond acceptor (cyan mesh, 





Figure 4.14: Pharmacophore search of a virtualized library of molecular fragments. A. A three-
point pharmacophore consisting of one anionic feature (radius = 0.7 Å), one hydrophobic/aromatic 
feature (radius = 0.9 Å), and one hydrogen bond accepting feature (radius = 1.0 Å) was used to 
search a virtual library of molecular fragment structures, yielding 139,444 matching conformations. 
B. Example 2-(1,2,4-oxadiazol-5-yl)benzoic acid fragment shown in a pharmacophore-matching 
conformation (rmsd = 0.1 Å). C. Example 2-(1,2,4-oxadiazol-5-yl)benzoic acid (green) fragment 
modeled into the active site of tPBP2WT. Polar contacts are indicated by black dashed lines. 
 
 
Predictably, while the screen revealed a few structures that diverge significantly 
from known inhibitors, it predominantly yielded matches that represent simple derivatives 
of the above scaffolds. A majority of the putative hits can be divided into four structural 
categories. The first grouping is the most β-lactam-like, consisting of polycyclic carbonyl-
containing structures substituted at the β-position with a carboxylic acid (Figure 4.15). 
The carbonyl groups are varied and include lactams, lactones, and acyclic amides. 
Because β-lactams generally form low-affinity Michaelis complexes with PBPs, fragments 
i through iv are likely not the best starting points for the design of potent inhibitors. More 
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interesting are the bridged structures v through viii, which can be used to investigate the 
effects of bulk and volume of the hydrophobic feature, in comparison to monocyclic 
systems that are flat, flexible, or both. The second grouping (ix-xi) consists of saturated 
carbocyclic carboxylic acids substituted at the 2-position with an amide, similar to JEK-42 
but with more conformational flexibility at the position of the hydrophobic feature (Figure 
4.16). The third grouping contains benzoic acid analogues substituted at the 2-position 
with various amide isosteres, including esters (xii, acetyl salicylic acid), ketones (xiii), 
ureas (xiv and xv), and 5-membered heterocycles (i.e., 1,3,4-oxadiazole xvi,1,2,4-
oxadiazole xvii, thiazoles xviii and xix, imidazole xx, and 1,3,4-triazole xxi) (Figure 4.17). 
Incorporation of these types of functional groups in place of the amide seen in JEK-42 or 
the sulfonamide seen in JMT-1 would help to explore specific requirements of shape and 
conformational flexibility at the hydrogen bond accepting feature. The fourth grouping 
(xxii-xxvi) contains fragments that combine the structural modifications of the first three 
(Figure 4.18). In all, the results from this experiment provide multiple avenues for the 
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 In this work, we report the discovery of prototype PBP2 inhibitors and the creation 
of models for the identification or design of others. First, we show that JEK-42 and its 
isosteric derivative JMT-1 are PBP2-inhibitory scaffolds with antimicrobial activity against 
N. gonorrhoeae FA19 and H041. We also show that they are capable of inhibiting PBP3 
from ESKAPE pathogen P. aeruginosa. With this cross-inhibition in mind, we present 
models for the binding of these compounds in which they resemble β-lactam 
antimicrobials, presumably mimicking the C-terminal D-Ala-D-Ala motif of peptidoglycan in 
a similar manner. Finally, we present a pharmacophore model used in the identification of 
putative PBP2 inhibitors through screening of a fragment library, putative hits from which 
serve as a source of guidance for future analogue design. 
4.5.a. Arylamides and arylsulfonamides 
To date, two studies have reported inhibition of PBPs by arylamides: a small 
physical screen followed by a structural similarity search for inhibitors of S. aureus PBP2a 
and S. pneumoniae PBP2x,627 and subsequent combinatorial chemistry to explore the 
scaffold, conducted in the Gobec laboratory.628 Their best hit was 5-bromo-2-(3-
propoxybenzamido)benzoic acid, with an IC50 of 230 μM against PBP2a and 155 μM 
against PBP2x (Figure 4.19). They also observed that only amides of anthranilic acids 
(i.e., o-aminobenzoic acids) exhibit significant inhibition of either PBP2a or PBP2x, 
consistent with the results of our initial screen. The structures explored previously were 
limited to substituted phenyl systems, so the 1,1’-biphenyl system reported in JEK-42 
represents a departure into novel chemical space for PBP inhibition. In the same 
publications from the Gobec laboratory, arylsulfonamides derived from anthranilic acid 
were also shown to possess PBP-inhibitory activity.627,628 Around the same time, in a high-
throughput physical screen conducted by Fedarovich et al., additional arylsulfonamides 
were identified as inhibitors of N. gonorrhoeae PBP2.621 The best hits from those studies 
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were 5-bromo-2-(naphthalene-2-sulfonamido)benzoic acid (IC50 = 80 μM against 
SauPBP2a) and N-(4-hydroxynaphthalen-1-yl)naphthalene-1-sulfonamide (IC50 = 50 μM 
against NgPBP2), respectively (Figure 4.19). Notably, this scaffold, unlike its carboxamide 
isostere, does not seem to require a carboxylic acid for inhibition. However, the active 
compounds lacking a carboxylic acid do possess an ionizable phenolic OH situated para 
to the sulfonamide. The chemical space examined in previous studies was limited largely 
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While there are many available compounds belonging to these chemotypes for 
testing, future studies focusing on synthetic and medicinal chemistry may prove more 
useful. Amide synthesis from acyl chlorides is generally facile, and its broad functional 
group tolerance allows access to molecules with a variety of topologic and electronic 
structures. Most simple derivatives can be attained from their corresponding carboxylic 
acids and amines in two steps in excellent yield, as shown in Scheme 4.3. Fortunately, 
similar to the amides, the synthesis of sulfonamides from their corresponding sulfonyl 
chlorides and anthranilic acids can also be achieved in few steps in the presence of a 
variety of functional groups. In cases of derivatives for which the sulfonyl chloride is 
unavailable, other methods employing dediazotization or organometallic agents provide 




































































































































































































































4.5.b. Molecular dynamics and cross-inhibition of other class B PBPs – evidence 
for broad specificity 
Due to key structural similarities between cephalosporins and the described 
scaffolds, we propose that JEK-42 and JMT-1 may bind the transpeptidase active site in 
a manner similar to cephalosporins, where the 1,1’-biphenyl system corresponds to R1 
and the anthranilic acid substitution corresponds to R2. Docking and molecular dynamics 
of JEK-42 and JMT-1 yield poses similar to acylenzyme complexes of ceftriaxone with 
tPBP2WT and tPBP2H041 113,134 (Figure 4.20). In poses of both ligands in both receptors, 
the carbonyl or sulfonyl oxygen occupies the same position as the acyl oxygen of 
ceftriaxone within the oxyanion hole. While the positions of anionic groups are variable 
due to the different geometric constraints of each scaffold, they are generally in the same 
region of the active site in comparisons of the same tPBP2 variant. Moreover, the 1,1’-
biphenyl system projects in the same direction as the 2-aminothiazol-4-yl group of 
ceftriaxone. There is better overlap with the tPBP2H041-ceftriaxone structure, with the 
aromatic rings fitting into the hydrophobic area of PBP2 surface created by F420 and 
Y422. The basis for inhibition of both tPBP2WT and tPBP2H041 by JEK-42 and JMT-1 may, 
therefore, be that they 1) mimic the peptide C-terminus in a manner similar to β-lactams, 
and 2) avoid the requirement for β3-β4 hinging proposed to enhance contacts of the 
cephalosporin thiazole with the tPBP2WT active site. This, in combination with their 
predicted interactions with highly conserved residues, suggests that JEK-42 and JMT-1 
may be capable of inhibiting a variety of class B PBPs. This hypothesis is further 
strengthened by the compounds’ abilities to inhibit P. aeruginosa PBP3, another class B 
PBP with only 40% sequence identity. 
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Figure 4.20: Overlay of ceftriaxone (CRO) acyl structures with JEK-42 and, JMT-1. A. Published 
tPBP2WT-CRO complex superimposed on final positions of ligands from molecular dynamics 
simulations with tPBP2WT (receptor shown in grey, CRO shown as orange sticks, JEK-42 shown 
as purple sticks, JMT-1 shown as teal sticks). B. Published tPBP2H041-CRO complex superimposed 
on final positions of ligands from molecular dynamics simulations with tPBP2H041 (same color 





4.5.d. Guidance for further derivatization 
 The three-point pharmacophore screen of fragments proposes a number of 
changes that can be made to the anthranilic acid moiety, including replacement of the 
aromatic system with bridged polycyclic or flexible saturated carbocycles. The more 
interesting aspect of the fragment screen, however, is perhaps the variety of amide 
isosteres that emerged, including the 1,2,4-oxadiazoles. Many 1,2,4-oxadiazoles have 
now been reported with activity against S. aureus PBP2a,633-636 and the class is discussed 
in detail in Chapter 1. Briefly, shown in Figure 4.21 is the current lead compound from this 
series, exhibiting an MIC of 4 µg/mL against MRSA, low in vitro cytotoxicity, favorable 
murine pharmacokinetics, and efficacy in a murine model of staphylococcal peritonitis.635 
Another amide isostere emerging from the pharmacophore screen with precedent in the 
literature is urea. The 2-ureidobenzenesulfonic acids, also discussed in Chapter 1, were 
reported as inhibitors of S. pneumoniae PBP2x.630 The reported IC50 for the ureido 
compound shown in Figure 4.21 against PBP2x is 71 µM. Application of these isosteres, 
and others from the screen results, to our system will provide important information about 
the steric and electronic requirements of the PBP2 active site at the location occupied by 









Here we report the identification and initial characterization of two novel inhibitors 
of PBP2 from N. gonorrhoeae: 2-(arylamido)benzoic acid JEK-42 and 2-
(arylsulfonamido)benzoic acid JMT-1. The overall picture emerging from studies of these 
compounds is that they are not susceptible to the PBP2 modifications that result in 
cephalosporin resistance, and that they may be capable of inhibiting a number of other 
class B PBPs due to 1) their structural resemblance to β-lactams and 2) predicted 















































Chapter 4 outlines the discovery of novel PBP2-inhibitory chemotypes proposed 
to mimic the binding of β-lactams and, thus, the bacterial peptidoglycan D-Ala- D-Ala motif. 
The next phase of our investigation is the derivatization of these molecules, with the goal 
of enhancing in vitro potency against N. gonorrhoeae PBP2 and against the pathogen 
itself. In this chapter, the synthesis of 127 analogues of JMT-1, as well as their PBP2-






















5.2. Derivatization of JMT-1 sulfonamides 
Sulfonamide synthesis is achievable in two simple steps from commercially 
available sulfonyl chloride starting materials, shown in Scheme 5.1. The first step is 
substitution of the sulfonyl chloride (a) with either a methyl anthranilate or 2-
aminobenzonitrile. The methyl benzoate products are treated with lithium hydroxide (b) to 
afford the corresponding carboxylic acid, and benzonitrile products undergo a 1,3-dipolar 
cycloaddition with sodium azide under copper (II) sulfate catalysis (c) to generate the 






Scheme 5.1: Synthesis of JMT-1 derivatives. a. pyridine, DCM, N2, RT, 12 h. b. 1:1 THF/H2O, RT, 


























































Figure 5.2: Structures of compounds JMT-2 through JMT-15, which possess substitutions on the 
anthranilic acid moiety of JMT-1.  
 
To begin, we surveyed each position on the anthranilic acid moiety of JMT-1 to 
determine functional groups and substitution patterns that increase inhibition of PBP2. For 
all compounds synthesized, inhibition of tPBP2WT and tPBP2H041 was determined at 100 
µM using the previously described competition assay with Bocillin-FL. Compounds 
showing >80% inhibition of both variants at 100 µM were tested at 10 µM. Data for this 
initial series are shown in Figure 5.3 and Figure 5.4. Examining the compound set from 
Kirkpatrick et al. screened earlier (as described in Chapter 4), substitution at the 3-position 
was already found to abolish activity of carboxamido compounds related to JEK-42, so 
under the assumption that JEK-42 and its sulfonamide isostere JMT-1 bind similarly to 
PBP2, this position was not examined. The data show that the fully unsubstituted version 
(JMT-2) is less active at 100 µM than JMT-1, with 71 ± 4% inhibition of tPBP2WT compared 
to 93 ± 7% for JMT-1. A switch of the 5-fluoro moiety to the 4-position (JMT-3) did not 
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increase in potency, inhibiting tPBP2WT and tPBP2H041 fully at 100 µM and showing 87 ± 
6% inhibition against tPBP2H041 at 10 µM. Note the 6-fluoro product was not obtained in 
sufficient yield and purity for testing.  
 
Figure 5.3: Inhibition data for JMT-2 through JMT-15 against tPBP2WT and tPBP2H041 at 100 µM. 
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM 
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of 
the DMSO control. Error bars are standard deviation. 
 
 
Figure 5.4: Inhibition data for selected anthranilic acid-substituted derivatives of JMT-1 against 
tPBP2H041 at 10 µM. Compounds exhibiting greater than 80% inhibition of both tPBP2WT and 
tPBP2H041 activity at 100 µM (Figure 5.3) were tested. Values were determined in a purified protein 
assay in which tPBP2H041 was preincubated with 10 µM compound, followed by addition of 1 µM 
Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are standard 
deviation. 
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To examine the effects of increasing atomic radius at the 4- and 5-positions, 
analogues with additional halogens were synthesized. Analogues chlorinated (JMT-5 & 
JMT-6) or brominated (JMT-7 & JMT-8) at 4- and 5-positions are active at 100 µM, with 
the 5-bromo compound JMT-8 exhibiting 96 ± 2% inhibition of tPBP2H041 at 10 µM. The 5-
iodo product could not be synthesized in sufficient yield for testing. Further increases in 
bulk were explored with a series of methyl substitutions at the 4- and 5-positions, revealing 
the 4-methyl analogue JMT-9 to be the more active. Interestingly, while JMT-9 exhibits 85 
± 9% inhibition of tPBP2H041 at 10 µM, the 5-methyl analogue JMT-10 fails to inhibit 
tPBP2H041 fully at 100 µM. The 6-position was also surveyed by testing 6-methyl analogue 
JMT-11, whose relatively weak inhibition indicates that substitution at this position is not 
favored.  
Given the lesser activity of methyl compounds compared to their halogenated 
analogues, it can be inferred that either activity is dependent upon a very specific van der 
Waals radius of substituents to the anthranilic acid, or upon the polarizability of these 
substituents. To answer this question, analogues possessing a trifluoromethyl group at 
the 4- (JMT-12) or 5-position (JMT-13) were synthesized and potently inhibited both 
tPBP2WT and tPBP2H041. The relative potencies of compounds JMT-12 and JMT-13 (97 ± 
1% and 99 ± 1% inhibition, respectively, of tPBP2H041 at 10 µM) suggest that both van der 
Waals radius and polarizability of substituents correlate positively with PBP2 inhibition. 
All generated compounds discussed to this point possess anthranilic acid moieties 
substituted with hydrophobic functional groups. In order to assess the effects of polarity, 
4- (JMT-14) and 5-methoxy (JMT-15) compounds were generated. JMT-14 is more active 
than JMT-15 against tPBP2H041 but not more than the prototype JMT-1, indicating 
tolerance of modestly polar groups at this position rather than any preference for them. To 
explore polarity further, synthesis of a 5-nitro analogue was also attempted, but the 
desired product was not found on mass spectrometric analysis of the crude reaction 
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mixture.  In all, the pattern emerging from these initial derivatization studies suggests the 
following in terms of tPBP2 inhibition: 
4-CF3 ~ 5-CF3 ~ 5-Br > 4-Cl ~ 4,5-diF ~ 4-Br ~ 4-Me >  
5-Cl > 4-OMe > 5-OMe ~ 4-F > H > 6-Me 
Compounds exhibiting >75% inhibition of tPBP2H041 at 10 µM were tested in disc 
diffusion assays against N. gonorrhoeae FA19 and H041 (Figure 5.5). Consistent with 
their enzymatic inhibition, compounds JMT-12, and JMT-13 exhibit the most potent 
antimicrobial activity against both strains. JMT-12, a 4-trifluoromethyl analogue of 
prototype JMT-1, inhibits growth of N. gonorrhoeae FA19 and H041 up to 20.5 ± 0.7 mm 
and 15.5 ± 1.8 mm, respectively, from the edge of a disc impregnated with 10 µg 
compound. JMT-13, the 5-trifluoromethyl analogue, shows a 19.0 ± 1.0 mm zone of 
inhibition against FA19 and a 16.3 ± 1.1 mm zone of inhibition against H041. JMT-5 also 
shows good antimicrobial activity against both strains, in contrast with JMT-8, which 
shows a stark reduction in potency against H041.  
 
 
Figure 5.5: Disc diffusion data for potent anthranilic acid-substituted derivatives of JMT-1 against 
N. gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041 
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug 
resistant H041 at 10 µg per disc. 























5.2.b. Modifications to the anthranilic acid moiety II: Isosteric replacement of the 





Figure 5.6: Structures of compounds JMT-16 through JMT-25, which possess a 1H-tetrazol-5-yl 
moiety at C1 in place of the carboxylic acid seen in JMT-1. 
 
 
Next, we examined the effect of isosteric replacement of the carboxylic acid group 
of the anthranilic acid moiety on PBP2 inhibition. The 1H-tetrazol-5-yl system was chosen 
for these derivatives, as it confers favorable drug-like properties (e.g., improved 
membrane permeability and resistance to some forms of xenobiotic metabolism) and is 
easily accessed from nitriles using a copper(II)-catalyzed 1,3-dipolar cycloaddition. 
Inhibition data for this initial set of phenyltetrazoles against tPBP2 are shown in Figure 
5.7 and Figure 5.8. The generated tetrazoles JMT-16 through JMT-25 generally show 
similar activity to their carboxylic acid analogues against tPBP2WT and tPBP2H041. Modest 
improvements in tPBP2 inhibition are seen in several cases of 5-substitution, including 5-
fluoro (JMT-17), 5-chloro (JMT-18), 5-methyl (JMT-21), and 5-methoxy (JMT-25) 
compounds. Consistent with results for the anthranilic acid compounds, substitution with 
a trifluoromethyl group yields excellent tPBP2 inhibition, with 4- (JMT-22) and 5-
substituted (JMT-23) molecules showing 89 ± 4% and 83 ± 12% inhibition, respectively, 
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Figure 5.7: Inhibition data for JMT-16 through JMT-25 against tPBP2WT and tPBP2H041 at 100 µM. 
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM 
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of 
the DMSO control. Error bars are standard deviation. 
 
Figure 5.8: Inhibition data for 1H-tetrazol-5-yl derivatives of JMT-1 against tPBP2H041 at 10 µM. 
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100 
µM (Figure 5.7) were tested against tPBP2H041 at 10 µM. Values were determined in a purified 
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are 
standard deviation. 
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As for the anthranilic acid compounds, the antimicrobial activity of the tetrazoles 
was tested against N. gonorrhoeae strains FA19 and H041. Overall, antimicrobial activity 
is weaker than for the carboxylic acid parent compounds (Figure 5.9). Trifluoromethyl 
compounds JMT-22 and JMT-23 inhibit growth of N. gonorrhoeae within less than 15 mm 
of the disc. Interestingly, whereas the 5-bromo carboxylic acid JMT-8 exhibits excellent 
activity against FA19 but only modest activity against H041, its tetrazole analogue JMT-
19 seems to show very little difference between strains. JMT-19 is the most potent of this 
series, exhibiting 17.3 ± 1.8 mm and 16.0 ± 1.4 mm zones of inhibition against FA19 and 
H041, respectively.  
 
Figure 5.9: Disc diffusion data for potent 1H-tetrazol-5-yl derivatives of JMT-1 against N. 
gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041 
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug 



























5.2.c. Modifications to the anthranilic acid moiety III: Replacement of aromatic ring 







Figure 5.10: Structures of compounds JMT-26 through JMT-30, which possess nitrogen-containing 
heterocyclic carboxylic acids in place of the anthranilic acid seen in JMT-1. 
 
 
A series of sulfonamides synthesized from nitrogen-containing heterocycles were 
attempted to create scaffolds more closely resembling β-lactam antimicrobials. Inhibition 
data for this series against tPBP2 are shown in Figure 5.11. Pyrrolidine (JMT-26) and 
thiazolidine (JMT-27) compounds inhibit tPBP2WT only weakly at 100 µM. Next, the 5,5-
dimethylthiazolidine analogue JMT-28 was tested. Although this has a structure very 
similar to most penams, it fails to show any inhibition at 100 µM. Cephem-like 6-membered 
ring systems were also examined, but the incorporation of neither piperidine (JMT-29) nor 
tetrahydro-1,3-thiazine (30) improves activity.  
To determine if loss of the anthranilic acid moiety abolishes PBP2 binding fully, the 
compounds were also tested at 1 mM. At this concentration, compounds JMT-26 through 
JMT-30 all inhibit tPBP2WT, indicating a severe reduction in affinity, but not a complete 
loss. Because of their low inhibition, none of these analogues was tested against N. 
gonorrhoeae. 
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Figure 5.11: Inhibition data for JMT-26 through JMT-30 against tPBP2WT and tPBP2H041 at 100 µM. 
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM 
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of 
the DMSO control. Error bars are standard deviation. 
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Figure 5.12: Structures of compounds JMT-31 through JMT-39, which lack the biphenyl 4’-methyl 
group seen in JMT-1. 
 
 
To determine the importance of the 4’-substituent to PBP2 inhibition, a series of 
4’-desmethyl analogues (JMT-31 through JMT-39) were synthesized. Inhibition data for 
this series against tPBP2 are shown in Figure 5.13 and Figure 5.14. The first of these, 
JMT-31 through JMT-35, possess entirely unsubstituted biphenyl secondary aromatic 
systems. These compounds are generally much less active than their 4’-methylated 
counterparts, showing minimal inhibition of tPBP2WT at 100 µM. However, the 5-bromo 
analogue JMT-35 inhibits both tPBP2WT and tPBP2H041 fully at this concentration, and it 
retains some activity against tPBP2H041 upon dose reduction to 10 µM (66 ± 17% 
inhibition). Its relative potency among compounds of this series supports the assertion that 
a large, polarizable, hydrophobic group at C5 enhances inhibition.  
To survey other positions on the biphenyl secondary aromatic ring, a small number 
of 3’-methyl analogues (JMT-36 through JMT-39) were generated, which are marginally 
less active than their 4’-methyl parent compounds. The most active of those synthesized 









  31:   R1 = H
  32:   R1 = F
  33:   R1 = H
  34:   R1 = H











  36:   R1 = F
  37:   R1 = H 
  38:   R1 = H










at 10 µM, again supporting the requirement for a large, polarizable group at C5. Overall, 
the lesser activity of 4’-desmethyl compounds indicates that substitution at the 4’-position 
enhances PBP2-inhibitory potency. 
 
Figure 5.13: Inhibition data for JMT-31 through JMT-39 against tPBP2WT and tPBP2H041 at 100 µM. 
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM 
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of 
the DMSO control. Error bars are standard deviation. 
 
Figure 5.14: Inhibition data for 4’-desmethyl derivatives of JMT-1 against tPBP2H041 at 10 µM. 
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100 
µM  (Figure 5.13) were tested against tPBP2H041 at 10 µM. Values were determined in a purified 
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are 
standard deviation. 
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Figure 5.15: Structures of compounds JMT-40 through JMT-58, which possess a 4’-methoxy in 
place of the 4’-methyl group seen in JMT-1. TTZ: 1H-tetrazol-5-yl 
 
 
Since the 4’-substituent appears to be important for inhibition of PBP2, compounds 
with various 4’-substituents were synthesized to explore physicochemical requirements at 
this position. First, the influence of polarity was assessed by incorporation of a 4’-methoxy 
group (JMT-40 through JMT-58). Inhibition data for this series against tPBP2 are shown 
in Figure 5.16 and Figure 5.17. In general, this change yields less active compounds by 
direct comparison with 4’-methyl analogues, indicating that a polar group at this position 
is not favored. However, there are a few in the series that inhibit PBP2 relatively well. For 
example, 4- (JMT-46, JMT-55) and 5-trifluoromethyl (JMT-47, JMT-56) compounds are 
active, as well as 5-bromophenyl tetrazole JMT-52. In fact, JMT-46 and JMT-56 exhibit 
94 ± 0% and 91 ± 2% inhibition of tPBP2H041, respectively, at 10 µM. Again, the activity 
conferred by these hydrophobic, polarizable 4- and 5-substitutions to the anthranilic acid 
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Figure 5.16: Inhibition data for JMT-40 through JMT-58 against tPBP2WT and tPBP2H041 at 100 µM. 
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM 
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of 
the DMSO control. Error bars are standard deviation. 
 
 
Figure 5.17: Inhibition data for 4’-methoxy derivatives of JMT-1 against tPBP2H041 at 10 µM. 
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100 
µM (Figure 5.16) were tested against tPBP2H041 at 10 µM. Values were determined in a purified 
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are 
standard deviation. 
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Figure 5.18: Structures of compounds JMT-59 through JMT-83, which possess a halogen in place 
of the 4’-methyl group seen in JMT-1. TTZ: 1H-tetrazol-5-yl 
 
 
The next parameter to be examined was a change in van der Waals radius at the 
4’-position. To this end, a series of 4’-halogenated molecules was synthesized, and 
inhibition data are shown in Figure 5.19 and Figure 5.20. While the 4’-fluoro (JMT-59 
through JMT-67) analogues are among the least active compounds reported in these 
studies, large hydrophobic substitutions on the anthranilic acid moiety again enhance 
PBP2-inhibitory activity. The 5-bromoanthranilic acid and 4-methylanthranilic acid 
analogues JMT-62 and JMT-63 are the only compounds of this group to fully inhibit both 
tPBP2WT and tPBP2H041 at 100 µM. They exhibit 45 ± 14% and 54 ± 18% inhibition of 
tPBP2H041, respectively, at 10 µM. In all cases, the 4’-chloro compounds (JMT-68 through 
JMT-83) are more potent than their 4’-fluoro analogues. However, the 4’-chloro 
substitution still appears to confer less activity than the 4’-methyl parent structure. Taken 
together, these data suggest that increasing van der Waals radius at the 4’-position is 
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cannot be dismissed. Consistent with data from other series, the 4- (JMT-74) and 5-
trifluoromethylanthranilic acid (JMT-75) compounds are still quite active, inhibiting 
tPBP2H041 89 ± 4% and 86 ± 6%, respectively, at 10 µM. 
 
Figure 5.19: Inhibition data for JMT-59 through JMT-83 against tPBP2WT and tPBP2H041 at 100 µM. 
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM 
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of 
the DMSO control. Error bars are standard deviation. 
 
Figure 5.20: Inhibition data for 4-fluoro and 4-chloro derivatives of JMT-1 against tPBP2H041 at 10 
µM. Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 
100 µM (Figure 5.19) were tested against tPBP2H041 at 10 µM. Values were determined in a purified 
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are 
standard deviation. 
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Figure 5.21: Structures of compounds JMT-84 through JMT-100, which possess a 4’-
trifluoromethyl group in place of the 4’-methyl group seen in JMT-1. TTZ: 1H-tetrazol-5-yl 
 
 
To examine the effects of polarizability at the 4’-position further, a series of 4’-
trifluoromethyl analogues was synthesized. Inhibition data for this series against tPBP2 
are shown in Figure 5.22 and Figure 5.23. Analogues JMT-84 through JMT-100 are the 
most active series of compounds from the collection of biphenyl 4’-position modifications, 
with nearly all exhibiting full inhibition of both tPBP2WT and tPBP2H041 at 100 µM. Their 
potent activity in the context of a variety of 4- and 5-substituted anthranilic acid and 
phenyltetrazole moieties suggests a role for both van der Waals radius and polarizability 
at the 4’-position. From the combined data on compounds derivatized at the 4’-position, 
the following pattern has emerged with respect to tPBP2 inhibition:  
CF3 > CH3 > Cl ~ OMe > F > H 
As in other series, the most active compounds from the 4’-trifluoromethyl series are the 4- 
and 5-trifluoromethylanthranilic acid analogues JMT-90 and JMT-91, which exhibit full 
inhibition of tPBP2H041 at 10 µM. By contrast with other series, however, there are several 









  84:   R1 = F
  85:   R1 = H 
  86:   R1 = F
  87:   R1 = H
  88:   R1 = Me
  89:   R1 = H
  90:   R1 = CF3 
  91:   R1 = H










    93:   R1 = H
    94:   R1 = F
    95:   R1 = H 
    96:   R1 = H
    97:   R1 = Me
    98:   R1 = H
    99:   R1 = OMe



























(4,5-difluoroanthranilic acid), JMT-87 (5-bromoanthranilic acid), JMT-88 (4-
methylanthranilic acid), JMT95 ((5-fluorophenyl)tetrazole), and JMT-98 ((5-
methylphenyl)tetrazole) all show greater than 90% inhibition of tPBP2H041 at 10 µM.  
 
Figure 5.22: Inhibition data for JMT-84 through JMT-100 against tPBP2WT and tPBP2H041 at 100 
µM. Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 
µM compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity 
of the DMSO control. Error bars are standard deviation. 
 
Figure 5.23: Inhibition data for 4’-trifluoromethyl derivatives of JMT-1 against tPBP2H041 at 10 µM. 
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100 
µM (Figure 5.22) were tested against tPBP2H041 at 10 µM. Values were determined in a purified 
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are 
standard deviation. 
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Several of the most active compounds from the 4’-derivatized collection, defined 
as exhibiting greater than 75% inhibition against tPBP2H041 at 10 µM, were tested against 
N. gonorrhoeae FA19 and H041 in disc diffusion assays (Figure 5.24). The most potent 
antigonococcal yet, JMT-84, is seen in this group. This anthranilic acid analogue with 4-
fluoro and 4’-trifluoromethyl substitutions inhibits the growth of N. gonorrhoeae FA19 and 
H041 up to 21.2 ± 1.9 mm and 17.5 ± 0 mm, respectively, from discs imbued with 10 µg 
compound. Consistent with what was seen for the initial derivatives, phenyltetrazole 
compounds appear to perform worse than their anthranilic acid analogues in measures of 




Figure 5.24: Disc diffusion data for potent 4’-substituted derivatives of JMT-1 against N. 
gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041 
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug 

































Figure 5.25: Structures of compounds JMT-101 through JMT-118, which possess a 4-
cyclohexylphenyl group in place of the 1,1’-biphenyl system seen in JMT-1. TTZ: 1H-tetrazol-5-yl 
 
 
Next, we wanted to observe the effect of increased flexibility at the distal ring 
system on PBP2-inhibitory activity. Inhibition data for this series against tPBP2 are shown 
in Figure 5.26 and Figure 5.27. Somewhat surprisingly, replacement of the secondary 
biphenyl aromatic ring with a cyclohexyl group (JMT-101 through JMT-118) yields active 
compounds despite the absence of a 4’-substituent. This indicates that flexibility at this 
position may allow a conformation that involves more or better contacts with the PBP2 
active site. The most active compound of the cyclohexylphenyl series is the 5-
trifluoromethylanthranilic acid JMT-108, which inhibits tPBP2H041 fully at 10 µM. Other 
potent inhibitors include 4,5-difluoroanthranilic acid JMT-103, (5-fluorophenyl)tetrazole 
JMT-112, and (5-methylphenyl)tetrazole JMT-115, all of which exhibit greater than 90% 
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Figure 5.26: Inhibition data for JMT-101 through JMT-118 against tPBP2WT and tPBP2H041 at 100 
µM. Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 
µM compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity 
of the DMSO control. Error bars are standard deviation. 
 
 
Figure 5.27: Inhibition data for 4-cyclohexylphenyl derivatives of JMT-1 against tPBP2H041 at 10 
µM. Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 
100 µM (Figure 5.26) were tested against tPBP2H041 at 10 µM. Values were determined in a purified 
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 













































































































Figure 5.28: Structures of compounds JMT-119 through JMT-128, which possess a bicyclo[4.4.0] 
ring system in place of the 1,1’-biphenyl system seen in JMT-1.  
 
 
Less conservative changes were also made to the 1,1’-biphenyl system, including 
fusion to naphth-2-yl (JMT-119 through JMT-121), 5,6,7,8-tetrahydronaphth-2-yl (JMT-
122 through JMT-124), and 1,4-benzodioxan-6-yl (JMT-125 through JMT-128) systems. 
Inhibition data for this series against tPBP2 are shown in Figure 5.29 and Figure 5.30. 
Each of these changes substantially decreases inhibition. The most active among this 
series of bicyclo[4.4.0] compounds are the 5,6,7,8-tetrahydronaphth-2-yl analogues, with 
4-fluoro compound JMT-122 exhibiting 97 ± 1% and 84 ± 2% inhibition of tPBP2WT and 
tPBP2H041, respectively, at 100 μM. JMT-122 was further tested against tPBP2H041 at 10 
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Figure 5.29: Inhibition data for JMT-119 through JMT-128 against tPBP2WT and tPBP2H041 at 100 
µM. Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 
µM compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity 
of the DMSO control. Error bars are standard deviation. 
 
 
Figure 5.30: Inhibition data for bicyclo[4.4.0] derivatives of JMT-1 against tPBP2H041 at 10 µM. 
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100 
µM were tested against tPBP2H041 at 10 µM. Values were determined in a purified protein assay in 
which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 µM Bocillin-FL. 
Data are presented as a fraction of activity of the DMSO control. Error bars are standard deviation. 
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Potent PBP2 inhibitors from the final set of biphenyl modifications were tested 
against N. gonorrhoeae FA19 and H041 in disc diffusion assays, revealing the second 
most potent antigonococcal to emerge from these studies (Figure 5.31). JMT-108, a 5-
trifluoromethylanthranilic acid analogue from the cyclohexylphenyl series, exhibits large 
zones of inhibition against both FA19 (20.0 ± 0 mm) and H041 (16.0 ± 0.7 mm). Other 
compounds showing good antimicrobial activity include JMT-103, JMT-107, and JMT-
113, all of which show zones of inhibition greater than 15 mm against both strains. No 
bicyclo[4.4.0] compounds were tested due to their poor performance in PBP2 inhibition 
assays. 
 
Figure 5.31: Disc diffusion data for potent cyclohexylphenyl derivatives of JMT-1 against N. 
gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041 
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug 










































5.3. Prediction of the binding modes of the most potent JMT-1 derivatives 
The most potent PBP2 inhibitors (JMT-13 and JMT-108) and the most potent 
antigonococcal (JMT-84) were docked to the active sites of tPBP2WT and tPBP2H041 with 
guidance from the molecular dynamics simulations of JEK-42 and JMT-1 reported in 
Chapter 4.  In the modeled complexes, a sulfonyl oxygen is positioned within the oxyanion 
hole created by the main chain nitrogens of Ser310 and Thr500, and the 1,1’-biphenyl 
system extends toward N364 and F420 (Figure 5.32). In the tPBP2WT complexes, the 
carboxylic acid forms hydrogen bonds with the side chains of S362, S483, K497 and T498, 
and in the tPBP2H041 complexes, it forms hydrogen bonds with the side chain of T500 and 
S545. Because the changes to JMT-1 represented in these molecules do not add 
opportunities for strong hydrogen bonding, the resulting increases in potency likely have 
to do with enhanced van der Waals interactions with the active site. Computationally, this 
appears to be the case. On the anthranilic acid moiety of the molecule, the 5-
trifluoromethyl groups of JMT-13 and JMT-108 contribute 2-fold more van der Waals 
interaction energy to ligand-receptor complex formation than the 5-fluoro group of JMT-1 
(-0.7 kcal·mol-1 v -1.7 kcal·mol-1) (Figures 5.33 & 5.34), while the 4-fluoro group of JMT-
86 augments interaction only marginally (-0.9 kcal·mol-1). With respect to the secondary 
ring of the 1,1’-biphenyl system, the cyclohexyl system seen in JMT-108 show similar 
receptor interactions to the methylphenyl group of JMT-1 and JMT-13 (-8.8 kcal·mol-1 v -
8.6 kcal·mol-1). However, the trifluoromethylphenyl system of JMT-84 makes more 
extensive contact with the active site surface (-10.5 kcal·mol-1). 
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Figure 5.32: Docked poses of compounds showing potent tPBP2 inhibition and antigonococcal 
activity. A. When docked to tPBP2WT with guidance from the predicted JMT-1 binding mode, potent 
compounds show similar interactions with the transpeptidase active site. The docked structure of 
JMT-13 is shown in green, JMT-84 is shown in orange, and JMT-108 is shown in purple. Predicted 
hydrogen bonds are shown as dashed lines. B. Potent compounds docked to tPBP2H041 with 
guidance from the predicted JMT-1 binding mode show similar interactions with the transpeptidase 
active site. The docked structure of JMT-13 is shown in green, JMT-84 is shown in orange, and 






Figure 5.33: Surface rendering of modeled JMT-1 derivatives in complex with tPBP2WT. A. The 
trifluoromethyl group seen on the anthranilic acid moiety of JMT-13 and JMT-108 (ligand shown as 
teal sticks, surface shown as teal mesh) and the 4-fluoro group of JMT-84 (ligand shown as 
magenta sticks, surface shown as magenta mesh) create more surface contact with the active site 
of tPBP2WT than the 5-fluoro group of JMT-1 (ligand shown as orange sticks, surface shown as 
orange mesh).  B. The trifluoromethylphenyl group of JMT-84 (ligand shown as magenta sticks, 
surface shown as magenta mesh) exhibits a closer contour to the tPBP2WT surface (shown in grey) 
than the methylphenyl group of JMT-1 and JMT-13 (ligand shown as teal sticks, surface shown as 
teal mesh), while the cyclohexyl group of JMT-108 (ligand shown as yellow sticks, surface shown 






Figure 5.34: Surface rendering of modeled JMT-1 derivatives in complex with tPBP2H041. A. As in 
tPBP2WT, the trifluoromethyl group seen on the anthranilic acid moiety of JMT-13 and JMT-108 
(ligand shown as teal sticks, surface shown as teal mesh) and the 4-fluoro group of JMT-84 (ligand 
shown as magenta sticks, surface shown as magenta mesh) create more surface contact with the 
active site of tPBP2H041 than the 5-fluoro group of JMT-1 (ligand shown as orange sticks, surface 
shown as orange mesh).  B. The trifluoromethylphenyl group of JMT-84 (ligand shown as magenta 
sticks, surface shown as magenta mesh) exhibits a closer contour to the tPBP2H041 surface (shown 
in grey) than the methylphenyl group of JMT-1 and JMT-13 (ligand shown as teal sticks, surface 
shown as teal mesh), while the cyclohexyl group of JMT-108 (ligand shown as yellow sticks, surface 







In this work, we present the derivatization of the prototype N. gonorrhoeae PBP2 
inhibitor JMT-1 with the goal of identifying modifications that enhance or diminish in vitro 
activity against both PBP2 and gonococci. First, we show that substitution of the JMT-1 
anthranilic acid moiety with hydrophobic groups at C4 or C5 is preferred for PBP2 
inhibition, and that isosteric replacement of the C1 carboxylic acid with a 1H-tetrazol-5-yl 
group results in compounds with similar activity. Next, we show that 4’-substitution of the 
1,1’-biphenyl system is required for potent inhibition, but that this requirement is eliminated 
if the structure is changed to a more flexible 4-cyclohexylphenyl system. Modeling of the 
most potent compounds suggest the modifications to JMT-1 responsible for increasing 
tPBP2 inhibition do so through augmented van der Waals interactions with the 
transpeptidase active site. 
 
5.4.a. Summary of potent antigonococcal compounds and structure-activity 
relationships  
 
Compounds showing potent tPBP2 inhibition and antigonococcal activity are 
shown in Table 5.1. Overall, the most potent JMT-1 derivatives possess lipophilic 
polarizable groups at the 4- and 5-positions of an anthranilic acid moiety. Increasing van 
der Waals radius at C4 or C5 appears to be correlated with greater activity as well, with 
six of the ten best compounds possessing a trifluoromethyl or bromo substituent. High 
activity is also observed in compounds 4,5-disubstituted with fluorine atoms, suggesting 
that there is a preference for a somewhat large area of hydrophobic surface at these 
positions. Phenyltetrazoles are generally less active against gonococci, and especially 
against H041, than their anthranilic acid analogues despite similar inhibition of tPBP2. This 
is perhaps due to the relative lipophilicity of the tetrazole-containing molecules (5-methyl-
1H-tetrazole logD7.4 = -2.2) compared to corresponding carboxylic acids (acetic acid 
logD7.4 = -3.0). In both FA19 and H041, compounds must traverse the outer membrane 
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through porins that select for highly solvated, hydrophilic molecules. In H041, not only are 
these porins mutated to restrict entry,306 but there is also an overexpressed MtrCDE efflux 
system with the ability to extrude hydrophobic xenobiotics.317.318 Exceptions to this trend 
are the 5-bromophenyltetrazoles, which show improved antigonococcal activity compared 
to their 5-bromoanthranilic acid analogues and have a very narrow difference in activities 
between FA19 and H041. 
Modifications to the 1,1’-biphenyl end of the JMT-1 scaffold also result in some 
improvements in activity. Overall, compounds with larger hydrophobic groups at the 4’-
position (i.e., 4’-methyl and 4’-trifluoromethyl) tend to have better activity compared to 
smaller or more hydrophilic derivatives. Interestingly, while elimination of the 4’-substituent 
greatly diminishes activity of 1,1’-biphenyl compounds, incorporation of a 4’-unsubstituted 
cyclohexyl group causes no such decrease in activity and in fact, yields some of the most 
potent antigonococcal compounds resulting from these studies. 
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Table 5.1: Summary data for the JMT-1 derivatives showing the most potent antigonococcal 
activity. aPurified protein assay in which PBP2 is pre-incubated with compound or DMSO for 1 hour, 
followed by the addition of 1 µM Bocillin-FL. Value reported is percent inhibition. bDisc diffusion 







































































































































The most active compounds identified in the course of these studies were flexibly 
aligned using a stochastic conformational search, yielding an eight-point pharmacophore 
shown in Figure 5.35. This pharmacophore is generally supported by previous data on 
the inhibition of S. aureus PBP2a and S. pneumoniae by similar compounds,627,628 with 
the unique addition of the 1,1’-biphenyl system. Representation of the 1,1’-biphenyl 
system with two hydrophobic features, where only one is required to be aromatic, 
increases design capabilities by allowing the incorporation of a variety of 4-substituted 




Figure 5.35: Flexible alignment and consensus pharmacophore based on the JMT-1 derivatives 
with the most potent antigonococcal activity.  
 
 
Experiments published by other laboratories have determined zones of inhibition 
by several FDA-approved antimicrobials against N. gonorrhoeae strains with varied 
susceptibility profiles63,678  (Table 5.2). For example, with 0.5 µg penicillin G, the 
susceptible reference strain WHO F is inhibited with a 13.2 mm zone of inhibition, while 
neither penicillin-resistant strain (WHO K and H041) is inhibited at all. Similarly, a 0.5 µg 
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ceftriaxone disc inhibits the growth of WHO F with a 14.2 mm zone of inhibition, while it 
displays a decrease in potency against WHO K (6.7 mm) and fails to inhibit H041. By 
contrast, the reported JMT-1 derivatives inhibit both FA19 and H041 to similar degrees. It 
should be noted that the masses of compound used in each disc is slightly different in the 
assays reported, as each takes into account the pharmacokinetic and pharmacodynamic 
factors determining efficacy, as well as epidemiologic values for susceptibility versus 
resistance. Since the reported JMT-1 analogues represent a novel, experimental class, 
no such data exists. Thus, the 10 µg quantity used in these studies is not calibrated for 
direct comparisons of potency. Nonetheless, the large zones of inhibition seen against 
both reference strain FA19 and multidrug resistant H041 indicate real antimicrobial activity 
that is quite promising for the early development of a new class of compounds. 
Table 5.2: Calibrated dichotomous sensitivity disc diffusion literature values for FDA-approved 
antimicrobials against N. gonorrhoeae with varied susceptibility profiles. †Taken from Mal et al., 










penicillin G (0.5) 13.2 mm 0 mm 0 mm 
ceftriaxone (0.5) 14.2 mm 6.7 mm 1 mm 
ciprofloxacin (1) 15 mm 0 mm 1 mm 
spectinomycin (100) 11 mm 16 mm 9 mm 
 
 
5.4.b. Future testing of potent antigonococcal compounds 
We have only just begun the hit-to-lead optimization and overall development 
processes for the reported scaffolds, and much more foundational work needs to be 
completed toward their biochemical and biological characterization. This includes more 
precise measures of potency against both the target (i.e., IC50 determinations against 
tPBP2WT and tPBP2H041) and pathogen (i.e., MIC determinations against N. gonorrhoeae 
strains), as well as measures of selectivity (i.e., cytotoxicity experiments against hepatic 
and renal lines). Additional experiments are needed to ensure the antigonococcal activity 
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results from transpeptidase inhibition. Such experiments include macromolecular 
synthesis assays measuring the incorporation of [14C]-diaminopimelate, microscopy for 
the observation of filament formation, and peptidoglycan cross-link formation assays 
measuring D-Ala release. If compounds are identified that show potent, on-target, 
selective antigonococcal activity, these compounds can be tested in the murine infection 
model described in Chapter 3. 
Despite their lesser antigonococcal activity in vitro, tetrazole-containing derivatives 
should not yet be abandoned due to their potentially favorable properties in vivo. 
Xenobiotic carboxylic acids are commonly conjugated by phase II metabolic enzymes to 
acyl glucuronides and acyl coenzyme A thioesters.679,680 These modifications mask the 
acidic group critical to PBP2 inhibition, and the resulting acyl metabolites are reactive 
species implicated in hepatotoxicity. Tetrazoles, by contrast, are resistant to coenzyme A 
conjugation and form nonreactive N-glucuronide conjugates.681,682 Moreover, as 
mentioned above, tetrazole compounds are more lipophilic (5-methyl-1H-tetrazole logD7.4 
= -2.2) than analogous carboxylic acids (acetic acid logD7.4 = -3.0), potentially improving 
their lipid bilayer permeability and bodily distribution.683 This property may be 
advantageous in the treatment of gonococcal cervicitis and pharyngitis by increasing 
accumulation at the site of infection. Taking into account the modest losses in activity seen 
in JMT-1 analogues upon replacement of the carboxylic acid with a tetrazole, the potential 
for improved pharmacokinetics could ultimately outweigh such losses. 
5.4.c. Future design strategies 
In addition to biological characterization of the most potent compounds from these 
experiments, another immediate goal is further derivatization of the scaffolds, especially 
since the anthranilic acid moiety of JMT-1 provides ample opportunity to explore additional 
chemical space. First, there is a need for data on the 6-fluoroanthranilic acid compound. 
While the 6-methyl analogue exhibited poor activity, substitution with a smaller fluorine 
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may better approximate the shape of the post-covalent cephalosporin complex after 
elimination of the C3 leaving group (Figure 5.36). Thus, the potency of such an analogue 
will provide insight into whether these compounds adopt a binding mode similar to the β-
lactams after acylation. There is also a need for the investigation of less conservative 
substitutions on the anthranilic acid moiety, as the current dataset does not contain a great 
deal of structural diversity. Some modifications that can be incorporated to develop more 
comprehensive structure-activity relationships are the following: 1) polar hydrogen 
bonding substituents, including hydroxy and amino functionalities; 2) extended and 
branched aliphatics, such as ethyl and isopropyl groups; 3) bulkier 4,5-disubstitutions, 
including methylenedioxy and fused cyclopentyl groups; and 4) additional carboxylic acid 
isosteres, including those shown in Figure 5.37.684 
 
Figure 5.36: Overlay of ceftriaxone after leaving group departure and 2-(4’-methyl-[1,1'-biphenyl]-






Figure 5.37: Carboxylic acid bioisosteres. HA: hydroxamic acid, HIT: 3-hydroxyisothiazole, HIO: 
3-hydroxyisoxazole, TZD: thiazolidinedione, OZD: oxazolidinedione, CPD: 1,3-cyclopentanedione, 
TNA: tetronic acid, TMA: tetramic acid, OODZ: 5-oxo-1,2,4-oxadiazole, OTDZ: 5-oxo-1,2,4-
thiadiazole, TODZ: 5-thioxo-1,2,4-oxadiazole, TTDZ: 5-thioxo-1,2,4-thiadiazole. 
 
There is also opportunity to explore the 1,1’-biphenyl moiety of JMT-1. In our 
dataset, it was observed that incorporation of a methyl or trifluoromethyl group at the 4’-
position enhances PBP2-inhibitory activity compared to substituents with smaller van de 
Waals radii (i.e., H, F, and Cl). In this vein, the effects of shape and bulk should be 
assessed further by the incorporation of larger, more diverse groups, including branched 
aliphatics (e.g., isopropyl and t-butyl) and small carbocycles (e.g., cyclopropyl and 
cyclobutyl). The effect of 2’-substitution, as well as disubstitution, should also be 
examined. Finally, replacement of one or both rings with various aromatic or saturated 
heterocycles and carbocycles should be attempted. Sulfonyl chloride starting materials 
can be obtained through Suzuki cross-coupling reactions with thioacetate compounds, 





































pKa ~ [4, 5]
OH
pKa ~ [8, 9] pKa ~ [6, 7]




pKa ~ [4, 5]
logD7.4 ~ -1 logD7.4 ~ 1 logD7.4 ~ [0, 1] logD7.4 ~ 0





Scheme 5.2: Proposed synthesis of 4’-methyl[1,1’-biphenyl]-4-sulfonyl chloride from S-acetyl 4-
bromothiophenol. a. Pd(dppf)2Cl2·CH2Cl2, Cs2CO3, 10:1 THF/H2O, 100°C. b. 1:5 2 M HCl / MeCN, 
RT. 
 
Amide analogues similar to JEK-42 should be made for the most active JMT-1 
derivatives as well. Fortunately, benzoic acid starting materials can be obtained from 
similar syntheses using Suzuki cross-coupling reactions with methyl esters, followed by 
alkaline hydrolysis (Scheme 5.3). For a discussion of other possible changes to the 





Scheme 5.3: Proposed synthesis of 4’-methyl[1,1’-biphenyl]-4-carboxylic acid from methyl 4-





 Here we describe the synthesis 127 novel structures and their testing for inhibition 
of N. gonorrhoeae PBP2. We found that larger hydrophobic substitutions at C4 and C5 of 
the anthranilic acid moiety (e.g., bromo, trifluoromethyl) improve PBP2 inhibition, as does 
a trifluoromethyl substitution at C4’ of the 1,1’-biphenyl system. Interestingly, we also 
found that while lack of substitution at the C4’ position results in decreased inhibition, 





















yields strong inhibition. Docked models predict the increased potency imparted by these 
substitutions is due to more favorable van der Waals interactions with the PBP2 active site 
compared to prototype JMT-1. Overall, the activity data coming from these early hit-to-
lead optimization studies show the promise of this scaffold. It is capable of inhibiting PBP2 
variants derived from both β-lactam-susceptible and -resistant strains and shows 













CHAPTER 6: Conclusion  
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6.1. Summary 
Over the last several decades, N. gonorrhoeae has developed resistance to 
sulfonamides, penicillin, spectinomycin, tetracyclines, macrolides, fluoroquinolones, and 
now cephalosporins. With this proclivity for resistance development in mind, the CDC 
began recommending dual antimicrobial regimens of ceftriaxone with azithromycin or 
doxycycline, but patterns of increasing resistance to these agents globally have raised 
concerns of a future in which gonorrhea is untreatable. Therefore, continued efforts to 
identify antigonococcal compounds using all avenues of drug discovery are necessary to 
keep pace with the development of resistance. The body of work coming out of our 
laboratory has focused for several years on the structural biology of the penicillin-binding 
proteins, and more recently on the mechanisms of β-lactam resistance conferred by 
mutations in PBP2 of N. gonorrhoeae. In this project, emphasis was placed on ligand 
structure, specifically on the identification of features enhancing PBP2 inhibition, with the 
ultimate goal of designing novel antigonococcal agents. We report three studies to this 
end. 
In Chapter 3, we outlined structure-activity relationships (SAR) for the 
cephalosporin class of β-lactams against cephalosporin-resistant Neisseria gonorrhoeae 
H041. We found that structural features of the C7 acylamino side chain (R1) correlate 
highly with the second-order rate of tPBP2H041 acylation, with larger groups of modest 
lipophilicity containing multiple ring systems (e.g., the 2,3-dioxopiperazine side chain of 
cefoperazone) conferring greater activity. While the data suggest that the C3 side chain 
(R2) plays a less obvious role, a combination of electronegative elements and planarity 
(e.g., the pyridylthiazole side chain of ceftaroline) can enhance tPBP2H041 acylation 
considerably. 
Through molecular docking simulations of the precovalent ligand-receptor 
complex, we gained insight into how these features may enhance inhibition. In the docked 
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models, aromatic and hydrophobic groups on R1 are shown extending toward a 
hydrophobic patch of the tPBP2H041 active site, and in a preliminary crystal structure of 
cefoperazone in complex with tPBP2H041, the 2,3-dioxopiperazine moiety lies flat in this 
hydrophobic patch against the side chain of Y422. The models also show electronegative 
elements of R2 interacting with K361. The importance of this residue for cephalosporin 
binding is supported by a stark reduction in the rate of acylation by ceftriaxone upon its 
mutation to a glutamate. We also found that many of the features enhancing target 
inhibition (e.g., lipophilicity, aromaticity, etc.) diminish antimicrobial activity against the 
H041 strain, perhaps due to decreased accumulation in the periplasm. Finally, we 
observed that cefoperazone acylates tPBP2H041 much more rapidly than most other 
cephalosporins, and it exhibits comparable activity to ceftriaxone against N. gonorrhoeae 





Figure 6.1: Features of cephalosporins enhancing the second-order rate of tPBP2H041 acylation, 
illustrated by cefoperazone. 
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In Chapter 4, we applied qualitative trends emerging from the cephalosporin SAR 
to identify novel noncovalent PBP2 inhibitors possessing a 1,1’-biphenyl system. JEK-42 
and its isosteric derivative JMT-1 inhibit both tPBP2WT and tPBP2H041, and are capable of 
inhibiting growth of both β-lactam-susceptible (FA19) and -resistant (H041) gonococcal 
strains. Their cross-inhibition of P. aeruginosa PBP3 provides evidence of their potential 
for broader activity against class B PBPs. Models of their binding modes show that these 
molecules may bind in a way that mimics the precovalent complex formed by β-lactam 
antimicrobials. These models also show the 1,1’-biphenyl system interacting with highly 
conserved residues N364 and F420. Using the structural similarities between JEK-42, 
JMT-1, and bicyclic β-lactam scaffolds (i.e., penam, carbapenem, and cephem), a three-
point pharmacophore was generated that was then used to screen a virtual library of 
molecular fragments, yielding many structures for testing against PBP2 and N. 







Figure 6.2: Predicted tPBP2 binding mode of antigonococcal prototypes.  JEK-42 is shown in its 
predicted binding mode with tPBP2WT. Areas of interaction for the shared acidic (red), hydrophobic 





In Chapter 5, we began the process of hit-to-lead optimization by exploring the 
chemical space surrounding the prototype molecules to determine the effects of specific 
substitutions on PBP2 inhibition and antigonococcal activity. In all, 127 derivatives of JMT-
1 were synthesized and tested. First, PBP2 inhibition by the JMT-1 sulfonamide scaffold is 
improved by the presence of hydrophobic, polarizable groups (e.g., bromo, trifluoromethyl) 
at C4 or C5 of the anthranilic acid moiety. Second, replacement of the C1 carboxylic acid 
with a bioisosteric 1H-tetrazol-5-yl group results in compounds with similar target inhibition 
but lesser antimicrobial activity. Third, a substitution at the 4’-position of the 1,1’-biphenyl 
system promotes potent inhibition, but is not required when the secondary aromatic ring is 
modified to a more flexible cyclohexyl group. In all, 10 molecules show promise as 
antigonococcal agents from in vitro measures of target inhibition and antimicrobial activity 





Figure 6.3: Structures of JMT-1 derivatives. A. JMT-13 and JMT-108 are the most potent inhibitors 
of N. gonorrhoeae PBP2. Both show 99 ± 1% inhibition of tPBP2H041 at 10 µM. JMT-84 shows 
slightly lesser target inhibition but is the most potent antigonococcal agent, yielding 21.2 ± 1.9 mm 
and 17.5 ± 0 mm zones of inhibition against N. gonorrhoeae FA19 and H041, respectively. B. There 
is additional space in the tPBP2 active site that can be explored by derivatization of the JMT series. 
Composite surface for superimposed inhibitors shown in orange mesh. Receptor surface of 




6.2. Common features among published PBP-inhibitory compounds 
 
 Returning to the literature with additional insight and sharper focus provided by 
these studies, pervasive trends become apparent in reported inhibitors of diverse PBPs 
from a variety of bacterial species. Many inhibitors are structurally similar to the JMT series 
(Figure 6.4). In combination with the inhibition of P. aeruginosa PBP3 reported for JMT-1 
and JMT-2 in Chapter 4, these similarities suggest that JMT compounds may be capable 
of inhibiting the growth of a variety of pathogens. What is novel about the molecules 
reported in this work is the incorporation of the 1,1’-biphenyl system, whose secondary 
aromatic ring is uniquely capable of interacting with highly conserved N364 (of the SxN 
motif) and F420 of N. gonorrhoeae PBP2 according to the modeling data presented in 
Chapters 4 and 5. The predicted interactions with highly conserved residues provide 
further support for the hypothesis that these compounds may exhibit broad spectrum 




Figure 6.4: Flexible alignment of JMT-84 with published noncovalent PBP inhibitors. 
Commonalities among the compounds examined include acidic (red), aromatic (orange) and 
hydrogen bond accepting (cyan) features. 
 
 
6.3. Future Directions 
The data presented on cephalosporin activity against N. gonorrhoeae H041 and 
its PBP2 provide a means of identifying cephalosporins with high activity against ESCR 
strains harboring mosaic penA alleles. First, cefoperazone should be investigated further 
for its application to gonococcal infections through the determination of murine 
pharmacokinetic parameters and subsequent dose optimization. Second, the generated 
QSAR models can also be applied to additional cephalosporins reported in the literature, 
including experimental compounds that were never developed, as well as those currently 
used solely in veterinary medicine. Finally, because the QSAR has been constructed using 
features of R1 and R2 separately, it can be used to computationally evaluate a series of 
carboxylic acids (R1) and sulfur nucleophiles (R2) for attachment to 7-





Scheme 6.1: Proposed synthesis of novel cephalosporins from 7-aminocephalosporanic acid. 
 
Hit-to-lead optimization for JEK-42 and JMT-1 is underway, and many additional 
substitutions have been proposed for the scaffolds in Chapter 5, including less 
conservative modifications of the anthranilic acid and 1,1’-biphenyl moieties. Importantly, 
more biochemical and biological characterization is needed for the most potent molecules, 
including the determination of half-maximal inhibitory concentrations (IC50) against PBP2, 
minimum inhibitory concentrations (MIC) against N. gonorrhoeae strains, and half-
maximal eukaryotic cytotoxic doses (TD50). Macromolecular synthesis assays, 
microscopic observation of gonococcal morphology, or peptidoglycan cross-linking assays 
should also be conducted to confirm the compounds are on-target. If potent, on-target, 
selective antigonococcal compounds emerge, these compounds can be tested in the 
murine infection model described in Chapter 3. Potent antigonococcal compounds should 
also be tested for inhibition of additional class B PBPs, as well as for antimicrobial activity 



















































6.4. Overall impact 
Together, these studies lay the groundwork for an antimicrobial discovery program 
targeted against the PBPs, with possibilities ranging from β-lactams to derivatives of the 
JMT series to entirely new, as yet unidentified chemotypes. The structure-activity 
relationships for cephalosporins against N. gonorrhoeae H041 provide mathematical 
models for in silico prediction of cephalosporin potency that can be employed in selecting 
semisynthetic cephalosporins from the literature, or in the design of entirely novel 
structures. In the latter case, such a model helps to reduce attrition by guiding the 
synthesis of molecules that are likely to be active in both enzymatic assays against 
tPBP2H041 and antimicrobial assays against N. gonorrhoeae H041. The synthesis and 
testing of JEK-42 and JMT-1 marks the discovery of two novel antimicrobial scaffolds that 
act through the inhibition of PBPs. These scaffolds are likely not susceptible to β-
lactamases, and based on preliminary data, it appears they are not vulnerable to the same 
PBP2 modifications that result in resistance to cephalosporins. Finally, the creation of 
pharmacophore models from structural similarities in PBP inhibitors allows the in silico 
discovery of yet other scaffolds to pursue, opening the possibilities for chemically diverse 
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Figure A.1: Placement constraints for docking of cephalosporins to tPBP2H041. Criteria for 
placement in the docking protocol include: 1) a carboxylate centroid near proposed electrostatic 
anchor K497 and 2) a lactam ring adjacent S310 and projecting toward the oxyanion hole defined 




Figure A.2: Energy scores for pharmacophore-constrained docking of penams (A) and 
carbapenems (B). AMX: amoxicillin, AMP: ampicillin, MZC: mezlocillin, PNG: penicillin G, PNV: 
penicillin V, PPC: piperacillin, TCC: ticarcillin, IMI: imipenem, DORI: doripenem, MERO: 









Figure B.1: tPBP2H041 IC50 curves for cephalosporins reported in Chapter 3. CFP: cefoperazone 
(2.5 ± 0.3 µM, r2 = 0.966), CPT: ceftaroline (2.6 ± 0.4 µM, r2 = 0.987), BPR: ceftobiprole (0.9 ± 0.1 
µM, r2 = 0.990), CRO: ceftriaxone (1.8 ± 0.3 µM, r2 = 0.977), ZOX: ceftizoxime (2.9 ± 0.8 µM, r2 = 
0.974), CTX: cefotaxime (3.0 ± 0.5 µM, r2 = 0.993). BOC10x: co-incubation with 10 µM Bocillin-FL, 
BOC-100x: co-incubation with 100 µM Bocillin-FL. n ≥ 3 determinations for each. Error bars are 
standard deviation. 























































































Figure B.2: tPBP2H041 IC50 curves for cephalosporins reported in Chapter 3, continued. CAZ: 
ceftazidime (3.6 ± 0.6 µM, r2 = 0.991), CFM: cefixime (3.8 ± 0.4 µM, r2 = 0.983), FEP: cefepime 
(4.4 ± 0.4 µM, r2 = 0.966), CPD: cefpodoxime (4.7 ± 1.0 µM, r2 = 0.979), TOL: ceftolozane (14.7 ± 
1.8 µM, r2 = 0.985), CDR: cefdinir (33.8 ± 2.9 µM, r2 = 0.968). BOC10x: co-incubation with 10 µM 
Bocillin-FL. n ≥ 3 determinations for each. Error bars are standard deviation. 
 
 























































































Figure B.3: tPBP2H041 IC50 curves for cephalosporins reported in Chapter 3, continued. CEC: 
cefaclor (97.0 ± 16.5 µM, r2 = 0.908), CTB: ceftibuten (144 ± 1 µM, r2 = 0.932), CXM: cefuroxime 
(400 ± 10 µM, r2 = 0.931), FOX: cefoxitin (840 ± 130 µM, r2 = 0.878), CMZ: cefmetazole (770 ± 10 
µM, r2 = 0.959), CFS: cefsulodin (3.7 ± 0.5 mM, r2 = 0.911). BOC10x: co-incubation with 10 µM 
Bocillin-FL. n ≥ 3 determinations for each. Error bars are standard deviation. 
 
 























































































Figure B.4: tPBP2H041 inhibition data for cephalosporins classified in Chapter 3 as inactive. LOT: 
cefelothin (13 ± 4% inhibition), LEX: cephalexin (54 ± 8% inhibition), CFZ: cefazolin (26 ± 4% 
inhibition), LOR: cephaloridine (12 ± 9% inhibition). 1,000x Ceph:BOC: co-incubation of 10 mM 
cephalosporin with 10 µM Bocillin-FL. Error bars are standard deviation. 
 
 
Figure B.5: tPBP2H041-K361E IC50 curves for cephalosporins reported in Chapter 3. CFP: 
cefoperazone (1.6 ± 0.2 µM, r2 = 0.975), CRO: ceftriaxone (2.0 ± 0.5 µM, r2 = 0.984), CAZ: 
ceftazidime (11.1 ± 3.6 µM, r2 = 0.950), FEP: cefepime (13.4 ± 5.1 µM, r2 = 0.955). BOC10x: co-
incubation with 10 µM Bocillin-FL, BOC-100x: co-incubation with 100 µM Bocillin-FL. n ≥ 3 
determinations for each. Error bars are standard deviation. 
  






































































Appendix C. Quantitative structure-activity relationship descriptors 
 
Table C.1: Definitions of physicochemical descriptors using the quantitative structure-activity 




Number of hydrogen bond acceptor atoms 
(excluding acidic atoms, but including 
atoms that function as both hydrogen bond 
donors and acceptors) 
a_donacc 
Number of hydrogen bond donor atoms 
plus number of hydrogen bond acceptors 
atoms 
a_ICM 
Mean atom information content / entropy of 
element distribution. Sum of pilogpi for all i, 
where pi = ni/n, ni is the number of 
occurrences of atomic number i in the 
molecule, and n is the total number of 
atoms. 
BCUT_PEOE_0 
Smallest eigenvalue of a modified 
adjacency matrix in which each ij entry 
takes the value 1/sqrt(bij), where bij is the 
formal bond order between bonded atoms i 
and j. The diagonal takes the value of 
PEOE partial charges. 
BCUT_PEOE_3 
Largest eigenvalue of a modified adjacency 
matrix in which each ij entry takes the value 
1/sqrt(bij), where bij is the formal bond order 
between bonded atoms i and j. The 
diagonal takes the value of PEOE partial 
charges. 
BCUT_SLOGP_0 
Smallest eigenvalue of a modified 
adjacency matrix in which each ij entry 
takes the value 1/sqrt(bij), where bij is the 
formal bond order between bonded atoms i 
and j. The diagonal takes the value of 
atomic contribution to logP(o/w). 
BCUT_SLOGP_1 
Second eigenvalue of a modified adjacency 
matrix in which each ij entry takes the value 
1/sqrt(bij), where bij is the formal bond order 
between bonded atoms i and j. The 
diagonal takes the value of atomic 
contribution to logP(o/w). 
BCUT_SLOGP_3 
Largest eigenvalue of a modified adjacency 
matrix in which each ij entry takes the value 
1/sqrt(bij), where bij is the formal bond order 
between bonded atoms i and j. The 
diagonal takes the value of atomic 
contribution to logP(o/w). 
BCUT_SMR_3 
Largest eigenvalue of a modified adjacency 
matrix in which each ij entry takes the value 
1/sqrt(bij), where bij is the formal bond order 
between bonded atoms i and j. The 
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diagonal takes the value of atomic 
contribution to molar refractivity. 
chi0v 
Atomic valence connectivity index (order 0) 
from Hall, calculated as the sum of 1/sqrt(vi) 
over all heavy atoms i with vi > 0. 
 
For heavy atom i, let vi = (pi-hi)/(Zi-pi-1) 
where pi is the number of s and p valence 
electrons.   
chi1v_C 
Carbon valence connectivity index (order 
1), calculated as the sum of 1/sqrt(vivj) over 
all bonds between carbon atoms i and j 
where i < j. 
 
For heavy atom i, let vi = (pi-hi)/(Zi-pi-1) 
where pi is the number of s and p valence 
electrons.   
FCharge Total formal charge. 
GCUT_PEOE_1 
Second eigenvalue of a modified distance 
adjacency matrix in which each ij entry 
takes the value 1/sqrt(dij), where dij is the 
graph distance between atoms i and j. The 
diagonal takes the value of PEOE partial 
charges. 
GCUT_PEOE_2 
Third eigenvalue of a modified distance 
adjacency matrix in which each ij entry 
takes the value 1/sqrt(dij), where dij is the 
graph distance between atoms i and j. The 
diagonal takes the value of PEOE partial 
charges. 
h_logS 
log of aqueous solubility (mol/L) using a 7-
parameter model based on Hueckel Theory 
with r2 = 0.83, RMSE 0.85 on 1,708 
molecules. 
Kier1 
First kappa shape index: (n-1)2/m2, where n 
is the number of atoms in a hydrogen-
suppressed molecular graph and m is the 
number of bonds. 
KierA2 
Second alpha modified shape index: s(s-
1)2/m2 where s = n+a, where a is a 
correction factor derived from the covalent 
radii of bonded atoms. 
KierFlex Kier molecular flexibility index: (KierA1)(KierA2)/n. 
PEOE_VSA_FPNEG 
Fractional negative polar van der Waals 
surface area: sum of approximate van der 
Waals surface area vi (Å2) for each atom i 
with partial charge qi < -0.2, divided by the 
total van der Waals surface area. 
PEOE_VSA-1 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 




Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to PEOE qi is in the range [-0.2, 
-0.15). 
PEOE_VSA-4 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to PEOE qi is in the range [-
0.25, -0.2). 
PEOE_VSA+0 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to PEOE qi is in the range [0, 
0.05). 
PEOE_VSA+1 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to PEOE qi is in the range 
[0.05, 0.1). 
PEOE_VSA+3 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to PEOE qi is in the range 
[0.15, 0.2). 
PEOE_VSA+4 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to PEOE qi is in the range [0.2, 
0.25). 
PEOE_VSA+6 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to PEOE qi > 0.3. 
Q_RPC+ 
Relative positive partial charge: the largest 
positive qi divided by the sume of positive 
qi. 
SlogP_VSA0 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to logP(o/w) Li ≤ -0.4. 
SlogP_VSA1 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to logP(o/w) Li is in the range (-
0.4, 0.2]. 
SlogP_VSA2 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to logP(o/w) Li is in the range (-
0.2, 0]. 
SlogP_VSA4 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to logP(o/w) Li is in the range 
(0.1, 0.15] 
SlogP_VSA7 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to logP(o/w) Li is in the range 
(0.25, 0.30]. 
SMR_VSA3 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to molar refractivity Ri is in the 
range (0.35, 0.39]. 
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SMR_VSA4 
Sum of approximate van der Waals surface 
area vi (Å2) for each atom i whose 
contribution to molar refractivity Ri is in the 
range (0.4, 0.44]. 
vdw_area 
area of van der Waals surface (Å2) 
calculated using connection table 
approximation. 
zagreb 
Zagreb index: the sum of squares of heavy 




Appendix D. Characterization of synthesized compounds by ESI-MS and 1HNMR  
5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-carboxamido)benzoic acid (JEK-42). The reaction 
of 4'-methyl-[1,1'-biphenyl]-4-carboxylic acid afforded JEK-42 as a white powder. 1H NMR 
(600 MHz, D3COCD3): δ = 12.19 (s, 1H), 9.00 (dd, J = 5.2, 9.3 Hz, 1H), 8.09 (d, J = 8.4 
Hz, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.86 (m, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.50 (dq, J = 3.2, 
9.3 Hz, 1H), 7.32 (d, J = 7.9 Hz, 2H), 3.08 (s, 3H). ESI-MS for C21H16FNO3: [M-H]- 
calculated 348.1, found 348.2 
 
5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-1). The reaction of 
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-1 as a beige powder. 1H NMR (600 MHz, D3COCD3): δ = 10.73 (s, 1H), 7.87 (d, J = 
8.5 Hz, 2H), 7.80 (m, 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.67 (dd, J = 3.1, 9.1 Hz, 1H), 7.57 (d, 
J = 8.1 Hz, 2H), 7.43 (dq, J = 3.0, 10.3 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 2.35 (s, 3H). ESI-
MS for C20H16FNO4S: [M-H]- calculated 384.1, found 384.2 
 
2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-2). The reaction of 4'-
methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-
2 as a white powder.  ESI-MS for C20H17NO4S: [M-H]- calculated 366.1, found 366.2 
 
4-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-3). The reaction of 
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-2 as a beige powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found 384.2 
 
4,5-difluoro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-4). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-4 as a beige powder. ESI-MS for C20H15F2NO4S: [M-H]- calculated 402.1, 
found 402.2 
 
4-chloro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-5). The reaction of 
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-5 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.27 (s, 1H), 8.02 (d, J = 
8.5 Hz, 1H), 7.96 (d, J = 8.6 Hz, 2H), 7.84 (d, J  = 8.5 Hz, 2H), 7.74 (d, J = 2.0 Hz, 1H), 
7.58 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.26 (dd, J = 2.0, 8.5 Hz, 1H), 2.35 (s, 
3H). ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.0, found 400.2, 402.2 
  
5-chloro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-6). The reaction of 
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-6 as a white powder. ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.0, found 
400.2, 402.2 
 
4-bromo-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-7). The reaction of 
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-7 as a white powder. ESI-MS for C20H16BrNO4S: [M-H]- calculated 444.0, found 
444.1, 446.1 
 
5-bromo-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-8). The reaction of 
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 




4-methyl-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-9). The reaction of 
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-9 as a white powder. ESI-MS for C21H19NO4S: [M-H]- calculated 380.1, found 380.2 
 
5-methyl-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-10). The reaction 
of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-10 as a white powder. ESI-MS for C21H19NO4S: [M-H]- calculated 380.1, found 380.2 
 
6-methyl-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-11). The reaction 
of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-11 as a white powder. ESI-MS for C21H19NO4S: [M-H]- calculated 380.1, found 380.3 
 
4-(trifluoromethyl)-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-12). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-12 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.29 (s, 1H), 
8.23 (d, J = 8.2 Hz, 1H), 8.02 (d, J = 0.6 Hz, 1H), 7.95 (d, J  = 8.6 Hz, 2H), 7.84 (d, J = 8.7 
Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.46 (dd, J = 1.1, 8.2 Hz, 1H), 7.29 (d, J = 7.8 Hz, 2H), 
2.35 (s, 3H). ESI-MS for C21H16F3NO4S: [M-H]- calculated 434.1, found 434.2 
 
5-(trifluoromethyl)-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-13). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-13 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.39 (s, 1H), 
8.29 (s, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.84 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 
7.9 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 2.35 (s, 3H). ESI-MS for C21H16F3NO4S: [M-H]- 
calculated 434.1, found 434.2 
 
4-methoxy-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-14). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-14 as an off-white powder. ESI-MS for C21H19NO5S: [M-H]- calculated 396.1, 
found 396.2 
 
5-methoxy-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-15). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 




The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-16 as a white powder. ESI-MS for C20H16FN5O2S: [M-H]- 
calculated 408.1, found 408.3 
 
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-17). 
The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-17 as a white powder. ESI-MS for C20H16FN5O2S: [M-H]- 
calculated 408.1, found 408.2 
 
N-(2-(1H-tetrazol-5-yl)-4-chlorophenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-18). 
The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-18 as a white powder. ESI-MS for C20H16ClN5O2S: [M-H]- 




The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-19 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 10.70 
(s, 1H), 8.15 (d, J = 2.3, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.79 (m, 1H), 7.73 (dd, J = 2.3, 8.9 
Hz, 1H), 7.53 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H), 7.03 (d, J = 8.6 Hz, 2H) 2.35 
(s, 3H). ESI-MS for C20H16BrN5O2S: [M-H]- calculated 468.0, found 468.2, 470.2 
 
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-
20). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-20 as a white powder. ESI-MS for C21H19N5O2S: [M-H]- 
calculated 404.1, found 404.3 
 
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-
21). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-21 as a white powder. ESI-MS for C21H19N5O2S: [M-H]- 
calculated 404.1, found 404.3 
 
N-(2-(1H-tetrazol-5-yl)-5-(trifluoromethyl)phenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide 
(JMT-22). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to 
General Procedure II afforded JMT-22 as a white powder. ESI-MS for C21H16F3N5O2S: [M-
H]- calculated 458.1, found 458.2 
 
N-(2-(1H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide 
(JMT-23). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to 
General Procedure II afforded JMT-23 as a white powder. ESI-MS for C21H16F3N5O2S: [M-
H]- calculated 458.1, found 458.2 
 
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-
24). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-24 as a beige powder. ESI-MS for C21H19N5O3S: [M-H]- 
calculated 420.1, found 420.3 
 
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-
25). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-25 as an off-white powder. ESI-MS for C21H19N5O3S: [M-H]- 
calculated 420.1, found 420.3 
 
((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)proline (JMT-26). The reaction of 4'-methyl-[1,1'-
biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-26 as a white 
powder. ESI-MS for C18H19NO4S: [M-H]- calculated 344.1, found 344.2 
 
3-((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)thiazolidine-4-carboxylic acid (JMT-27). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 




(JMT-28). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to 
General Procedure I afforded JMT-28 as a white powder. ESI-MS for C19H21NO4S2: 
calculated 390.1, found 390.2 
 
 303 
1-((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)piperidine-2-carboxylic acid (JMT-29). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-29 as a white powder. ESI-MS for C19H21NO4S: [M-H]- calculated 358.1, 
found 358.3 
 
3-((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)-1,3-thiazinane-4-carboxylic acid (JMT-30). The 
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-30 as a white powder. ESI-MS for C18H19NO4S2: [M-H]- calculated 376.1, 
found 376.2 
 
2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-31). The reaction of [1,1'-biphenyl]-4-
sulfonyl chloride according to General Procedure I afforded JMT-31 as a white powder. 
ESI-MS for C19H15NO4S: [M-H]- calculated 352.1, found 352.2 
 
4-fluoro-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-32). The reaction of [1,1'-
biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-32 as a beige 
powder. ESI-MS for C19H14FNO4S: [M-H]- calculated 370.1, found 370.2 
 
5-fluoro-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-33). The reaction of [1,1'-
biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-33 as an off-
white powder. ESI-MS for C19H14FNO4S: [M-H]- calculated 370.1, found 370.2 
 
5-bromo-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-34). The reaction of [1,1'-
biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-34 as a white 
powder. ESI-MS for C19H14BrNO4S: [M-H]- calculated 430.0, found 430.0, 432.1 
 
5-methyl-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-35). The reaction of [1,1'-
biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-35 as a white 
powder. ESI-MS for C20H17NO4S: [M-H]- calculated 366.1, found 366.2 
 
4-fluoro-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-36). The reaction 
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-36 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found 
384.2 
 
5-fluoro-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-37). The reaction 
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-37 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found 
384.2 
 
5-bromo-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-38). The reaction 
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-38 as a white powder. ESI-MS for C20H16BrNO4S: [M-H]- calculated 444.0, found 
444.1, 446.2 
 
5-methyl-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-39). The reaction 
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 




4-fluoro-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-40). The reaction 
of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-40 as a beige powder. ESI-MS for C20H16FNO5S: [M-H]- calculated 400.1, 
found 400.2 
 
5-fluoro-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-41). The reaction 
of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-41 as an off-white powder. ESI-MS for C20H16FNO5S: [M-H]- calculated 
400.1, found 400.3 
 
4,5-difluoro-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid  (JMT-42). The 
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure 
I afforded JMT-42 as a beige powder. ESI-MS for C20H15F2NO5S: [M-H]- calculated 418.1, 
found 418.2 
 
5-bromo-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-43). The 
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure 
I afforded JMT-43 as a beige powder. ESI-MS for C20H16BrNO5S: [M-H]- calculated 460.0, 
found 460.0, 462.1 
 
4-methyl-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-44). The 
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure 
I afforded JMT-44 as an off-white powder. ESI-MS for C21H19NO5S: [M-H]- calculated 
396.1, found 396.3 
 
5-methyl-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-45). The 
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure 
I afforded JMT-45 as a white powder. ESI-MS for C21H19NO5S: [M-H]- calculated 396.1, 
found 396.3 
 
4-(trifluoromethyl)-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-46). 
The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-46 as a white powder. ESI-MS for C21H16F3NO5S: [M-H]- 
calculated 450.1, found 450.2 
 
5-(trifluoromethyl)-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-47). 
The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-47 as a white powder. ESI-MS for C21H16F3NO5S: [M-H]- 
calculated 450.1, found 450.1 
 
4-methoxy-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-48). The 
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure 
I afforded JMT-48 as a beige powder. ESI-MS for C21H19NO6S: [M-H]- calculated 412.1, 
found 412.3 
 
5-methoxy-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-49). The 
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure 
I afforded JMT-49 as an off-white powder. ESI-MS for C21H19NO6S: [M-H]- calculated 




50). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-50 as a white powder. ESI-MS for C20H16FN5O3S: [M-H]- 
calculated 424.1, found 424.3 
 
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT-
51). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-51 as a white powder. ESI-MS for C20H16FN5O3S: [M-H]- 
calculated 424.1, found 424.2 
 
N-(2-(1H-tetrazol-5-yl)-4-bromophenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT-
52). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-52 as a white powder. ESI-MS for C20H16BrN5O3S: [M-H]- 
calculated 484.0, found 484.2, 486.2 
 
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT-
53). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-53 as a white powder. ESI-MS for C21H19N5O3S: [M-H]- 
calculated 420.1, found 420.3 
 
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT-
54). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-54 as a white powder. ESI-MS for C21H19N5O3S: [M-H]- 
calculated 420.1, found 420.3 
 
N-(2-(1H-tetrazol-5-yl)-5-(trifluoromethyl)phenyl)-4'-methoxy-[1,1'-biphenyl]-4-
sulfonamide (JMT-55). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride 
according to General Procedure II afforded JMT-55 as a white powder. ESI-MS for 
C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3 
 
N-(2-(1H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl)-4'-methoxy-[1,1'-biphenyl]-4-
sulfonamide (JMT-56). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride 
according to General Procedure II afforded JMT-56 as a white powder. ESI-MS for 
C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3 
 
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT-
57). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-57 as an off-white powder. ESI-MS for C21H19N5O4S: [M-H]- 
calculated 436.1, found 436.2 
 
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT-
58). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-58 as an off-white powder. ESI-MS for C21H19N5O4S: [M-H]- 
calculated 436.1, found 436.3 
 
4-fluoro-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-59). The reaction of 
4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 




5-fluoro-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-60). The reaction of 
4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-60 as a beige powder. ESI-MS for C19H13F2NO4S: [M-H]- calculated 388.1, found 
388.1 
 
4,5-difluoro-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-61). The 
reaction of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-61 as a beige powder. ESI-MS for C19H12F3NO4S: [M-H]- calculated 406.0, 
found 406.2  
 
5-bromo-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-62). The reaction of 
4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-62 as a white powder. ESI-MS for C19H13FBrNO4S: [M-H]- calculated 448.0, found 
448.0, 450.0 
 
4-methyl-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-63). The reaction 
of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-63 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, 
found 384.2 
 
5-methyl-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-64). The reaction 
of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-64 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found 
384.2 
 
5-methoxy-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-65). The reaction 
of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 




The reaction of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-66 as a white powder. ESI-MS for C19H13F2N5O2S: [M-H]- 
calculated 412.1, found 412.2 
 
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-fluoro-[1,1'-biphenyl]-4-sulfonamide (JMT-67). 
The reaction of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-67 as a white powder. ESI-MS for C20H16FN5O2S: [M-H]- 
calculated 408.1, found 408.3 
 
4-fluoro-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-68). The reaction of 
4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-68 as an off-white powder. ESI-MS for C19H13ClFNO4S: [M-H]- calculated 404.0, 
found 404.1, 406.1 
 
5-fluoro-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-69). The reaction of 
4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 




4,5-difluoro-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-70). The 
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-70 as an off-white powder. ESI-MS for C19H12ClF2NO4S: [M-H]- calculated 
422.0, found 422.2, 424.1 
 
5-bromo-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-71). The reaction 
of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-71 as a white powder. ESI-MS for C19H13BrClNO4S: [M-H]- calculated 463.9, found 
464.1, 466.1 
 
4-methyl-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-72). The reaction 
of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-72 as a white powder. ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.0, found 
400.2, 402.1 
 
5-methyl-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-73). The reaction 
of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded 
JMT-73 as a white powder. ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.1, found 
400.1, 402.2 
 
4-(trifluoromethyl)-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-74). The 
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-74 as a white powder. ESI-MS for C20H13ClF3NO4S: [M-H]- calculated 454.0, 
found 454.1 
 
5-(trifluoromethyl)-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-75). The 
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-75 as a white powder. ESI-MS for C20H13ClF3NO4S: [M-H]- calculated 454.0, 
found 454.2, 456.0 
 
4-methoxy-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-76). The 
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-76 as an off-white powder. ESI-MS for C20H16ClNO5S: [M-H]- calculated 
416.0, found 416.2, 418.2 
 
5-methoxy-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-77). The 
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I 
afforded JMT-77 as an off-white powder. ESI-MS for C20H16ClNO5S: [M-H]- calculated 
416.0, found 416.2, 418.2 
 
N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-78). 
The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-78 as a white powder. ESI-MS for C19H13ClFN5O2S: [M-H]- 
calculated 428.0, found 428.2, 430.3 
 
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-79). 
The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-79 as a white powder. ESI-MS for C19H13ClFN5O2S: [M-H]- 




The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-80 as a white powder. ESI-MS for C20H16ClN5O2S: [M-H]- 
calculated 424.1, found 424.3, 426.2 
 
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-81). 
The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-81 as a white powder. ESI-MS for C20H16ClN5O2S: [M-H]- 
calculated 424.1, found 424.2, 426.2 
 
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-
82). The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-82 as a beige powder. ESI-MS for C20H16ClN5O3S: [M-H]- 
calculated 440.1, found 440.2, 442.2 
 
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-
83). The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure II afforded JMT-83 as an off-white powder. ESI-MS for C20H16ClN5O3S: [M-H]- 
calculated 440.1, found 440.2, 442.2 
 
4-fluoro-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-84). The 
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-84 as a beige powder. 1H NMR (600 MHz, D3COCD3): δ = 11.60 
(s, 1H), 8.11 (dd, J = 6.5, 8.9 Hz, 1H), 8.06 (d, J = 8.5 Hz, 2H), 7.95 (d, J  = 8.7 Hz, 2H), 
7.93 (d, J = 8.5 Hz, 2H), 7.83 (d, J = 8.2 Hz, 2H), 7.47 (dd, J = 2.5, 11.1 Hz, 1H), 6.93 (dt, 
J = 2.5, 8.1 Hz, 1H). ESI-MS for C20H13F4NO4S: [M-H]- calculated 438.0, found 438.2 
 
5-fluoro-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-85). The 
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-85 as an off-white powder. 1H ESI-MS for C20H13F4NO4S: [M-
H]- calculated 438.0, found 438.2 
 
4,5-difluoro-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-86). 
The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-86 as a beige powder. 1H NMR (600 MHz, D3COCD3): δ = 11.14 
(s, 1H), 8.02 (d, J = 8.6 Hz, 2H), 7.93 (m, 5H), 7.83 (d, J  = 8.3 Hz, 2H), 7.67 (dd, J = 7.1, 
12.4 Hz, 1H). ESI-MS for C20H12F5NO4S: [M-H]- calculated 456.0, found 456.2 
 
5-bromo-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-87). The 
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-87 as a white powder. ESI-MS for C20H13BrF3NO4S: [M-H]- 
calculated 498.0, found 498.1, 500.2 
 
4-methyl-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-88). The 
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-88 as an off-white powder. ESI-MS for C21H16F3NO4S: [M-H]- 





5-methyl-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-89). The 
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-89 as an off-white powder. ESI-MS for C21H16F3NO4S: [M-H]- 
calculated 434.1, found 434.2 
 
4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-
90). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to 
General Procedure I afforded JMT-90 as a white powder. ESI-MS for C21H13F6NO4S: [M-
H]- calculated 488.0, found 488.2 
 
5-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-
91). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to 
General Procedure I afforded JMT-91 as a white powder. ESI-MS for C21H13F6NO4S: [M-
H]- calculated 488.0, found 488.2 
 
4-methoxy-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-92). 
The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-92 as an off-white powder. ESI-MS for C21H16F3NO5S: [M-H]- 
calculated 450.1, found 450.2 
 
5-methoxy-2-(4'-trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-93). 
The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General 
Procedure I afforded JMT-93 as a white powder. ESI-MS for C21H16F3NO5S: [M-H]- 
calculated 450.1, found 450.2 
 
N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide 
(JMT-94). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according 
to General Procedure II afforded JMT-94 as a white powder. ESI-MS for C20H13F4N5O2S: 
[M-H]- calculated 462.1, found 462.2 
 
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide 
(JMT-95). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according 
to General Procedure II afforded JMT-95 as a white powder. ESI-MS for C20H13F4N5O2S: 
[M-H]- calculated 462.1, found 462.2 
 
N-(2-(1H-tetrazol-5-yl)-4-bromophenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide 
(JMT-96). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according 
to General Procedure II afforded JMT-96 as a white powder. ESI-MS for C20H13BrF3N5O2S: 
[M-H]- calculated 522.0, found 522.1, 524.2 
 
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide 
(JMT-97). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according 
to General Procedure II afforded JMT-97 as an off-white powder. ESI-MS for 
C21H16F3N5O2S: [M-H]- calculated 458.1, found 458.2 
 
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide 
(JMT-98). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according 
to General Procedure II afforded JMT-94 as a white powder. ESI-MS for C21H16F3N5O2S: 




sulfonamide (JMT-99). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl 
chloride according to General Procedure II afforded JMT-99 as a beige powder. ESI-MS 
for C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3 
 
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-
sulfonamide (JMT-100). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl 
chloride according to General Procedure II afforded JMT-100 as a white powder. ESI-MS 
for C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3 
 
2-((4-cyclohexylphenyl)sulfonamido)-4-fluorobenzoic acid (JMT-101). The reaction of 4-
cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-101 
as a beige powder. ESI-MS for C19H20FNO4S: [M-H]- calculated 376.1, found 376.2 
 
2-((4-cyclohexylphenyl)sulfonamido)-5-fluorobenzoic acid (JMT-102). The reaction of 4-
cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-102 
as an off-white powder. ESI-MS for C19H20FNO4S: [M-H]- calculated 376.1, found 376.2 
 
2-((4-cyclohexylphenyl)sulfonamido)-4,5-difluorobenzoic acid (JMT-103). The reaction of 
4-cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-
103 as a beige powder. ESI-MS for C19H19F2NO4S: [M-H]- calculated 394.1, found 394.2 
 
2-((4-cyclohexylphenyl)sulfonamido)-5-bromobenzoic acid (JMT-104). The reaction of 4-
cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-104 
as a white powder. ESI-MS for C19H20BrNO4S: [M-H]- calculated 436.0, found 436.1, 
438.1 
 
2-((4-cyclohexylphenyl)sulfonamido)-4-methylbenzoic acid (JMT-105). The reaction of 4-
cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-105 
as a white powder. ESI-MS for C20H23NO4S: [M-H]- calculated 372.1, found 372.3 
 
2-((4-cyclohexylphenyl)sulfonamido)-5-methylbenzoic acid (JMT-106). The reaction of 4-
cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-106 
as a white powder. ESI-MS for C20H23NO4S: [M-H]- calculated 372.1, found 372.3 
 
2-((4-cyclohexylphenyl)sulfonamido)-4-(trifluoromethyl)benzoic acid (JMT-107). The 
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure I 
afforded JMT-107 as a white powder. ESI-MS for C20H20F3NO4S: [M-H]- calculated 426.1, 
found 426.2 
 
2-((4-cyclohexylphenyl)sulfonamido)-5-(trifluoromethyl)benzoic acid (JMT-108). The 
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure I 
afforded JMT-108 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.27 (s, 1H), 
8.28 (s, 1H), 7.87 (m, 4H), 2.60 (tt, J  = 2.8, 11.5 Hz, 1H), 1.79 (dt, J = 2.8, 12.2 Hz, 4H), 
1.70 (dtt, J = 1.5, 3.0, 12.9 Hz, 1H), 1.40 (ddt, J = 1.7, 12.7, 24.0 Hz, 4H), 1.25 (ddt, J = 
3.1, 12.7, 23.9 Hz, 1H). ESI-MS for C20H20F3NO4S: [M-H]- calculated 426.1, found 426.3 
 
2-((4-cyclohexylphenyl)sulfonamido)-4-methoxybenzoic acid (JMT-109). The reaction of 
4-cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-109 
as an off-white powder. ESI-MS for C20H23NO5S: [M-H]- calculated 388.1, found 388.3 
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2-((4-cyclohexylphenyl)sulfonamido)-5-methoxybenzoic acid (JMT-110). The reaction of 
4-cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-110 
as an off-white powder. ESI-MS for C20H23NO5S: [M-H]- calculated 388.1, found 388.3 
 
N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4-cyclohexylbenzenesulfonamide (JMT-111). The 
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II 
afforded JMT-111 as a white powder. ESI-MS for C19H20FN5O2S: [M-H]- calculated 400.1, 
found 400.3 
 
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4-cyclohexylbenzenesulfonamide (JMT-112). The 
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II 
afforded JMT-112 as a white powder. ESI-MS for C19H20FN5O2S: [M-H]- calculated 400.1, 
found 400.2 
 
N-(2-(1H-tetrazol-5-yl)-4-bromophenyl)-4-cyclohexylbenzenesulfonamide (JMT-113). The 
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II 
afforded JMT-113 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 10.63 (s, 1H), 
8.14 (d, J = 2.2, 1H), 7.75 (d, J = 8.9, 1H), 7.71 (m, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.31 (d, 
J = 8.3 Hz, 2H), 2.53 (d, J = 8.3 Hz, 2H), 2.53 (tt, J = 2.9, 11.6 Hz, 1H), 1.76 (dt, J  = 4.2, 
22.3 Hz, 4H), 1.69 (dtt, J = 1.5, 2.9, 12.8 Hz, 4H), 1.36 (ddt, J = 2.0, 12.8, 23.0 Hz, 1H) 
1.24 (ddt, J = 3.5, 12.7, 22.9 Hz, 1H). ESI-MS for C19H20BrN5O2S: [M-H]- calculated 460.0, 
found 460.2, 462.2 
 
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4-cyclohexylbenzenesulfonamide (JMT-114). 
The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II 




The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II 




116). The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General 
Procedure II afforded JMT-116 as a white powder. ESI-MS for C20H20F3N5O2S: [M-H]- 
calculated 450.1, found 450.2 
 
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4-cyclohexylbenzenesulfonamide (JMT-117). 
The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II 
afforded JMT-117 as an off-white powder. ESI-MS for C20H23N5O3S: [M-H]- calculated 
412.1, found 412.3 
 
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4-cyclohexylbenzenesulfonamide (JMT-118). 
The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II 
afforded JMT-118 as a white powder. ESI-MS for C20H23N5O3S: [M-H]- calculated 412.1, 
found 412.3 
 
4-fluoro-2-(naphthalene-2-sulfonamido)benzoic acid (JMT-119). The reaction of 
naphthalene-2-sulfonyl chloride according to General Procedure I afforded JMT-119 as a 
beige powder. ESI-MS for C17H12FNO4S: [M-H]- calculated 344.0, found 344.2 
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5-fluoro-2-(naphthalene-2-sulfonamido)benzoic acid (JMT-120). The reaction of 
naphthalene-2-sulfonyl chloride according to General Procedure I afforded JMT-120 as 
an off-white powder. ESI-MS for C17H12FNO4S: [M-H]- calculated 344.0, found 344.1 
 
5-methyl-2-(naphthalene-2-sulfonamido)benzoic acid (JMT-121). The reaction of 
naphthalene-2-sulfonyl chloride according to General Procedure I afforded JMT-121 as 
an off-white powder. ESI-MS for C18H15NO4S: [M-H]- calculated 340.1, found 340.2 
 
4-fluoro-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid (JMT-122). The 
reaction of 5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride according to General 
Procedure I afforded JMT-122 as a beige powder. ESI-MS for C17H16FNO4S: [M-H]- 
calculated 348.1, found 348.2 
 
5-fluoro-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid (JMT-123). The 
reaction of 5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride according to General 
Procedure I afforded JMT-123 as an off-white powder. ESI-MS for C17H16FNO4S: [M-H]- 
calculated 348.1, found 348.2 
 
5-methyl-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid (JMT-124). The 
reaction of 5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride according to General 
Procedure I afforded JMT-124 as an off-white powder. ESI-MS for C18H19NO4S: [M-H]- 
calculated 344.1, found 344.2 
 
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)benzoic acid (JMT-125). The reaction 
of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General Procedure I 
afforded JMT-125 as an off-white powder. ESI-MS for C15H13NO6S: [M-H]- calculated 
334.0, found 334.1 
 
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)-4-fluorobenzoic acid (JMT-126). The 
reaction of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General 
Procedure I afforded JMT-126 as a beige powder. ESI-MS for C15H12FNO6S: [M-H]- 
calculated 352.0, found 352.1 
 
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)-5-fluorobenzoic acid (JMT-127). The 
reaction of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General 
Procedure I afforded JMT-127 as an off-white powder. ESI-MS for C15H12FNO6S: [M-H]- 
calculated 352.0, found 352.1 
 
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)-5-methylbenzoic acid (JMT-128). 
The reaction of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General 
Procedure I afforded JMT-128 as an off-white powder. ESI-MS for C16H15NO6S: [M-H]- 
calculated 348.1, found 348.2 
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Figure E.1: Pharmacophore search of a virtualized library of FDA-approved drugs. A. A three-point 
pharmacophore consisting of one anionic feature (radius = 0.7 Å), one hydrophobic/aromatic 
feature (radius = 0.9 Å), and one hydrogen bond accepting feature (radius = 1.0 Å) was used to 
search a virtual library of FDA-approved drug structures, yielding 1,862 matching conformations. 
B. Enalapril shown in a pharmacophore-matching conformation (rmsd = 0.6 Å). 
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Figure E.3: Example structures of other C-terminal peptide and peptoid drugs matching the three-





































































Figure E.5: Modeled binding modes of example FDA-approved pharamacophore matches with 
tPBP2WT. A. Enalapril (ENP, green). B. Lifitegrast (LFG, green). C. Argatroban (AGB, green). Polar 
contacts are indicated by black dashed lines. 
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Figure F.1: In silico screen performance characteristics. A. Physicochemical properties of ligands (β-
lactams) and matched decoys, C. Comparison of ligand and decoy energy scores (***p < 0.001). D, 
E. Receiver-operator curves for true ligand detection. F, G. Enrichment curves for true ligands versus 




Figure F.2: High-throughput virtual screen against P. aeruginosa PBP3. A. Rigid-receptor dock 
rank-ordered energy scores. B. Rigid-receptor dock energy score distribution. C. Induced fit 
consensus dock rank-ordered energy scores. D. Induced fit consensus dock energy score 
distribution. E. Inhibition of P. aeruginosa PBP3 by 1 mM of purchased compounds exhibiting 
favorable scores from the high-throughput virtual screen. F. Least energy conformer for 
NSC605657, a mid-micromolar, dose-dependent inhibitor of PBP3 identified from the high-




Figure F.3: NSC605657 (norbadione A) inhibition of P. aeruginosa PBP3. A. NSC605657 is a 2-
oxatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),4,6,8(12),9-pentaen-3-one comprising two pulvinic acid 
moieties. B. NSC605657 exhibits dose-dependent inhibition of PBP3 with half-maximal activity at 








Figure F.4: Screening of 2H-chromene (A) and cinnamic acid (B) compounds against PBP3. 
Values were determined in a purified protein assay in which PBP3 was preincubated with 







Figure F.5: 2H-chromene inhibition of P. aeruginosa PBP3. A. NSC119893, NSC122391, and 
Z19713177 are 2H-chromenes with carboxylate or phenolate moieties.  B. NSC119893, 
NSC122391, and Z19713177 exhibit dose-dependent inhibition of PBP3 with half-maximal 
inhibitory activities at 41.1 ± 2.5 µM (n = 3 replicates per concentration, r2 = 0.982), 75.0 ± 14.1 μM 
(n = 4 replicates per concentration, r2 = 0.924), and 83.5 ± 17.2 μM (n = 3 replicates per 







Figure F.6: Proposed mode of PBP3 inhibition by 2H-chromenes. A) Flexible alignment to show 
common features of most potent inhibitors from the class (hydrogen bond donors, magenta; 
hydrogen bond acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red; 
aromatic centers, orange; hydrophobic atoms, green). B) Least energy conformer for 2H-chromene 





Figure F.7: Screening of 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones against PBP3. Values were 
determined in a purified protein assay in which PBP3 was preincubated with compound, followed 




Figure F.8: STK577136 and STK704344 inhibition of P. aeruginosa PBP3. A. STK57716 and 
STK704344 are 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones with aromatic substitutions at their 1-, 4-, 
and 5-positions. B. STK577136 and STK704344 exhibit dose-dependent inhibition of PBP3 with 
half-maximal activities at 25.8 ± 1.9 μM (n = 3 replicates per concentration, r2 = 0.980) and 24.9 ± 





































































Figure F.9: Proposed mode of PBP3 inhibition by 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones. A) 
Flexible alignment to show common features of most potent inhibitors from the class (hydrogen 
bond donors, magenta; hydrogen bond acceptors, cyan; interchangeable donors/acceptors, rose; 
anionic atoms, red; aromatic centers, orange; hydrophobic atoms, green). B) Least energy 
conformer for 3-hydroxy-1,5-dihydro-2H-pyrrol-2-one STK704344 docked against P. aeruginosa 




Figure F.10: Structures of additional PBP3-inhibitory chemotypes. Other non-β-lactam PBP 
inhibitors found in the course of this work include quinolines and quinoline analogues Q, 
arylsulfonamides S, triazoles and tetrazoles T, 4-thiazolidinones (rhodanines) R, and 2-
























Figure A.11: Screening of quinolones, quinazolines, and quinoxalines Q against PBP3. Values 
were determined in a purified protein assay in which PBP3 was preincubated with compound, 





Figure F.12: Proposed mode of PBP3 inhibition by quinoxalines Q. A. Flexible alignment to show 
common features of most potent quinolines (hydrogen bond donors, magenta; hydrogen bond 
acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red; aromatic centers, 
orange; hydrophobic atoms, green). B) Least energy conformer for quinoline STK549604 docked 


























































Figure F.13: Screening of sulfonamides S against PBP3. Values were determined in a purified 
protein assay in which PBP3 was preincubated with compound, followed by addition of 1 µM 





Figure F.14: Proposed mode of PBP3 inhibition by sulfonamides S. A. Flexible alignment to show 
common features of most potent arylsulfonamides (hydrogen bond donors, magenta; hydrogen 
bond acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red; aromatic 
centers, orange; hydrophobic atoms, green). B. Least energy conformer for arylsulfonamide 
















































Figure F.15: Screening of azoles (A), 4-thiazolidinones (B), and pyrimidine-4,6(1H,5H)-diones (C) 
against PBP3. Values were determined in a purified protein assay in which PBP3 was preincubated 




Figure F.16: Proposed modes of PBP3 inhibition by azoles, 4-thiazolidinones, and pyrimidine-
4,6(1H,5H)-diones. A-C. Flexible alignment to show common features of most potent azoles (A), 
4-thiazolidinones (B), and pyrimidine-4,6(1H,5H)-diones (C) (hydrogen bond donors, magenta; 
hydrogen bond acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red; 
aromatic centers, orange; hydrophobic atoms, green). D-F. Least energy conformers for 
aryltetrazole Z26552032 (D), 4-thiazolidinone CB6126765 (E), and pyrimidine-4,6(1H,5H)-dione 






Table F.1: PBP3 inhibition data for NSC605657 analogues identified through substructure and 
similarity searches of the PubChem database. Most potent hits (defined as >50% inhibition at 100 
µM) are highlighted in green. 
 
Compound Inhibition at 1 mM (%) Inhibition at 100 μM (%) 
NSC5897 13.7 ± 6.8 ND 
NSC167376 NS ND 
NSC311454 NS ND 
NSC338986 46.9 ± 12.9 NS 
NSC621468 57.5 ± 17.5 NS 
NSC81924 NS  ND 
NSC631509 22.8 ± 20.9 ND 
NSC155504 28.1 ± 5.8 ND 
NSC32899 79.8 ± 5.3 NS 
NSC347512 NS ND 
NSC3483 81.3 ± 15.8 8.5 ± 3.1 
NSC720435 NS ND 
NSC119893 92.3 ± 4.3 72.9 ± 3.6 
NSC157 98.5 ± 1.9 NS 
NSC19027 NS ND 
NSC19801 38.1 ± 29.7 ND 
NSC101137 NS ND 
NSC155476 9.1 ± 4.4 ND 
NSC215568 11.0 ± 9.9 ND 
NSC720435 NS ND 
EN300-41020 NS ND 
Z90122589 NS ND 
Z1946684614 NS ND 
Z905065810 50.7 ± 18.9 8.9 ± 2.5 
Z95232844 22.6 ± 11.7 ND 
Z223849600 51.3 ± 6.8 NS 
Z19713177 66.1 ± 12.8 53.1 ± 28.4 
EN300-305263 10.0 ± 2.7 ND 
NSC122391 74.8 ± 19.5 58.9 ± 3.9 
NSC622475 NS ND 
STL099530 NS ND 
STL099536 NS ND 
STK007398 26.2 ± 10.6 ND 
STK034285 47.3 ± 17.6 ND 
STK447520 13.9 ± 6.5 ND 
STK791461 NS ND 
STK837716 NS ND 
STK987640 NS ND 
STL058314 NS ND 
STL061985 NS ND 






Table F.2: PBP3 inhibition data for compounds predicted to have activity from structure-activity 
relationships of noncovalent inhibitors against PBP3.  
 
Compound Inhibition at 1 mM (%) Inhibition at 100 μM (%) 
STK369807 95.2 ± 2.4 21.5 ± 7.1 
STK888755 41.4 ± 10.7 ND 
STK270718 24.8 ± 19.6 ND 
STK522653 82.8 ± 16.4 31.4 ± 4.2 
STK549572 88.4 ± 4.7 39.8 ± 4.8 
STK522651 48.8 ± 14.2 ND 
STK522656 85.8 ± 7.8 NS 
STL048854 67.7 ± 23.1 43.4 ± 0.3 
STK541644 98.1 ± 1.4 44.5 ± 8.9 
STK328887 NS ND 
STK887542 NS ND 
STK994187 51.2 ± 9.8 NS 
STK191801 80.6 ± 11.3 NS 
STK718016 NS ND 
STK577136 88.3 ± 7.2 86.5 ± 0.7 
STL031938 55.5± 17.6 23.2 ± 10.3 
STK460513 NS ND 
CB6140541 NS ND 
CB6126765 80.9 ± 14.1 95.8 ± 3.8 
CB6130015 44.3 ± 8.1 ND 
STL031936 39.0 ± 27.9  ND 
STK704344 97.5 ± 2.2 96.2 ± 2.4 
STK818923 85.0 ± 7.8 10.3 ± 5.7 
Z26552032 95.9 ± 1.7 54.8 ± 14.6 
STK192475 97.2 ± 2.8 35.4 ± 9.3 
STK197617 97.3 ± 1.6 29.1 ± 1.4 
STK197649 95.1 ± 8.4 15.3 ± 3.0 
STK197654 96.0 ± 2.6 38.2 ± 1.9 
STK542406 66.3 ± 20.1 42.2 ± 8.0 
STK549604 90.7 ± 4.9 66.1 ± 5.9 
STL336609 75.9 ± 13.9 31.7 ± 3.0 
STK059577 90.3 ± 4.7 76.8 ± 7.0 
STK572022 94.3 ± 3.2 NS 
STK576161 96.1 ± 2.7 NS 
STK589175 NS ND 
STK596018 95.6 ± 4.7 NS 
STK626827 91.8 ± 4.4 NS 
STK631838 98.8 ± 2.4 NS 
STK818556 87.9 ± 7.1 NS 
STK818561 89.6 ± 5.6 NS 
STK819418 48.7 ±5.1 ND 
STK098795 NS ND 
STL361235 55.7 ± 12.4 9.8 ± 5.5 
STK095131 28.4 ± 14.4 ND 
STK052461 13.2 ± 4.5 ND 
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STK129507 20.6 ± 15.0 ND 
STK071540 8.6 ± 6.3 ND 
STK634916 NS ND 
STK029374 NS ND 
STK871156 NS ND 
STK871000 NS ND 
STK202948 30.6 ± 2.7 ND 
STK070625 NS ND 
STK084156 44.4 ± 23.3 ND 
STK010482 NS ND 
STK057971 NS ND 
STL040105 NS ND 
STK041773 NS ND 
CB5477031 96.2 ± 2.4 68.5 ± 7.9 
CB5530695 91.8 ± 6.1 NS 
CB6624338 51.9 ± 7.6 NS 
CB7647715 NS ND 
CB5151615 87.8 ± 6.9 NS 
CB5730506 96.4 ± 1.7 56.7 ± 7.3 
CB5729373 67.0 ± 10.5 NS 
CB5737652 88.2 ± 6.7 50.5 ± 17.4 
CB7630081 85.1 ± 3.6 66.8 ± 11.2 
CB5214931 66.9 ± 7.0 43.2 ± 7.1 
CB5218577 97.9 ± 1.2 61.0 ± 9.1 
CB5247550 39.5 ± 21.8 ND 
CB5238280 53.9 ± 28.0 ND 
CB5376753 83.7 ± 10.5 46.0 ± 5.5 
CB5376658 83.7 ± 5.9 NS 
CB5175181 66.4 ± 11.8 NS 
CB5228302 64.7 ± 5.5 4.3 ± 2.4 
CB5228304 64.0 ± 8.8 NS 
CB6155033 82.3 ± 8.0 36.8 ± 21.4 
CB7453894 76.1 ± 7.8 76.8 ± 4.5 
CB5940861 80.4 ± 3.2 33.1 ± 2.2 
 
 
